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The prevalence of diabetes mellitus is high among patients with developmental disabilities 
(Cerebral palsy, Autism, Down’s syndrome and Cognitive disabilities). Developmentally 
disabled (DD) individuals experience delays in detection of chronic comorbidities such as 
diabetes, obesity, high blood pressure, arthritis, CVD and chronic pain. They also have poor 
disease management, poor healthcare utilization and low quality of care.  Very few studies have 
looked at the diabetes related health outcomes in DD adults.   
Objective:  
This study examines the racial health disparities in medication adherence and medication 
persistence in DD adults with type 2 diabetes enrolled in Medicaid. This study also determines 
the association of race, medication adherence and its interaction with healthcare utilization and 
healthcare costs in Medicaid enrollees with DD and type 2 diabetes.  
Methods:  
This was a retrospective cohort study based on the Health belief model and Aday Anderson’s 
model of healthcare utilization. The dataset used for this study was the MarketScan® Multi-State 
Medicaid Database.  Adults aged 18-64 years with a prior diagnosis of a developmental 
disability (cerebral palsy/autism/down’s/cognitive disabilities) and a new diagnosis of type 2 
diabetes enrolled in Medicaid from January 1, 2004 and December 31, 2006, were included. 




excluded if they were dual eligible. Anti-diabetic medication adherence and diabetic medication 
persistence were measured using multivariate logistic regression and the Cox-proportional 
hazard regression respectively.  Probabilities of anti-diabetic healthcare utilization (inpatient, 
outpatient and emergency department visits) in DD adults were measured using multivariate 
logistic regression models. Multivariate negative binomial regression was used to measure the 
rate of change of type 2 diabetes related healthcare utilization in DD patients. Multivariate linear 
regression with log-transformation was used to determine type 2 diabetes related healthcare costs 
in DD Medicaid enrollees.  
Results:  
The study population comprised of 1529 patients. After controlling for covariates, African 
Americans had significantly lower odds (25%) of adhering to anti diabeticmedications compared 
to Caucasians (OR = 0.75, 95% CI = 0.58-0.97, p<0.05).  Also, after controlling for other 
covariates, the hazard was higher in African Americans compared to Caucasians (Hazard Ratio = 
1.03, 95% CI = 0.91-1.18, p<0.629). After controlling for all the covariates, compared to DD 
Caucasians, DD African Americans were more likely to have type diabetes related inpatient 
(OR=1.71; 95% CI, 1.02-2.85, p<0.05) and emergency department visits (OR, 1.67; 95% CI, 
1.03-2.73) respectively.  
Conclusion:  
Racial disparities exist in healthcare outcomes in DD Medicaid patients with type 2 diabetes.  
The needs of the developmentally disabled individuals are somewhat different than the needs of 
individuals without disabilities. Policy recommendations should focus on increasing the number 
of outpatient centers, culturally competent healthcare providers, and primary caregivers who can 




for the patients. There should be a focus on designing culturally appropriate health prevention 
























Chapter 1 Introduction 
 
1.1 Risk and Burden of type 2 diabetes in DD patients  
Research shows that adults with developmental disabilities (DD) tend to have a more sedentary 
lifestyle, do not exercise often and tend to consume high calorie diet (McGuire 2007, Temple 
2003, Ewing 2004). These practices can lead to obesity which is a risk factor for type 2 diabetes. 
Also, adults with DD have a higher life expectancy compared to a few decades back and this 
increase in the life expectancy is accompanied by a vulnerability to the development of a number 
of age related comorbid chronic conditions, including type 2 diabetes (Merrick 2004, Sohler 
2009). Diabetes management requires screening for various chronic disease conditions 
(Shiremen 2010). A study conducted in DD population residing in Canada showed that even 
though 94% of the study population visited their general practitioner on a regular basis, only 
52% and 44% had blood glucose and cholesterol measured respectively and only 29% and 19% 
were screened for diabetic retinopathy and microalbuminaria respectively.  This shows that the 
screening rates for chronic diseases is quite low in the DD population as compared to the 
recommended national guidelines.  Active engagement of the DD population in health education 
interventions and health screening interventions is not always possible which makes the 





1.2 Medication adherence and outcomes in adults with DD 
Individuals with DD face many issues that make the care process for them complex. These issues 
include accelerated aging and consequences of long term medication and systems issues like 
access to experienced caregivers and continuity of care. About 76% of individuals with DD 
reside at home and around 25% of them are cared for by family members who are 60 years or 
older. Increase in life expectancy also increases the care giving responsibility of families. 
Families of individuals with DD strive on a continuous basis to support DD patients to attain and 
maintain a certain degree of independence (Heller 2010). In many ways, the medication 
management issues of aging individuals with DD may be similar to that of older adults. 
However, there are many issues unique to their condition and require additional medication 
management considerations. Taking this into account, Healthy people 2020 adds nine new 
objectives to those of Healthy people 2010 to deal with appropriate medication management 
among older adults with disabilities (Healthy People 2020). 
In individuals with DD, many health complications may emerge with increasing age. In 
individuals with Down syndrome (DS) and Cerebral Palsy (CP), these complications may 
include obesity, accelerated aging and its interaction with accompanying secondary medical 
aspects, and long term medication use (Saxon 2010). Adult individuals with DD face increased 
risk of developing chronic conditions at a younger age, which may be rooted in not only 
biological factors but also in lack of appropriate healthcare, lifestyle and environmental issues. 
They may be more prone to health issues related to dental, respiratory, and cardiac health 
conditions, paricularly non-atherosclerotic heart disease. They may be also prone to issues such 
as problems with eating/swallowing, diabetes, hypercholesterolemia, hypertension, reduced 




Many factors contributing to non-adherence among adults with DD are similar to those in 
general aging population. However, for adults with DD desiring to achieve good health and 
maintain some degree of independence, factors contributing to medication non-adherence are 
also compounded by issues related to communication, vision, hearing, dexterity, and cognitive 
limitations (Ince 2009). Some of the common causes of non-adherence among adults with DD 
are fragmentation of care, comorbidity, polypharmacy, and considerations of medication side 
effects (Ince 2009). 
In order to increase medication adherence among aging individuals with DD, it is important to 
develop medication and treatment goals centered towards the need of the individual, coupled 
with careful assessment and understanding of the role of the caregiver and family based care 
(Heller 2011). Family and professional caregivers play an important role in supporting 
individuals with DD. However, in many situations they may be ill prepared to meet the needs of 
the patient’s needs (Marks 2010). This may have negative influence over the quality of care and 
may have other negative consequences. For example, caregivers may make erroneous assessment 
of client’s need for medication and thus negatively influence prescribing.  Therefore, it is very 
important to increase health literacy and awareness among caregivers about issues related to 
aging process and unique medication needs of individuals with DD (Lau 2010). Another problem 
faced by adults with DD, especially those whose care is publicly funded, is the occurrence of 
disruptive health events like inpatient visits and transition to another care unit. This leads to 
fragmentation of care and causes issues related to care continuity, whereby the individual has 
restricted access to caregivers and providers familiar with his/her specific needs. Issues related to 
communication and sharing of health information among health networks further complicate this 




to consider that care transition is not restricted only to the systems and healthcare providers but 
also should take into account the transition of care between physicians, patients, and caregivers. 
1.3 Importance of looking at comorbidities in Medicaid patients 
Medicaid enrollees have twice the prevalence rate of diabetes compared to the general US 
population. Almost 15% of the Medicaid enrollees had diabetes in 2005. These enrollees account 
for a big portion of the Medicaid expenditure, associated with many micro and macro vascular 
complications related to diabetes (Cohen 2007, Smith 2006). Comorbidities in patients with 
diabetes are quite common and a majority of the patients have at least one comorbidity (Druss 
2001). Comorbidity leads to increase in morbidity and mortality and can be a source of financial 
burden on the patients and the federal healthcare system. Comorbidity management also entails 
increase in the use of healthcare resources and failure to procure the same can increase the 
probability of poor patient outcomes.  
Debilitating comorbidities in diabetic patients can make the process of medication adherence 
challenging since more the conditions that the patient has, the more are the medications and more 
complex is managing several conditions at the same time. About 40% patients with diabetes have 
as many as three comorbidities (Maddigan 2005). Patients with DD who already have impaired 
physical and mental functioning face an additional burden in performing self-care tasks for 
managing diabetes and other associated comorbidities such as depression, CVD and arthritis 
(Bayliss 2003, Kerr 2007, Noel 2005). Some studies show that increase in the number of 
comorbidities leads to an increase in medication adherence. Some of the reasons that can be 
attributed to the above finding are that that the patients procure information about diabetes 




diabetes due to their perception about its severity and the perceived susceptibility towards the 
occurrence of diabetes related comorbidities. Researchers also posit that medication adherence 
and other clinical outcomes are characteristic of the primary disease condition and its related 
comorbidities (Kerr 2007, Piette 2004, Piette 2006).  
Comorbid conditions also have an impact on clinical practice. While treating patients with 
multiple comorbidities, physicians face several challenges since the treatment becomes more 
complicated, several treatment guidelines need to be taken into consideration and at the same 
times adhering to different treatment guidelines might not be possible. Also, increase in the risk 
of adverse drug events due to chronic physical and behavioral comorbidities in patients can 
impact physician’s perception of delivering care and patient’s perception of accepting care and 
this is turn can affect healthcare utilization, clinical outcomes such as survival and economic 
outcomes such as cost of care (Ford 2004). Lack of management of comorbid conditions can 
increase disease severity, impair quality of life and physical and mental functioning in the 
patients and lead to higher risk of mortality.  
Medicaid population is a highly vulnerable population since majority of the enrollees belong to a 
low income group and have multiple chronic comorbidities, disabilities, severe mental disorders 
and substance abuse problems compared to enrollees in Medicare or other commercial healthcare 
plans (Adelmann 2003). Hence medication adherence and healthcare utilization patterns might 
be very different from the enrollees in Medicare or commercial plans (Higashi 2007, Desai 2002, 
2004, Goldberg 2007). Studying the impact of comorbid conditions on diabetes care and 
accordingly designing interventions for provision of comprehensive and cost effective care 





1.4 Multiple medication adherence 
Nearly 44% of the US population has at least 1 chronic disease condition and almost 33% of 
these people have 3 or more chronic disease conditions. Ageing will increase this percentage in 
the future as it increases the risk of development of chronic disease conditions. 50% of the 
people aged 60 years and more take at least 3 medications and 10% of this population take at 
least 7 or more medications (Paez 2009). Hayes (1979) defines adherence to medications, diet or 
lifestyle as a process that is directed by health or medical advice. Perceptions related to 
medication intake and medication related expenditures can play an important role in adhering to 
medications for patients with multiple chronic conditions. The list of medications that patients 
with a number of chronic conditions have to consume can be quite long and different conditions 
require patients to adhere to different medication therapies. As medication adherence decreases, 
medication failure rates increase and the severity of the multiple disease conditions also 
increases (Paez 2009). Taking or refilling medications only when symptoms become severe, 
refilling only those medications which are affordable or talking alternate doses of the 
medications that are more expensive might be some of the factors that can be attributed towards 
lower adherence.  
1.5 Adherence improves healthcare outcomes in type 2 diabetes  
Medication adherence provides several advantages such as reducing healthcare costs, patient 
suffering, and HbA1c level by less than 8% and the risk of mortality by half (Gibson 2010, 
Simpson 2006, Ruelas 2009). Even though medication adherence improves health and clinical 
outcomes by reducing the risk factors related to chronic disease conditions such as diabetes, non-




(Lehane 2009, DiMatteo 2002, Ruelas 2009, Simpson 2006). Medication adherence rates in the 
developed countries are as low as 50% and in the developing countries; the numbers are lower 
than 50% (WHO 2003). Non adherence is a problem seen not only with diabetes but with many 
other conditions and it presents challenges in making the treatment prescribed by physicians a 
success (Lehane 2009). A systematic review conducted by Cramer et al (2004) which included 
20 studies dated 1966 to 2003, showed that adherence rates that impacted blood glucose levels 
varied and were suboptimal. Identifying barriers to medication adherence and designing 
interventions to reduce them can improve adherence to chronic disease medication therapies.  
1.6 Significance of the study 
Medicaid covers uninsured and unemployed individuals, mainly comprising of pregnant women, 
children, adults with physical and developmental disabilities, elderly and frail individuals.  
Individuals with disabilities make up just 14% of all the Medicaid enrollees and yet are 
accountable for 42% of the total Medicaid expenses.  Research has shown that people with 
disabilities have higher rates of diabetes characteristic of the type of disability (McDermott 2007, 
McDermott 2006). Among people with disabilities, rates of diabetes in patients with sensory or 
psychiatric disabilities are 31.6% and 24.7% respectively compared to 15.8% in patients without 
sensory or psychiatric disabilities. Diabetes is seen in only 10.4% patients with DD. However, 
the rates of obesity are 67% in patients with DD, sensory and psychiatric disabilities  
(McDermott 2006). Adults with DD experience disparity in receipt of healthcare due to their 
physical and mental chronic comorbidities  (Havercamp 2004, Fisher 2004, Parish 2006, Phillips 
2002). Limited information exists about the prevalence and management of type 2 diabetes in 
adults with DD.  Chronic disease conditions including diabetes, are not managed properly in 




patients with DD and diabetes. Results from one study state that the quality of care received by 
DD patients with diabetes was poorer compared to the national recommended standards 
(Shiremen 2010). The other study showed that adults with physical disabilities and diabetes had 
better screening rates for chronic disease conditions compared to the national recommended rates 
(Reichard 2012). There is not a single study to date that has looked at the medication intake 
patterns, healthcare utilization and costs in adults with DD and type 2 diabetes. The life 
expectancy of adults with DD has increased in recent decades but the additional years brought 
along by the increase in life expectancy have also increased the burden of morbidity. There is a 
national concern about the health of adults with DD. They possess a higher risk for developing 
type 2 diabetes, need special accommodations for getting the appropriate care and face a number 
of challenges in accessing healthcare. Hence, this study looks at the fulfillment of type 2 diabetes 
needs in terms of medication adherence and healthcare utilization in adults with DD enrolled in 
Medicaid.   
1.8 Objectives and hypotheses 
Objective 1: To describe select patient characteristics (sociodemographic factors and 
medication-related factors) of Medicaid-enrolled DD patients with a diagnosis of type 2 diabetes 
and examine the predictors of medication adherence in Medicaid-enrolled DD patients with a 
diagnosis of type 2 diabetes, after adjusting for select confounders. (Manuscript 1)  
Hypothesis 1: Compared with Caucasian DD patients with type 2 diabetes, African American 
DD patients with type 2 diabetes will have lower medication adherence, after adjusting for select 
confounders. (Manuscript 1)  




patients with a diagnosis of type 2 diabetes, after adjusting for select confounders. (Manuscript 
1)  
Hypothesis 2: Compared with Caucasian DD patients with type 2 diabetes, African American 
DD patients with type 2 diabetes will have lower medication persistence after adjusting for select 
confounders. (Manuscript 1) 
Objective 3: To examine the effect of race, medication adherence, and the combined effects of 
race and medication adherence on type 2 diabetes related health resource utilization (outpatient 
visits, inpatient visits and emergency room (ER) visits) in Medicaid enrolled DD patients with a 
diagnosis of type 2 diabetes after adjusting for select confounders. (Manuscript 2) 
Hypothesis 3: DD African-American patients with type 2 diabetes with lower medication 
adherence have a higher type 2 diabetes related inpatient visits and ER visits but lower outpatient 
visits, after adjusting from select confounders when compared with three other groups: DD 
Caucasian patients with type 2 diabetes and lower medication adherence, DD Caucasian patients 
with type 2 diabetes and higher medication adherence and DD African-American patients with 
type 2 diabetes and higher medication adherence. (Manuscript 2) 
Objective 4: To examine the effect of race, medication adherence , and the combined effects of 
race and medication adherence on type 2 diabetes related costs (medication costs, medical costs 
and overall costs) in Medicaid enrolled DD patients after adjusting for select confounders. 
(Manuscript 2) 
Hypothesis 4: Among Medicaid enrollees, African American DD patients with type 2 diabetes 
and lower medication adherence will have higher type 2 diabetes related costs (medication costs, 




type 2 diabetes and lower medication adherence, DD Caucasian patients with type 2 diabetes and 
higher medication adherence and DD African-American patients with type 2 diabetes and higher 
















Chapter 2 Literature review 
2.1 Diabetes Mellitus 
2.1.1 Prevalence and economic burden of Diabetes:  
Diabetes Mellitus, a serious metabolic disorder is a seventh leading cause of death in the United 
States (US) (CDC 2011).  According to the Centers for Disease Control and Prevention (CDC) 
2011 estimates, 25.8 million children and adults out of 311 million have diabetes and out of these 
25.8 million, there are about 7 million people who have undiagnosed diabetes. In 2009, the 
number of diabetic people were 23.6 million so in just 2 years, this number has increased by 2.2 
million. The number of people with pre-diabetes is also very high and it amounts to about 79 
million adults and children (CDC 2011, U.S. Census Bureau). Diabetes is a leading cause of 
morbidity, mortality, functional disability, reduced quality of life and several micro and macro 
vascular complications such as cardiovascular illness and blindness (Norris 2011, Gregg 2002). 
There are three forms of diabetes mellitus: 
a) Type 1 diabetes: This type is seen generally among 5% of the population, mostly children 
and young adults and insulin injection or pump is the preferred form of treatment. The 
causes of type 1 diabetes can be attributed to autoimmune, genetic or environmental 
factors.  
b) Type 2 diabetes: This type is seen among the remaining 95% of the adult population. The 





help either delay the onset or control the symptoms of type 2 diabetes. 
c) Gestational diabetes: This occurs in about 2%-10% pregnant females. Women diagnosed 
with gestational diabetes have a 35%-60% risk of developing type 2 diabetes in 10-20 
years. Also the newly born has an increased risk of developing type 2 diabetes (Hunt 
            2007, Dabelea 2011, Kitzmiller 2007).  
Age and race are risk factors for developing type 2 diabetes. Adults older than 65 years have a 
seven times higher risk of developing type 2 diabetes compared to adults aged 20-44 years 
(Diabetes Report Card 2012). The prevalence of diagnosed diabetes in the US from 2007-2009 
was 2.6% among adults aged 20-44 years, 11.7% among adults aged 45-64 years and 18.9% 
among adults aged 65 years and older respectively. Diabetes disproportionately affects racial 
minorities in the US and they have an increased risk of developing diabetic complications at a 
much younger age compared to non-Hispanic Caucasians. American Indians and Alaskan 
Indians are diagnosed with diabetes at a rate twice compared to non-Hispanic Caucasians (Geiss 
2011). In 2007-2009, the age estimated numbers stated that adults diagnosed with diabetes aged 
20 years or more constituted 16.1% American Indians and Alaskan Natives, 12.6% non Hispanic 
African Americans, 11.8% Hispanics, 8.4% Asian Americans and 7.1% non Hispanic Caucasians 
(CDC 2011). One of the main reasons for the increased incidence of diabetes can be attributed to 
the increasing incidence of obesity. Management of diabetes can be achieved by both 
pharmacologic treatment such as treating glycemia and non-pharmacologic treatment such as 
patient education, evaluating and minimizing micro and macro vascular risks (Qaseem 2012).  
It is estimated that the worldwide incidence of diabetes will increase from 171 million in 2000 to 




and undiagnosed patients) out of a population of 386 million in 2034 and to 48.3 million 
(diagnosed patients) out of a population of 439 million respectively (Wild 2004, U.S Census 
Bureau, Huang 2009, Deshpande 2008, Narayan 2006). The cost of diabetes related healthcare 
places a huge burden on the US economy with treatment costs and loss of productivity 
accounting for $174 billion in 2007. These costs are estimated to rise to $336 billion in 2034 
(CDC 2011, Deshpande 2008, Huang 2009, Narayan 2006, Wild 2004, Huang 2009). There is a 
need to design and implement interventions that can mitigate the complex and expensive 
healthcare needs related to diabetes (American Diabetes Association). 
2.1.2 Disease progression to type 2 diabetes  
The symptoms of type 2 diabetes are not very alarming upon their occurrence which is one of the 
reasons for its late detection. Pre-diabetic patients do not show symptoms of diabetes. However, 
if  pre-diabetic people get their blood glucose checked on a regular basis,  it is possible to know 
that the blood sugar level is above normal but not as high as diabetic patients. Long term damage 
to the circulatory and cardiovascular system starts to occur in pre-diabetic stage. As severity of 
the condition increases, occurrence of micro vascular and macro vascular problems such as 
retinopathy, coronary artery disease, cerebrovascular disease, neuropathy, peripheral vascular 
disease and nephropathy also increase (ADA website, Diabetes Report Card 2012).  
The estimates of the development of micro vascular conditions in patients with type 2 diabetes 
are as follows: 
a) Severe kidney disease and end stage renal disease in 10%-40% patients 
b) Number one cause of diabetic retinopathy in patients aged 20-74 years 




d) Non traumatic lower limb amputations in more than 60% patients with comorbid severe 
nerve disease (National Diabetes Information Clearinghouse 2008). 
The estimated occurrence of macro vascular conditions which are more common and which are 
the leading cause of deaths in 80% patients with type 2 diabetes are as follows: 
a) Ten times higher risk of co-occurrence of cardiovascular diseases in patients aged less 
than 45 years (Vijan 2004). 
b) Two times higher cardiovascular mortality rate in male patients and four times higher 
cardiovascular mortality rate in female patients (Winer 2004). 
2.1.3 ADA treatment guidelines 
The American Diabetes Association (ADA) publishes evidence based guidelines for screening, 
diagnosis and therapy of patients with diabetes on an annual basis. The ADA guidelines assist 
clinicians, patients, researchers, payers, and other interested individuals with designing and 
providing diabetes treatment that can improve patients’ health outcomes, achieve treatment goals 
and establish diabetes quality of care standards (ADA 2008). Type 2 diabetes is a complex 
condition with many related comorbidities and therefore ADA has mentioned several guidelines 
for the overall management of the disease. Some of the most important recommendations 
necessary for the initiation and maintenance of type 2 diabetes management therapy are: HbA1c 
< 7.0%, blood pressure < 130/80 mmHg, and low-density lipoprotein (LDL) cholesterol < 100 
mg/dl, diet modification, initiation of metformin therapy, taking additional OHAs if blood sugar 
levels do not subside, and eventually initiating insulin therapy if all the above fail. The above 
comprehensive standards of care are evidence based and are regularly upadated. They consist of 




maintain medication therapy, screen for diabetes related comorbid conditions and begin lifestyle 
modifications for long term management of diabetes. The ADA recommends, given the evidence 
in large sample randomized controlled trials showing association of medication therapy and 
reduction in micro vascular and macro vascular risk, that diabetes therapy should be formulated 
and changed with regards to the characteristics of type 2 diabetes patients (ADVANCE 2007, 
ACCORD 2008, Duckworth 2009, UKPDS 1998). Measuring glycosylated hemoglobin A1c is 
of prime importance since the HbA1c level remains consistent over several months and is a 
strong indicator of diabetes complications (Sacks 2002, Knowler 2002, Sttraton 2000). Hence the 
HbA1c test should be done initially while making the diagnosis and later at regular intervals in 
diabetic patients (ADA 2008). Research states that a 1 percent reduction in mean HbA1c level is 
correlated with a 21 percent reduction of risk of micro vascular complications, myocardial 
infarction, amputation and stroke (UKPDS 1998, Sttraton 2000). 
Evidence about the association of mortality and intensive treatment in diabetes patients is 
inconclusive. Results of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) 
study indicate that among the two groups that aimed to reduce CVD with intensive interventions 
targeting a HbA1c level of less than 6 versus a HbA1c level of less than 7-7.9 percent 
respectively, the group that aimed achieving a HbA1c level of less than 6 showed higher CVD 
mortality (Gerstein 2008). Two other trials, the Action in Diabetes and Vascular Disease: 
Preterax and Diamicron MR Controlled Evaluation (ADVANCE) trial, and the Veterans Affairs 
Diabetes Trial had different interventions than the ACCORD trial and both the trials showed no 
CVD mortality in patients aiming for an HbA1c level of 6.5 percent unlike the ACCORD study 
(Patel 2008). There is also evidence showing improvement in CVD outcomes as a result of 




Examination Survey data to study the 1999-2006 national trends in achieving diabetes 
therapeutic goals, mainly looking at diabetes prevalence, treatment, and management. The study 
looked if the 17,306 study participants aged 20 years or older met ADA standards of medical 
care by achieving HbA1c level of less than 7 percent, blood pressure of 130/80 mmHg and LDL 
less than 100 mg/dl. Study results showed that from 1999-2006, the prevalence of diabetes 
increased from 6.6% to 7.8%, number of overweight people with HbA1c level of less than 7 
percent significantly increased from 43.1% to 57.1%, number of people with blood pressure of 
130/80 mmHg increased from 39.2% to 45.5% and the number of obese people with LDL less 
than 100 mg/dl increased from 36.1% to 46.5%. The number of patients achieving all the three 
targets increased from 7% to 12.2%. Difficulty in achieving all the three target goals at the same 
time was evident from the fact that only one in every eight study participant could do it (Cheung 
2009, Kuritzky 2011). The main goal of diabetes management is providing affordable and 
effective treatment to the patients with minimum risk of side effects. In a meta-analysis study 
looking at the impact of adding a third OHA to the medication regimen of type 2 diabetes 
patients who were already on a metformin and a sulfonylurea and had HbA1c of more than 7 
percent, the results indicated that HbA1c reduced by 0.7 percent and 1.08 percent for acarbose 
and insulin users respectively, hypoglycemic episodes doubled in frequency with insulin intake, 
weight increased by 2.84 kg and 4.25 kg with insulin and thiazolidinedione intake and weight 
reduced by 1.63 kg with glucagon-like peptide-1 agonist intake respectively. The researchers 
concluded that addition of a third OHA was not of significant benefit and if a third OHA was 





Enforcing of stringent A1c goals through treatment intensification should be done with caution 
in children, patients with severe hypoglycemia, and patients with comorbid conditions such as 
CVD, stable micro vascular complications, short life expectancy and long standing diabetes 
(ADA 2008). Research states that intensive glycemic control is not very beneficial in 
functionally impaired elderly patients with multiple comorbidities so treatment intensification or 
A1c reduction should be based on clinical judgment, the existent treatment plan and need for 
appropriate care (Nathan 2009, Huang 2008). According to the ADA recommendations, the 
frequency of A1c testing in patients with glycemia under control should be twice annually 
whereas in patients with unstable glycemia or patients managed with highly intensive therapy 
such as pregnant women with type 1 diabetes, the frequency should be four times annually (ADA 
2008). 
2.1.4 Treatment of type 2 diabetes  
2.1.4.1 Lifestyle interventions: 
People in general, are at a risk of developing chronic disease conditions if they do not lead a 
healthy lifestyle. Statistics such as one in every 3 Americans developing diabetes over their 
lifetime, even though surprising, indicate the need to proactively adopt healthy eating habits, be 
physically active and have optimal weight (Narayan 2003). This proactive approach known as 
“primordial prevention” consists of preventive measures to alleviate the risk factors of chronic 
disease conditions by modifying the environmental factors and social values that shape people’s 
health behavior. Primordial prevention is effective in people with a low risk of developing 
chronic disease conditions but in people with a high risk of developing chronic disease 




blood glucose levels are impaired, there is a need for more intensive lifestyle interventions. Such 
interventions are part of “primary prevention” and involve incurring costs, screening of high risk 
individuals, and using medications to delay or prevent the early onset of diabetes.  Many 
randomized controlled trials conducted worldwide have attested to the delay or prevention of 
early onset type 2 diabetes as a result of intensive lifestyle interventions involving diet, exercise 
and medication usage (Pan 1997, Tuomilehto 2001, Knowler 2002, Ramachandran 2006, 
Chiasson 2002, Gerstein 2006). 
The National Diabetes Education Program (NDEP) has a number of educational materials that 
consists of interventions to prevent the progression of pre diabetes to type 2 diabetes for people 
belonging to racial minorities such as African Americans and Latinos who are at a higher risk of 
developing type 2 diabetes (NDEP website (c,d)). To reduce the incidence of micro and macro 
vascular complications associated with type 2 diabetes especially cardiovascular conditions, the 
NDEP, ADA and AACE (American Association of Clinical Endocrinologists)/ACE (American 
College Of Endocrinology) recommends the achievement of the following goals: A1c levels less 
than 7, blood pressure of 130/80, low density cholesterol less than 100 and high density 
cholesterol more than 40 (NDEP website (a,b)). Lifestyle interventions for preventing or 
delaying the transition of pre diabetes to type 2 diabetes are recommended by healthcare 
providers, insurance providers and employers. A randomized controlled trial “Diabetes 
Prevention Program” (DPP) conducted over a period of 3 years showed that a 16-week intensive 
lifestyle counseling intervention comprising of instructions on consuming the right diet and 
performing physical activity contributed to an average weight loss of 5.6 kg. About half the 
participants of the trial lost 7% of their initial body weight and the transition of pre diabetes to 




another 7 years, 85% of the participants who remained in the trial did regain about 5 kg of the 
lost weight. Compared to the placebo group, there was a reduction in the transition from pre 
diabetes to type 2 diabetes by 34% and 18% among the participants in the intensive lifestyle 
group and the metformin group respectively (Knowler 2009). The results of another randomized 
controlled multicenter trial AHEAD (Action for Health in Diabetes) showed that during a period 
of 4 years, patients with type 2 diabetes who were provided education, support, diet restricted in 
calories and who exercised regularly lost 6.15% weight compared to the control group patients 
with type 2 diabetes who received only support and education and lost only 0.88% weight. In 
addition, changes such as reduction in A1c levels, blood pressure and triglyceride levels and 
increase in the high-density lipoprotein cholesterol levels were seen in the participants in the 
intensive treatment group (Wing 2010). The ADA and AACE/ACE guidelines for the patients 
with pre diabetes and diabetes recommend strength training two times per week, medical 
nutrition therapy for weight loss and dyslipidemia, 150 minutes per week moderate physical 
activity, smoking cessation and loosing 7% of the body weight for overweight/obese patients. 
The last recommendation is in response to the findings of the DPP study (Handelsman 2011, 
ADA 2011). 
2.1.4.2 Medications: 
Medication therapy in type 2 diabetes helps in achieving the optimum glycemic control and also 
controlling the related micro and macro vascular complications (UKPDS 33 1998, Stratton 
2000). Two decades ago, the favored therapy of choice for type 2 diabetes comprised of proper 
diet control, frequent exercising, using sulphonlyurea as medication and injecting insulin if the 
medications failed to work (Scheen 1998). Overall, oral hypoglycemic agents (OHAs) do help in 




number of factors such as the duration of type 2 diabetes, previous therapy, clinical and 
biochemical markers and baseline glycemia. Selection of a particular OHA or a class of OHAs or 
decision to change OHAs is primarily linked to obtaining the desired level of glycemic control 
(Peters 1996, Krentz 2005). In order to achieve the desired glycemic control, the dosing of OHA 
is individualized for every type 2 diabetes patient based on a variety of factors like side effects of 
OHAs, ease of use, tolerance, long term adherence and cost of OHAs (Nathan 2009). Often, in 
type 2 diabetes patients newly starting OHA therapy, OHAs are initiated at a lower dose and the 
dosing is adjusted accordingly upon regularly monitoring the HbA1c levels (Krentz 2005).  The 
National Diabetes Statistics estimated by the 2007-2009 National Health Interview Survey show 
that among US based adults with either type 1 or type 2 diabetes, 58% consume only oral 
medications, 14% take both insulin and oral medications, 12% take only insulin and the 
remaining 16% do not take either of the two (National Diabetes Statistics 2011).  Type 2 diabetes 
patients have insulin deficiency. Initiating diabetes medication therapy is based on the accurate 
judgment of either insulin resistance or defective insulin secretion. If the HbA1c levels are more 
than 8.5%, OHAs with rapid glucose lowering effects or a combination dose are recommended 
compared to patients with new onset of type 2 diabetes who have HbA1c level less than 7.5% 
and in whom OHAs with slower glucose lowering effect that can be recommended (Peters 1996). 
As type 2 diabetes progresses with worsened glycemic control, the dosage and the number of 
OHAs are increased accordingly (Nathan 2009). 
OHAs can be categorized into three groups on the basis of their mechanism of action:  
(a) insulin secretagogues: OHAs that increase insulin secretion 
(b) α-glucosidase inhibitors: OHAs that delay absorption and digestion of carbohydrates 




Table 2.1: Pharmacologic Therapy to Type 2 Diabetes Patients 






Dipeptidyl-peptidase 4 inhibitors 
a-Glucosidase inhibitors 
Monitor and titrate medication for 2-3 months 
Consider combination therapy if glycemic goals are not met at the end of 2-3 months 
B) Initiate combination therapy when HbA1C levels are 7%-8% 
Options include: 
 
Secretagogue + metformin 
Secretagogue + thiazolidinedione 
Secretagogue + a-glucosidase inhibitor 
Thiazolidinedione + metformin 
Dipeptidyl-peptidase 4 inhibitor + metformin 
Dipeptidyl-peptidase 4 inhibitor + thiazolidinedione 
Secretagogue + metformin + thiazolidinedione 
Fixed-dose (single pill) therapy 
Thiazolidinedione (pioglitazone) + metformin 
Thiazolidinedione (rosiglitazone) + metformin 
Thiazolidinedione (rosiglitazone) + secretagogue (glimepiride) 
Thiazolidinedione (pioglitazone) + secretagogue (glimepiride) 
Secretagogue (glyburide) + metformin 
Rapid-acting insulin analogs or premixed insulin analogs may be used in special situations 
Inhaled insulin may be used as monotherapy or in combination with oral agents and long-acting insulin 
analogs 
Insulin-oral medications; all oral medications may be used in combination with insulin; therapy 
combinations should be selected based on the patient’s self-monitoring of blood glucose profiles 
Initiate/intensify combination therapy using options listed above when HbA1C levels are 8%-10% to 
address fasting and postprandial glucose levels 
C) Initiate/intensify insulin therapy when HbA1C levels are >10% 
Options include: 
 
Rapid-acting insulin analog or inhaled insulin with long-acting insulin analog or NPH 







(a)Insulin secretagogues:   
(i)Sulfonylureas:  
Sulfonylureas have been used as OHAs since 1950s. Tolbutamide belonging to the class of 
sufonlyureas is an insulin secretagogue and was the first OHA introduced in 1956 (Scheen 
1998). Besides tolbutamide, some other older and first generation sulfonylureas that have been 
since the last four decades are acetohexamide, chlorpropamide and tolazamide. Compared to the 
first-generation sulfonylureas, the second generation sulfonylureas were prescribed in smaller 
doses since they had higher potency with lower side effects (Luna 2001). The third generation 
sulfonylureas are glipizide (brand names Glucotrol® and Glucotrol XL®), glyburide 
(Micronase®, Glynase®, and Diabeta®), and glimepiride (Amaryl®). All drugs under the 
sulfonylurea class have a similar mode of action. They stimulate secretion of insulin from 
pancreas, thereby reducing the concentration of blood glucose. Sulfonylureas are well tolerated, 
have simple dosing; are inexpensive and are given as first line therapy once or twice per day 
before meals to patients in whom non pharmacologic attempts have failed to achieve glycemic 
control.  Though the mode of action among the different drugs belonging to sufonlyurea class is 
similar, the side effects differ with regards to the method of intake and the interaction with other 
drugs. Sulfonylureas are compatible with all classes of OHAs except with insulin secretagogues. 
Sulfonylureas are potent, safe and cost effective OHAs for diabetes management but they have 
certain side effects which include hypoglycemia, hypoglycemic coma, secondary failure, weight 
gain, cutaneous sensitivity reactions and severe hypoglycemia (with long acting sulfonylureas) 
(Luna 2001, Chipkin 2005, Riddle 1999).  
(ii)Meglitinides: 
Derivatives of meglitinides and phenylalanine used in patients with type 2 diabetes are 




market in 1998 and 2001 respectively and are non-sulfonylurea secretagogues. Their mode of 
action is similar to sulfonylureas but their half life is just 1 hour which is much shorter compared 
to sulfonylureas. They are directed to be consumed before or during meals. Since repaglinide and 
nateglinide are similar to sulpohnlyureas, there is no added advantage taking them in addition to 
sulphonlyureas (Luna 2001, Quillen 2002, Chipkin 2005). Repaglinide and nateglinide offer 
several advantages. Both the drug classes are preferred by people who do not follow a regular 
schedule of eating meals or people who generally forget to eat their meals. They can be taken as 
monotherapy, are associated with a low risk of hypoglycemia and do not lead to weight gain 
compared to sulfonylureas. Repaglinide and nateglinide are also preferred in patients with renal 
insufficiency since they are metabolized and excreted by hepatic mechanism. On the downside, 
repaglinide and nateglinide have to be taken a number of times during the day since they do not 
sustain high levels of insulin and they are also more expensive than sulfonlyureas (Luna 2001, 
Chipkin 2005, Riddle 1999).  
(b) Insulin sensitizing agents:  
(i)Biguanides:  
Phenformin was released in the US in 1976 but was withdrawn due to high risk of fatal lactic 
acidosis. Then in 1994, another biguanide metformin (brand name Glucophage®) was released. 
Metformin improves insulin sensitivity and lowers blood glucose levels. It does not cause 
hypoglycemia. For metformin to be clinically effective, insulin should be present since it does 
not stimulate insulin release. It reduces blood glucose level by increasing the insulin sensitivity 
of the muscle tissue, thereby improving glucose absorption and by decreasing glucose production 
from the liver. Metformin acts in presence of beta-cell function and is not related to age or 




overweight type 2 diabetes patients since it leads to a slight weight loss by acting as an appetite 
suppressant. It is a cheap OHA, used as monotherapy or in combination with other OHAs or 
insulin, has a favorable lipid and antihypertensive effect and works effectively in patients with 
normal weight. Research has shown reduction in the risk of myocardial infarction in overweight 
patients taking metformin (UKPDS 34, 1998). Metformin is contraindicated in patients with 
renal impairment and liver disease. Renal impairment can lead to a rare life threatening 
occurrence of lactic acidosis caused by intake of metformin with mortality rates as high as 50%  
(Qullien 2002, Luna 2001, Chipkin 2005, Riddle 1999). Other side effects of metformin include 
gastrointestinal (GI) problems such as diarrhea and bloating, metallic taste in the mouth and 
changes in the vitamin B12 levels (Luna 2001, Chipkin 2005, Riddle 1999). 
(ii)Thiazolidinediones (TZD):  
 Troglitazone was the first thiazolidinedione (TZD) introduced in the US in 1997, followed by 
rosiglitazone and pioglitazone in 1999. Troglitazone, unlike rosiglitazone and pioglitazone was 
withdrawn from the market due to hepatotoxicity in 2000 (Vasudevan 2004, Bailey 2000, Krentz 
2000, Quillen 2002). TZDs act via various modes. They improve insulin sensitivity by the 
stimulation of a nuclear receptor PPARγ. TZDs do not stimulate insulin production by pancreas 
but improve insulin sensitivity by increasing the GLUT-1 and GLUT-4 glucose transport 
proteins and up-regulating insulin responsive genes. Genes involved in lipid and carbohydrate 
metabolism are activated by TZDs as a result of gene regulation.  TZDs increase skeletal muscle 
sensitivity and enhance glucose and fatty acid uptake by adipose tissues leading to increased 
lipogenesis, glycolysis, and glucose oxidation. In liver, there is decreased gluconeogenesis, 
glycongenolysis and increased lipogenesis (Vasudevan 2004). TZDs are expensive, can cause 




can be used as monotherapy or in combination with metformin, sulfonylureas and insulin. 
Substitution of TZD with sulfonylurea or metformin is not preferred (Riddle 2005).  
Rosiglitazone and pioglitazone are contraindicated in patients with liver disease, cardiovascular 
diseases, congestive heart failure or other fluid overloaded diseases and both the drugs reduce 
portion of smaller atherogenic low density lipid (LDL) cholesterol (Lago 2007, Singh 2007). 
Anti-atherogenic actions of TZDs and its association with the risk of CVD can have important 
clinical implications and the related research is being conducted currently through clinical trials. 
Rosiglitazone leads to a rise in the total cholesterol concentration for upto three months of 
initiating the TZD therapy whereas pioglitazone decreases triglyceride concentrations and the 
effectiveness of oral contraceptives (Roberts 2003, Luna 2001, Chipkin 2005, Riddle 1999).  
(c) alpha-glucosidase inhibitors:  
These OHAs have a non systematic mode of action. They block the breakdown of starches in the 
intestine, inhibit the α-glucosidase enzyme which converts carbohydrates to glucose and leads to 
a delay but not prevention in the absorption of carbohydrates and complex sugars. There are 
three types of alpha-glucosidase inhibitors available for treatment, out of which two are available 
in the US market: acarbose (brand name Precose®) and meglitol (Glyset®). The third alpha-
glucosidase inhibitor unavailable in the US is voglibose. These OHAs are a bit on the enpensive 
side and can be used individually or in combination. Some advantages of alpha-glucosidase 
inhibitors are that they do not cause weight gain and have plasma triglyceride concentration 
lowering ability (Ogawa 2004, Chiasson 2004). They target postprandial hyperglycemia and 
therefore are suitable for use in patients consuming complex carbohydrates since they have 
slightly raised basal glucose concentration. Acarbose leads to hepatic toxicity and hence meglitol 




discomfort; mostly flatulence, diarrhea, and bloating (Kuritzky 1999). Hence, they are 
contraindicated in patients with limited gastrointestinal tolerance or with chronic intestinal 
diseases (Luna 2001, Chipkin 2005, Riddle 1999). 
2.1.4.3 Insulin therapy: 
In case of type 2 diabetes patients, in whom the medication therapy does not help in controlling 
blood glucose levels, insulin therapy is recommended (DeFronzo 1999). Insulin therapy is 
generally used in patients when one medication or a combination of medications alone fail to 
lower blood glucose level or in pregnant patients or in patients with severe hepatic or renal 
impairment. Insulin therapy is not widely used in type 2 diabetes patients due to potential 
disadvantages such as hypoglycemia, weight gain, and non-adherence to complicated insulin 
therapy (Brunton 2006, Riddle 2002). Besides the above disadvatnages associated with insulin 
therapy, patients feel anxious due to use of needles, pain caused by injection, social stigma 
associated with insulin intake, difficulty in administration, perceived severity of the disease 
condition and frequent dosing (Polonsky 2004, Korytkowski 2002, Peyrot 2003). Insulin therapy 
does have several benefits. Not only does it improve insulin sensitivity and causes reversal of 
insulin resistance in type 2 diabetes patients, it also improves HbA1c levels when used in 











2.1.5 Medication adherence in patients with type 2 diabetes  
2.1.5.1 Impact of medication adherence on type 2 diabetes outcomes:  
Medication adherence is a crucial part of the treatment process; non-adherent behavior may 
create bottlenecks that may limit the effectiveness of medication and care provided by the 
healthcare system. In the context of diabetes, this bottleneck is evident in poor adherence rates to 
diabetes medication (36% to 93%) that limit the effectiveness of newly developed drugs and 
therapies (Cramer 2004). This may also explain, to some extent, the low proportion (43%) of 
diabetes mellitus patients with acceptable HbA1c levels of below 7%, recommended by 
American Diabetes Association (Saaddine 2002, Kerr 2004, ADA, 2008). 
In context of diabetes, medication adherence has been found to be related with a wide range of 
outcomes, both medical and non-medical. Adherence has been associated with enhanced blood 
glucose control (Rozenfeld 2008, Ho 2006, Krapek 2004, Lawrence 2006, Schectman 2002, 
Pladevell 2004), and reduced mortality (Ho 2006). Among economic and administrative 
outcomes, adherence has been associated with fewer inpatient visits (Lau 2005) and lower 
health‐care costs (Sokol 2005, Hepke 2004).  
Various adherence studies in the context of diabetes have focused on glycemic control, economic 
burden (Abegunde 2007, Pohar 2007), complications associated with diabetes (UKPDS 1998) 
and medication cost-effectiveness (Salas 2002, Valentine 2007). A study in a managed care 
setting demonstrated higher glycemic control among adherent patients and found that high OHA 
medication adherence was associated with lower HbA1c levels. Using baseline HbA1c and 
therapy regimen as controls, the study found that with each 10% increase in OHA medication 




(2004), higher adherence levels were associated with a 10% reduction in HbA1c (Krapek 2004). 
Looking at economic and administrative outcomes, another study of 57,687 diabetic patients in 
an HMO showed that those with increased OHA medication adherence had fewer emergency 
department visits, fewer inpatient admissions, and decreased medical care costs (Hepke 2004). In 
a retrospective cohort (N = 11 532) analysis by Ho and colleagues, 62 non-adherent diabetic 
patients had higher all cause inpatient visits and all‐cause mortality than adherent diabetes 
patients (Ho 2006). In a range of studies, low medication possession ratios (MPRs), an indicator 
of poor medication adherence, were generally associated with higher costs among patients with 
type 2 diabetes. A study by Balkrishnan et al (2003) reported a 10% increase in anti- diabetic 
medication adherence to be associated with 8.6% reduction in total annual healthcare costs 
(Balkrishnan 2003). Another study by Wagner reported that the mean annual costs for Medicaid 
patients with baseline HbA1c<8 were $4475, whereas mean annual cost for patients with 
HbA1c>10 were $8088 (Wagner 2001). Connecting these findings with the previous findings 
associating adherence and HbA1C levels, it can be argued that since adherence levels are 
inversely proportional to HbA1c levels, mean annual costs will be higher for non-adherent 
patients who are more likely to have higher HbA1C levels.  
2.1.5.2 Barriers to medication adherence in type 2 diabetes patients: 
WHO classifies the factors impacting pharmacologic and non-pharmacologic adherence to type 2 
diabetes as:  
A) Treatment and disease characteristics:  
This factor consists of three components, namely complexity of treatment, duration of disease 




frequent dosage intake (Paes 1997, Dailey 2001).  Longer duration of diabetes is associated with 
less likelihood to take insulin or perform physical activity and higher likelihood of consuming 
inappropriate food (Glasgow 1987, Jarosz 2000). Cost of care affects access to care which in turn 
impacts metabolic control. Diabetic patients visiting their physicians for diabetes rather than for 
an acute condition have a higher probability of receiving counseling on adherence to diet and 
medications (Yawn 2001, Kern 2001). 
B) Intra-personal factors: 
These factors consist of age, gender, self-esteem, self-efficacy, stress, depression and alcohol 
abuse. Older age, being a female, positive self-esteem and higher self-efficacy  are associated 
with higher adherence to diabetes self-care including insulin administration,  monitoring blood 
glucose, performing physical activity, higher life satisfaction and medication adherence 
(Andersen 1997, Stetson 2000, Kneckt 2001, Plotnikoff 2000, Senecal 2000, Ott 2000, Aljasem  
2001). On the other hand, stress, emotional problems, depression and alcohol abuse are 
associated with poor adherence to OHAs, diet and self-care, worsened glycemic control, more 
diabetes complications and less frequent glucose monitoring (Andersen 1997, Peyrot 1999, De 
Groot 2001, Lustman 2000, Ciechanowski 2001, Johnson 2000). 
C) Inter-personal factors: 
Two important inter-personal factors such as a positive patient physician relationship and 
availability of social support can lead to better adherence to OHAs (Ciechanowski 2001), diet 
and insulin administration (Ruggieron 1990) and regular monitoring of blood glucose level 
(Anderson 1997).   
D) Environmental factors:  




are situations that lead to reduced adherence. Such situations can arise at home, at work or in 
public. Some of the high risk situations that are associated with poor adherence to diabetes self-
care are over eating and under eating, loneliness, social events, time pressure, holidays, eating 
out and competing priorities (Schlundt 1994 (a), Schlundt 1994 (b), Schlundt 1989).  
Environmental factors such as economic, agricultural, political, healthcare related, geographical, 
ecological and culture related affect people over a longer course of time rather than impacting 
immediately or in a shorter duration (Ramlogan 1997, Miller 2002).  
 Table 2.2: Factors affecting adherence to diabetes therapy for the control of diabetes and 
interventions for improving it (WHO 2003): 
Diabetes 
 
Factors affecting adherence 
 
Interventions to improve adherence 
Socioeconomic- 
related factors 
(-)Cost of care, patients aged over 
25 years, environmental high-risk 
situations,(+) social support , 
family support , patients aged less 
than 25 years 
Mobilization of community-based organizations; 





 (-)Poor relationship between 
patient and physician  
Multidisciplinary care; training of health 
professionals on adherence; identification of the 
treatment goals and development of strategies to 
meet them; continuing education; continuous 
monitoring and reassessment of treatment; 
systems interventions: health insurance for 
nutrition therapy, telephone reminders to 




(-)Depression; duration of disease  Education on use of medicines  
Therapy-related 
Factors 
(-)Complexity of treatment, (+) 
Less frequent dose; monotherapy 
with simple dosing schedules; 
frequency of the self-care 
behaviour  
Patient self-management; simplification of 
regimens ; education on use of medicines 
Patient-related 
Factors 
(-)Depression; stress and 
emotional problems; alcohol 
abuse, (+)Positive self-
esteem/self-efficacy 
Behavioural and motivational interventions, 
assessment of psychological needs 
 




2.1.5.3 Different measures of medication adherence:  
Diabetes treatment is a multidimensional process that involves elements like medications, dietary 
controls and other behavioral and lifestyle changes. However, one of the frequently used 
adherence measure focuses on medication adherence and is considered one of the most important 
adherence measures. Nonadherence specific to medication has been associated with increased 
economic burden and adverse health conditions (Hearnshaw 2006, Dunbar-Jacob 2001, Lau 
2004, Lee 2006, Sokol 2005). Medication adherence measures are being used as part of the 
Healthcare Effectiveness Data and Information Set (HEDIS) quality measures to assess plan 
quality and plan payment systems, and since Medicare provides Medication Therapy 
Management  (MTM) services, many MTM providers develop and validate adherence measures 
to evaluate MTM services ( Touchette 2006, Christensen 2003).  
In 2001–2003, 57% of diabetic patients were using oral medications, whereas only 12% patients 
were using a combination of oral medications and insulin (CDC 2005). Since diabetes is a 
chronic disease and medication adherence plays an important role in its management, 
standardizing adherence calculations for diabetic patients has become an important objective. 
Use of administrative claims data is emerging as one of the most prominent sources for 
adherence calculations. Though adherence measures based on administrative claims data are 
highly likely to overestimate adherence due to their inability to access consumption, and also 
pose issues in cases where multiple medications are being procured from multiple pharmacies by 
the patient, they tend to provide a practical, unobtrusive, relatively inexpensive and effective way 
of collecting data for large populations. Anderson et al (1997) demonstrated that out of 136 
studies using administrative claims data for adherence calculations, about 57% used MPR and 




gaps. Adherence measures using pharmacy claims data have been validated when used with 
other measures such as patient reports, pill counts, questionnaires, and interviews (Garber 2004, 
Choo 1999, Cook 2005, Grymonpre 2006, Kwon 2003, McKenzie 2000).  
Some of more common adherence measures are Medication possession ratio (MPR), Medication 
refill adherence (MRA), and Continuous measure of medication acquisition (CMA),  Proportion 
of days covered (PDC), days between fills adherence rate (DBR) and refill compliance rate 
(RCR), Compliance ratio (CR), Medication possession ratio modified (MPRm), Continuous 
measure of medication gaps (CMG) , Continuous multiple interval measure of oversupply 
(CMOS) and Continuous, single interval measure of medication acquisition (CSA). Out of these 
measures, MPR, MRA, and CMA seem to be similar and yield equivalent values. Similarly, 
DBR and RCR measures provide equivalent values. Karve et al (2008) found most medication 
adherence measures to be significant predictors of inpatient admission; RCR, CR, and CSA were 
the measures that did not predict inpatient admission significantly. Among the rest of measures 
considered in the study, PDC, MPR, CMOS, and CMG were the best predictors of future 
inpatient visits (any cause and diabetes related). While predicting any cause inpatient visits, 
MPR and CMOS were similar to PDC and CMG; they were also the second best predictors of 
inpatient visits due to diabetes. PDC, MPR, CMOS, and CMG were found to be better predictors 
of inpatient visits than other measures, and PDC and MPR both provided higher values for more 
compliant patients. Overall, measures using the entire index period of 365 days as denominator 
in the formula predicted inpatient visits better than measures using period between first and last 






Table 2.3: Formulae for measuring adherence (Karve 2008): 
Adherence measure  Formula  
Medication possession ratio (MPR)  Number of days supply in index period/number of 
days in the study period (365 days) 
Medication refill adherence (MRA)  
 
[number of days supply in index period/number of 
days in the study period (365days)]×100 
Continuous measure of medication acquisition 
(CMA)  
 
Number of days supply/total days to  
next fill or end of observation period  
(365 days)  
Proportion of days covered (PDC)  
 
[Number of days supply in index period/  
number of days in the study period (365  
days)] ×100 capped at 1  
Refill compliance rate (RCR)  (Number of days supply/last claim date -index 
date) × 100  
Days between fills adherence rate (DBR)  
 
1 – [(last claim date ‐ index date) ‐ total  
days supply/last claim date] index date] x 100 
Compliance ratio (CR)  
 
Number of days supply in the index  
period ‐ last days supply/last claim date ‐ 
index date  
Medication possession ratio modified (MPRm)  [Number of days supply/(last claim date‐ index 
date + last days supply)] × 100  
Continuous measure of medication gaps (CMG)  
 
Total days of treatment gaps/total days  
to next fill or end of observation period (365 days)  
Continuous multiple interval measure of 
oversupply (CMOS)  
 
Total days of treatment gaps (+) or surplus (‐)/ total 
days to next fill or end of observation period (365 
days) 
Continuous, single interval measure of 
medication acquisition (CSA) 
Days supply obtained at the beginning of the 
interval/days in interval 
 
2.1.5.4 Measuring medication adherence in type 2 diabetes patients:  
Though compliance has been of interest to researchers for a long time, there is no standard way 
to define and measure compliance (Cleemput 2002). Compliance essentially is the level to which 
a patient follows the medication regimen prescribed by the healthcare provider (Osterberg 2005). 
Some researchers prefer to use the term ‘adherence’ instead of ‘compliance’ because the use of 




indicator of the more active role that the patient plays in the treatment process and implies a 
patient centric conceptualization of the treatment process (Tabor 2004).  
One of the key problems for compliance researchers is the variability in compliance 
measurement methods (Murray 2004). The lack of standardized compliance measurement may 
be primarily due to the range of variation in the nature of health problems and medication 
regimens. Diseases with multimodal treatment regimen may need different measures than 
diseases with simple medication regimens (Kyngas 2000). For example, in a multimodal regimen 
consisting of medication and behavioral therapy, it may be hard to identify compliance for each 
component and associate them with the health outcomes. In other words, compliance with one 
component of the regimen may not be appropriate when the success is caused by other 
components, or by the interaction of all the components of the regimen.  
Existing methods for measuring compliance can be categorized into two types; direct methods, 
and indirect methods. Direct methods mostly involve medical testing such as assessment of 
blood, urine and saliva to determine drug concentration levels. Though these provide relatively 
objective, reliable and quantifiable data, the cost and resources involved in such measurements 
may prove barriers to their widespread use in real life medical settings (Kyngas 2000). Indirect 
methods are based on collecting information that may be considered a predictor of compliance; 
such information may include patient reports, pill counts, refill adherence, and electronic 
monitoring using microchip technologies. Though indirect methods are more viable in terms of 
resources and costs involved, they also suffer from various limitations to their reliability. For 
example, pill counting takes the consumption over a period of time into account and cannot 
measure the timing of the dosage; this not only limits the reliability but also makes the method 




(MEMS), a relatively expensive method than pill counting, provides a better compliance 
measurement but is not able to ensure if the patient takes the medication or not. Another indirect 
method used at the pharmacy level is refill adherence that involves tracking of patient medication 
refills using computerized prescription records. There are two commonly used measures of refill 
adherence; Proportion of days covered (PDC), and Medication possession ratio (MPR). PDC is 
calculated by dividing the number of days of drug coverage by the number of days in the refill 
interval; it avoids double counting of days and provides a value between 0 and 1. MPR, on the 
other hand, involves counting the number of days supplied by the prescriptions filled during the 
period. Though more viable in terms of costs and resources, refill adherence methods suffer from 
limitations similar to ‘pill counting’: it is not possible to get data about actual medication 
consumption on a daily basis. 
In previous studies, medication adherence has been found to display a wide range of variations. 
A systematic review study conducted from 1966 to 2003 using adherence data for oral 
hypoglycemic agents (OHAs) and insulin reviewed 20 reports looking at correlations between 
adherence and glycemic control (Cramer 2004). The findings showed that adherence to OHAs 
reported by retrospective studies ranged from 36% to 96% (among patients on medication for 6-
24 months), whereas prospective studies using electronic monitoring devices showed adherence 
rates ranging from 67% to 87%. The review indicated that electronic-monitoring devices may be 
more effective in measuring adherence and may capture medication consumption missed by 






Table 2.4 Methods for measuring medication adherence (Osterberg 2005):  
Methods Advantages Disadvantages 
Direct Methods   
Directly observed 
therapy 
Most accurate Patients can hide pills in the mouth and then 
discard them; impractical for routine use  
Measurement of the 
level of medicines or 
metabolite in blood 
Objective Variations in metabolism and “white‐cost 
adherence” can give a false impression of 
adherence; expensive  
Measurement of the 
biologic maker in 
blood  
Objective  Requires expensive quantitative assays and 
collection of bloody fluids 
Indirect Methods:   
Patient 
questionnaires, 
patient self‐reports  
Simple; inexpensive; the 
most useful method In the 
clinical setting 
Susceptible to error with increases in time 
between visits; results are easily distorted by the 
patient  
Pill counts  Objective, quantifiable, and 
easy to perform 
Data easily altered by the patient (e.g., pill 
dumping)  
Rates of prescription 
refills  
Objective; obtain easy to 
data 
A prescription refill is not equivalent to ingestion 
of medication; requires a closed pharmacy 
system  
Assessment of the 
patient’s clinical 
response 
Simple, generally easy to 
perform 
Factors other than medication adherence can 
affect clinical setting 
Electronic medication 
monitors 
Precise; results are easily 
quantified; tracks patterns of 
taking medication 
Expensive; require return visits and downloading 




(eg: heart rate in 
patients taking beta-
blockers) 
Often easy to perform Marker may be absent for other reasons (e.g., 
increased metabolism, poor absorption, lack of 
response  
Patient diaries  
 
Help to correct for poor 
recall 
Easily altered by the patient  
When the patient is a 
child, questionnaire 
for caregiver or 
teacher  
Simple; objective Susceptible to distortion 
 
2.1.6 Burden of type 2 diabetes and related resource utilization in Medicaid patients  
Chronic diseases place a substantial disease burden on the society. From a clinical perspective, a 




showed that around 50% of the overall U.S. healthcare expenditures can be accounted for by one 
or more of the five conditions that affects about one quarter of the U.S. population. These 
conditions are mood disorders, diabetes, heart disease, asthma, and hypertension. Comorbidity 
was found to be most common among diabetics and infections, microvascular and macrovascular 
diseases accounted for a large portion of clinical and economic burden of diabetes. 
From the economic burden standpoint, a secondary data analysis of the 2002 National Survey of 
America’s Families by Shen et al (2006) analyzing out-of-pocket spending on healthcare 
reported that health insurance did not necessarily reduce the financial healthcare burden. This 
was demonstrated by the fact that a substantial number of two million people experiencing 
medical bankruptcy in 2002 had health insurance. In spite of having insurance, medical costs did 
create financial constraints, which were experienced more severely by people from low-income 
group and affected their usage of medication and emergency services. Insured people in low-
income groups with serious health issues spent less on healthcare than people in high-income 
groups. Another secondary study of the 2000-2004 Medical Expenditure Survey (MEPS) by 
Banerjee et al (2010) showed that among adults enrolled in Medicaid, after controlling for 
employment and health status, individuals with more than one transition in health insurance 
status were more likely to have higher rates of healthcare utilization than those with one or no 
transition. Among people without continuous Medicaid coverage, the use of emergency 
department and office visits and inpatient visits increased by 10% and 36%, whereas the use of 
prescription medications decreased by 19%. 
Financial constraints may reduce access to prescriptions and may lead to non-adherence that may 
increase overall economic burden. A pre-post study of 36 patients with lower socioeconomic 




charges dropped from $838,145 to $459,962 from 6 months prior to the study to 6 months during 
the study (NyKamp 2000). The costs of drugs were $27,588 for the program and the cost 
avoidance was $378,183. This cost was avoided due to decrease in inpatient visit rates by 39.5% 
and increase in outpatient visits by 64.4%. This shows that though among under or uninsured 
people, the economic burden for chronic disease management is high (Banerjee 2010, Bogner 
2010, Druss 2001, Shen 2006), focus on increasing adherence may restrict hospital and 
emergency department visits and may result in overall cost saving.  
This relationship between adherence and utilization of healthcare service has been examined by 
numerous studies. A review of 37 studies by Asche et al (2011) analyzed the association between 
adherence and glycemic control, healthcare resource utilization, quality of life and mortality 
among diabetic patients. In 23 out of 37 studies examining glycemic control and adherence, 57% 
patients reported a positive relationship. Seven of the eight studies examining relationship 
between adherence and inpatient visits reported that higher level of adherence was associated 
with decrease in inpatient visit rates. Two of the three studies examining adherence and 
emergency department visits reported that increased adherence was associated with decrease in 
emergency department visits. A study by Lu et al (2004) used the administrative claims data 
from 2000 to 2001 for studying type 2 diabetes patients. The study reported that patients’ non-
adherent (MPR<80%) to antihyperglycemic agents in 2000 faced greater risk of inpatient visits 
in 2001. 
Though adherence may reduce inpatient visits and emergency visits, it may not always result in 
reduction of overall medical care expenditures. A prospective cohort study by Hepke et al (2004) 
used insurance claims to examine the association between adherence to pharmaceutical therapy 




adherence to be associated with decreased inpatient and emergency department visits. However, 
the researchers also found that even though increased adherence was associated with decreased 
medical care costs, it was not associated with reduction in overall healthcare costs as high 
medication costs offset the decrease in medical care costs. Similarly, Sokol et al (2005) 
conducted a large retrospective cohort observation study to examine the association between 
adherence and healthcare utilization. Sample population included patients that were continuously 
enrolled in medication and prescription plans for two years (June 1997 to May 1999). The study 
looked at medication adherence, cost, and utilization in patients with four chronic conditions: 
diabetes, hypertension, hypercholesterolemia, and congestive heart failure. The study reported 
lower inpatient visit rates for patients with high adherence for all four chronic conditions. 
However, though they found that for diabetes and hypercholesterolemia, high adherence was 
associated with lower disease related medical costs, medical care cost savings were offset by 
higher medication costs. 
2.1.7 Healthy People 2020:  
Racial disparities are one of the key public health challenges faced by health policy makers. 
According to Healthy People 2010, health disparities are differences in health indicators and 
outcomes based on gender, race, education, income, disability, geographic location, or sexual 
orientation. One of the primary focus areas for health disparities is diabetes, which occurs 
disproportionately in certain ethnic populations (Flegal 1991;Healthy people 2020; Vinicor 
1994). African Americans, Hispanics, American Indians, certain Pacific Islander and Asian 
American populations are affected disproportionately by diabetes compared to Caucasians. This 
disparity is also observed among economically disadvantaged and older populations. American 




1.7 times more likely and Mexican American/Puerto Rican adults are 2 times more likely to be 
affected by diabetes respectively, compared to non-Hispanic Caucasians of similar age. Minority 
groups constitute 25 percent of type 2 diabetes patients in United States and account for majority 
of child and adolescent type 2 diabetes patients.  Diabetes can lead to serious consequences such 
as amputation and death and can cause hyperglycemia and other comorbid conditions that may 
increase the disease related burden and severely impact the quality of life of patients (Shenolikar 
2006). Diabetes can lower life expectancy upto 15 years and increase the risk of heart diseases 
by two to four times (Healthy People 2020). 
One of the key issues to address diabetes related disparities is that of access to healthcare system 
and awareness of options available to patients. Various diabetes services like self-management 
training programs and eye-retina exams can be helpful in addressing diabetes and its associated 
conditions. However, many vulnerable populations lack access to these services for various 
reasons, one primary reason being systems problems such as vulnerable populations living in 
medically underserved areas (Healthy People 2020, Shenolikar 2006).    
In light of these disparities, Healthy people 2020 initiative by government proposes a 
multidimensional approach to address health disparities and attain long term national health 
objectives (Healthy People, 2020). The initiative proposes to involve academicians, practitioners, 
government agencies, and public in a concerted effort to attain nationwide health objectives over 
a period of 10 years. The key objective of the program is to enhance quality and duration of life 
across the society. More specifically, the key goals of the initiative are four-fold; 1) enhancing 
quality and duration of life by controlling preventable diseases and other key health threats such 
as disability, injury and premature deaths, 2) attaining overall health improvement across society 




health across communities, and 4) promoting healthy behaviors and development in order to 
enhance quality of life. The approaches to be used to attain these objectives focus on better 
assessment of health priorities, increasing public awareness about factors contributing to health 
related quality of life, use of measurable goals and objectives at national, state and local levels, 
involving multiple stakeholders in policy making and practice improvement, and identifying 
critical areas for research, evaluation and data collection. Based on the objectives and approaches 
presented above, the Healthy people 2020 proposes four health measures; 1) general health 
status, 2) health-related quality of life, 3) determinants of health, and 4) disparities.  
In Healthy People 2020, diabetes is one of the key health areas due to its impact on quality of life 
and the degree of health disparity observed in diabetes occurrence. The focus is on understanding 
diabetes and the nature of disparities in order to develop effective solutions. The initiative 
identifies four transitions points in diabetes healthcare, which present opportunities for 
addressing the disease. These transition points are; 1) primary prevention, 2) early diagnosis, 3) 
access to care to everyone, and 4) improved quality of healthcare. These points focus not only on 
disease related issues but also intend to address access barriers that have been identified as one of 
the key systems problems. Some examples of the focus on disparities involve identification of 
vulnerable populations, introduction of new diagnostic criteria, and implementation of 
prevention oriented community based interventions.   
2.1.8 Racial disparities in medication adherence and healthcare utilization in patients with 
diabetes mellitus:  
Racial health disparities in diabetes control are observed through a wide range of health 




compared to non- Hispanic whites. Both African American and Hispanics are significantly more 
likely to have borderline or poorly controlled hypertension, diabetes associated neuropathy, 
retinopathy, and diabetes-related amputations than non-Hispanic whites (Bonds 2003, Ness 
1999,Harris 1998).  Similarly, micro vascular complications of the eyes, nerves, kidneys, and 
lower extremity amputations are more frequent among African-Americans and Hispanic 
Americans compared to non-Hispanic Caucasians (Haffner 1988, Franklin 1990, Haffner 1989, 
Resnick 1999, Cowie 1989). 
According to Adams et al (2005), African Americans were more likely to have increased Hba1c 
in a HMO setting, after adjusting for baseline Hba1c, Body Mass Index (BMI), age, types of 
diabetes medications, diabetes-related inpatient visits, number of Hba1c tests, physician visits, 
and non-diabetes medications. In African American males with previously diagnosed diabetes, 
Hba1c levels were higher than white men by 0.11 units. Similarly, in African-American women 
previously diagnosed with diabetes, the adjusted average Hba1c was 0.30 units higher than white 
women. Among newly diagnosed African American men, the observed average Hba1c levels 
were 0.49 units higher than white men whereas no significant difference was observed in Hba1c 
levels by race among women (Adams 2005). 
African Americans are more likely to be affected by poor blood pressure and poor glycemic 
control than whites (Konen, 1999). African American men are more likely to suffer from blurred 
vision and hypertension but are less likely to suffer from peripheral atherosclerotic disease 
(Konen 1999). African American women are more likely to be affected by constipation and 
hypertension but are less likely to be affected by peripheral vascular disease (Konen 1999).  
Though the contributing factors to these disparities need a deeper understanding, some factors 




burden of disease among minority populations might be lower level of health awareness, and 
inadequate access to care and disease prevention programs.  
Socioeconomic factors emerge as an important indicator of health disparities. Socioeconomic 
barriers comprise of financial inadequacy and problems with housing, education, family and 
access to care (Hill-Briggs 2002). Paying for healthcare and prescriptions may compete with 
other basic needs and priorities and may create strong bottlenecks for access and adherence. 
Exploring the nature of these bottlenecks, a study by Heisler et al (2005) found that non whites 
were twice as likely to cut down on necessities and incur debt in order to cope with medication 
costs compared to the white respondents (Heisler, 2005). A comparison between prescription use 
among eligible Medicare beneficiaries in 10 states showed lower rates of filled prescriptions and 
pharmacy costs among African Americans in 8 states (Schore 2003). A study based on 2000 
Behavioral Risk Factor Surveillance System data demonstrated that uninsured diabetic patients 
were more likely to have low incomes; African Americans and Hispanic patients were also more 
likely to be uninsured. Uninsured patients were less likely to report having annual dilated eye 
exams, foot examinations, Hba1c tests, and glucose monitoring than those with private health 
insurance (Nelson 2005). In another study of diabetic individuals based on the 3rd National 
Health and Nutrition Examination Survey (NHANES), Harris et al (1999) found that among 
those aged 20-64 years, higher proportion of non-Hispanic whites and non-Hispanic blacks were 
insured compared to Mexican Americans. Non-Hispanic whites (81%) had highest rate of private 
insurance coverage, followed by non-Hispanic blacks (56%) and Mexican-Americans (45%) 
(Harris 1999). Another study exploring relationships between access to diabetes care and health 
outcomes demonstrated that patients with restricted access to healthcare had higher HbA1c levels 




significantly higher Hba1c levels than patients receiving care at doctor’s clinics (Rhee 2005). It 
has to be noted that the interaction of access issues and systems factors is not straight forward 
and more nuanced understanding of these factors need to be developed.  A study found that in 
the context of diabetes, though access to healthcare is important, provider specialty 
(endocrinologist/primary care physician) might not have as much impact on quality of care  
(Greenfield 1995).  Another study by Harris et al (2000) based on The National Health and 
Nutrition Examination Survey (NHANES) data found that high healthcare access and utilization 
rates for diabetes patients do not necessarily predict satisfactory health outcomes (Harris 2000), 
and factors such as health literacy, knowledge about disease management and trust in healthcare 
system may also play a significant part. 
2.2 Developmental Disabilities (DD): 
2.2.1 Introduction: 
Developmental disabilities (DD) are a group of conditions that begin during the developmental 
period, and may result in physical, learning, language, or behavioral impairments. These 
conditions, affecting around one in six children in U.S., may impact a person’s everyday 
functioning, and usually last through a person’s lifetime (Boyle 2011). 
Factors causing these disabilities are not specifically known. However, complex mix of factors 
such as genetics, parental health and behaviors during pregnancy, mother/child health during 
pregnancy/birth, exposure to toxins like lead, are thought to predispose individuals to 
developmental disabilities. According to recent estimates, about 15%, of children aged 3 through 




cerebral palsy, hearing loss, intellectual disability, learning disability, vision impairment and 
other developmental delays (Boyle 2011).  
2.2.2 Cerebral Palsy: 
Cerebral palsy (CP), the most common childhood motor disability, affects a person’s ability to 
move and maintain balance and posture. CP is caused by brain impairments affecting a person’s 
ability to control his or her muscles. A person with severe CP may not be able to move at all, but 
someone with mild CP may be able to move, though slightly awkwardly, without special 
assistance. The manifestation of CP may vary depending upon the area of the brain being 
affected. These manifestations may include spasticity or stiff muscles, dyskinesia or diminished 
control over movement, and ataxia or poor control over balance and coordination (American 
Academy of Pediatrics Healthy Children website). Almost 40% of children with CP have 
intellectual disability (Kirby 2011). 
According to CDC, the lifetime cost to care for an individual with CP is nearly $1 million (2003) 
dollars (CDC 2004). CP has no cure but early treatments may restrict the severe consequences to 
some extent. The available treatment options include medicines, surgery, braces, and physical, 
occupational, and speech therapy. Oral medications such as diazepam, baclofen, dantrolene 
sodium, and tizanidine are generally used to facilitate muscle movement and control.  These 
drugs, in many cases, may have to be used in quantities that may cause side effects such as 
drowsiness, upset stomach, high blood pressure, and possible liver damage as a result of long-
term use (National Institute of Neurological Disorders and Stroke website). 
2.2.3 Down syndrome: 




is born with an extra copy of chromosome instead of the normal 46 chromosomes. This extra 
copy influences physical and mental development patterns and leads to physical and mental 
problems. Some usual physical signs of Down syndrome are: a flat face slanted towards the eyes, 
short neck, small ears, large tongue, small hands and feet, white spots on iris, a single crease 
across the palm of the hand, a small pinky finger curved towards the thumb, and poor muscle 
tone (National Center on Birth Defects and Developmental Disabilities website). 
According to CDC estimates, in U.S., around 6000 babies are born each year with Down 
syndrome (Parker 2010). The manifestation of Down syndrome varies across children; some 
children with Down syndrome may have serious birth defects whereas some people with Down 
syndrome grow to adulthood and are relatively less affected. One of the key factors identified to 
be associated with Down syndrome is the mother’s age; children born to mothers 35 years or 
older are more likely to have Down syndrome (Besser 2007). Though there is no known way to 
cure or prevent Down syndrome, therapy regimens including speech, occupational, and physical 
therapy are found helpful in infants and children (National Center on Birth Defects and 
Developmental Disabilities website(b)).  
2.2.4 Autism: 
Autism spectrum disorders (ASDs) refer to a group of developmental disabilities caused by some 
unidentified problem with the brain. Autistic people may not look different from people without 
ASD but they may be different in terms of learning, communication and behavior. The thinking 
and learning abilities among people with ASD may vary across a wide range, ranging from gifted 
to severely challenged. Besides, autistic disorder, one of the more commonly known ASDs, there 




(PDD-NOS) and Asperger Syndrome (National Center on Birth Defects and Developmental 
Disabilities website(a)). 
According to CDC, about 1 in 88 children in U.S. is affected by ASD, which is five time more 
common among boys than girls starting in early childhood, ASDs last through a person’s lifetime 
(CDC 2012). People with ASD have higher medical expenditure than those without ASDs. 
Considering mean expenditure, the difference is $4,110-$6,200/year; the mean expenditure for 
people with ASDs is 4.1-6.2 times greater than those without ASDs. Similarly, difference in 
median expenditure between those with ASDs and those without ASDs is $2,240-$ 3,360 per 
year; median expenditure for those with ASDs being 8.4-9.5 times greater than those without 
ASDs (Shimabukuro 2008). 
Available treatments for ASDs include therapy and training and some FDA approved 
medications. Therapies and training may involve a wide range of options depending on the 
symptoms. Some examples include auditory training, discrete trial training, vitamin therapy, 
anti-yeast therapy, facilitated communication, music therapy, occupational therapy, physical 
therapy, and sensory integration (Reichow 2009, Rogers 2008, Myers 2007, the National 
Institute of Mental Health website). The only two FDA approved medications for ASDs are 
antipsychotics risperidone (Risperdal) and aripripazole (Abilify) that can reduce irritability, 
aggression and the chances of individuals with ASDs harming themselves. Off label medications 
are prescribed by doctors if the medications have been approved to treat disorders with ASD like 
symptoms.  (The National Institute of Mental Health website) 
2.2.5 Intellectual disabilities:  




condition that limits an individual’s ability to develop and function at an expected level. The 
severity of ID varies in children and this creates challenges for them to express themselves or 
communicate their needs on a daily basis. The physical development and learning is delayed in 
individuals with ID compared to their peers without ID ((National Center on Birth Defects and 
Developmental Disabilities website(c)). ID is the most commonly occurring developmental 
disability. About 6.5 million people have ID in the US. 1 in 10 children receiving special 
education in the US has ID. In 2003, 7,98,345 Medicaid enrollees were disabled and out of these 
disabled enrollees, 13% had diabetes (National Dissemination Center for children with 
disabilities). In 2008, the Medicaid expenditure associated with disability was $136.61 billion 
(Cohen 2007). ID can be caused due to genetic mutation (Downs syndrome, fragile X syndrome, 
phenylketonuria), problems at birth (lack of oxygen during labor), health issue (whooping cough, 
the measles, or meningitis), malnutrition, exposure to poisons (lead, mercury), drinking during 
pregnancy, rubella infection in pregnant women and improper development of the fetus in 
mother’s womb.  (National Dissemination Center for children with disabilities website) ID can 
occur in individuals anytime before the age of 18 (American Association on Intellectual and 
Developmental Disabilities website). Children with ID might learn to talk, walk and run much 
later than other children of their age. They might also have trouble understanding social norms, 
rules, consequences of their actions and solving problems. ID can be diagnosed by healthcare 
professionals through intellectual functioning and through adaptive behavior. To measure 
intellectual functioning, the child’s IQ is tested and to measure adaptive behavior, the abilities of 
the child with ID are compared with other children without ID ((National Center on Birth 





Table: 2.5 Levels of intellectual/cognitive disabilities (Rocha 2013): 
Mild  Moderate Severe Profound 
 IQ 50-70 
 Slower than normal 
in all areas 
 No unusual 
physical signs 
 Can learn practical 
skills 
 Reading and math 
skills up to grades 
3-6 
 Can conform 
socially 
 Can learn daily 
task skills 
 Functions in 
society 
 
 IQ 35-49 
 Noticeable delays, 
particularly speech 
 May have unusual 
physical signs 
 Can learn simple 
communication 
 Can learn 
elementary health 
and safety skills 
 Can participate in 
simple activities 
and self-care 
 Can perform 
supervised tasks 
 Can travel alone to 
familiar places 
 
 IQ 20-34 
 Significant delays 
in some areas; may 
walk late 
 Little or no 
communication 
skills, but some 
understanding of 
speech with some 
response 
 Can be taught daily 
routines and 
repetitive activities 
 May be trained in 
simple self-care 




 IQ <20 
 Significant delays 




 Needs close 
supervision 
 Requires attendant 
care 
 May respond to 
regular physical 
and social activity 




2.2.6 Barriers and facilitators influencing access to care and healthcare utilization in 
patients with DD: 
A) Availability:  
There is a dearth of primary care physicians available to assist minority patients with DD 
residing in rural areas due to insufficient training. Among the few primary care health 
professionals willing to assist DD patients, the main reason for insufficient availability of health 
professionals is often attributed to the fact that their only source of payment is Medicaid. Factors 
such as low Medicaid reimbursements, need for prior reauthorization, long treatment duration, 
tiring paperwork, challenging process to coordinate services, rampant failure to treatment 
compliance, transportation issues for patients residing in rural areas, and poor follow up upon 




a) Provider availability:  
Many physicians do not possess the knowledge to treat patients with  
DD (Scott 1993). It is often challenging for minority families to find trustworthy 
physicians, specialists and auxiliary healthcare providers to treat DD patients 
(Caudle 1993, Cornelius 1993, Friedman 1994, Kindig 1993). Often families have 
to hunt for competent physicians that can treat DD patients (Reichard 2004). 
b) Coordination of healthcare:  
                  Coordinating care for treating minority patients with DD is often challenging in 
absence of case managers and at times families of such patients tend to rely on 
friends and acquaintances for procuring services of the appropriate healthcare 
providers (Reichard 2004). 
c) Information and referral systems:  
Information and referrals are often obtained from community based 
developmental disability organizations which are part of the state Medicaid, 
family members/caregivers of minority patients with DD also seek advice from 
social workers, family support workers and friends (Reichard 2004). 
d) Distance and transportation:  
Patients with DD residing in rural areas have to travel long distances or wait for a 
long duration in a physician’s office to access specialized services. Caregivers 
who are family members, might, at times, have to miss work to take such patients 
for their physician visits. In case of adults with DD who cannot drive 




activity and recreation as well as attending health appointments and social 
exclusion (Rask 1994, Smith 1996, Crain 1998, Harbaugh 1998). 
e) Continuity of care:  
Continuity of care in minority patients with DD is associated with several factors 
such as presence of trust, good bedside mannerisms, affordability of care, good 
referrals, improvement in patient’s health, absence of the need to explain patient 
history repeatedly by family members and specialty providers avoiding moving 
the health records of the DD patient every time they change a primary healthcare 
provider. Patients with DD have special needs which their primary care provider 
might understand with whom they share a unique relationship. DD patients often 
have acute illnesses and a new primary care provider might be unable to view 
their pain or distress in the light of their chronic condition (Lubin 2012). 
B) Affordability: 
Lower Medicaid reimbursement rates for physicians, enrollee inability to pay out of pocket 
expenditures, lifetime of spending caps, presence of administrative barriers and narrow eligibility 
standards are some of the issues that make it difficult for patients with DD to get access to the 
care that they need (Bolden 1993, Kopac 1998, Hughes 1996’ Palfrey 1994). The basic care that 
is reimbursable for people eligible for Social Security Disability Insurance (SSDI) is often 
limited. For low income developmental disability patients who have other chronic conditions or 
disorders, often the cost of healthcare not covered by SSDI inhibits their access to care.  
C) Accessibility:  




patients with cultural values different than the physicians’ (Riddick, 1998, Vasquez 1991, 
Woloshin 1995). 
a) Clinical logistics:  
Apart from linguistic barriers, minority patients with DD tend to face physical 
barriers such as lack of wheel chair friendly examination rooms. Such patients 
might not be able to use the standard height examination table which might result 
in them wasting time changing tables during their visit; this may also make it 
difficult for the physician to properly position and examine the patient. Minority 
patients with DD might also have difficulty performing their daily activities at 
their homes without additional facilities such as enlarged door frames, ramps or 
additional bathroom equipment (Reichard 2004, Lubin 2012). 
b) Emotional support:  
Patients with DD with less community integration and lack of emotional support 
tend to feel isolated. The National Core Indicators Survey conducted among 
patients with DD residing in North Carolina in 2001 and in New York in 2009 
have shown that adults with DD feel that they receive inadequate social support 
almost seven times more than their peers without DD and many of them have no 
thriving social circles with no friends or dates (Havercamp 2004, NYS Core 






c) Competency of healthcare provider:  
I)Knowledge: 
Physicians and other healthcare providers should possess general knowledge 
about what constitutes disability, different types of DD, clinical knowledge of DD  
including causes, symptoms, characteristics, and the natural history of DD, as 
well as the specific comorbidities associated with developmental disabilities. In 
addition to knowing about the theoretical aspect of the different conditions that 
constitute DD, knowledge about providing actual care by means of performing 
diagnostic testing and developmental screening, providing psychotropic 
medications, designing behavioral interventions and using adaptive equipment for 
the management of the different conditions is also necessary for healthcare 
providers. Providing referrals to healthcare agencies and community resources to 
support DD patients and knowledge about the eligibility criteria to get access to 
care can impact the healthcare utilization and quality of care delivered among DD 
patients.  
II)Skills:  
(i) Patient healthcare practitioner relationship/communication  
The unique and complex medical condition of DD patients requires more 
     specialized considerations from physicians as well as the health delivery system 
including insurance and Medicaid. The relationship between patients and 
Healthcare practitioners is restricted, in many cases, by the inability of the patient 




that it is patients’ responsibility to advocate and communicate their health 
concerns (Boyer & Lutfey, 2010). Many patients struggle with complex sets of 
problems and symptoms and are not able to communicate effectively due to their 
condition. This inability to communicate not only affects their everyday lives but 
also extends to their treatment/therapy process. Practitioners expect patients and 
their families to share information with them that forms the basis of the 
treatment/care provided to them. This absence of effective information sharing 
and communication may affect the quality of care the patient receives. In order to 
address this issue, practitioners need to be more sensitive to the special needs of 
the patients. They should try to create more scope for effective communication 
and understanding of patients’ problems and needs by seeking information in a 
more understanding and patient manner and allowing additional time for 
consultation.  
From the systems perspective, the special needs of the patients should be 
acknowledged and should be incorporated while deciding on the nature of 
coverage they receive. Patients with DD have more complex health problems than 
general populations and may need more access to medical resources indicated by 
higher number of healthcare visits among DD population. Medicaid coverage for 
individuals with DD is same as the Medicaid coverage for general population, 
even though individuals with DD may have different types of issues at different 
rates that may experience differently than general population. This issue can be 




and developing solutions at systems level that are sensitive to these needs (Boyer 
& Lutfey,2010). 
(ii) Patient informal/paid caregiver relationship: 
Besides healthcare practitioners such as physicians, nurses, pharmacists, 
physiotherapists, and occupational therapists, many other people may help 
provide care to individuals with DD. These people, considered caregivers, may 
not necessarily have professional training in providing care and may involve 
informal caregivers such as family members, friends, and formal paid caregivers. 
Caregivers generally help manage medications and treatment, and help with 
activities involved with daily living, household chores and responsibilities, and 
communicate with healthcare practitioners. Caregivers may bring in advantages 
like life experience and understanding of patient’s needs and personalities that 
may enable them to have effective interpersonal relationship and communication 
with the patients (Lau 2010).  
Understanding of patient’s expectation and environments may also enable them to 
take decisive action and overcome fear of making medication errors. On the other 
hand, many factors may also form barriers in effective functioning of caregivers. 
These factors may involve cognitive and physical limitations, negative influences 
of close relationships with patients, negative emotional states, and competing 
responsibilities. Cognitive and physical limitations may involve conditions due to 
old age and various other factors like lack of literacy and lack of linguistic skills 
that may impede effective medication management and communication with 




caregivers and may lead to them resisting treatment plans and focusing on their 
own conveniences rather than on patients’ comfort and needs. Negative emotional 
states like grief, frustration, or fatigue may also influence caregiver’s decision-
making. Also, many caregivers, especially family members, may have other 
competing responsibilities such as managing their employment responsibilities, 
and running the household involving other dependents, that may influence their 
performance and decision making as caregivers. The burden on the primary 
caregiver can be reduced due to support from multiple caregivers that may also 
include hired caregiver. However, having multiple caregivers may also have 
drawbacks as bad interpersonal relationships and lack of communication and 
understanding between caregivers may negatively influence the medication 
management process (Lau 2010).  
(iii) Physician informal/paid caregiver relationship:  
Physicians should effectively communicate the patient’s condition and progress to 
the caregivers and family members and inform them about the patient’s wishes 
and values about advance care planning. Physicians should acknowledge the role 
of caregivers in providing intellectual and emotional transition for chronic disease 
patients on death bed, consider the challenges that caregivers who are 
geographically distant face, be able to detect distress among caregivers and 
provide them referrals accordingly, appreciate the role of caregivers as part of 
patient’s medical and psychosocial history, and make provisions for the wellbeing 
of the patients as well as their caregivers via a palliative care plan or a caregiver 




professional caregivers with regards to the specific services provided to prevent 
conflict, validate the caregiver’s role on a regular basis, and respect the 
caregiver’s commitment to provide patient care (MDNEWS website). 
(iv)Observation skills: 
                        Healthcare provider’s keen sense of observation can play an important role in 
proactively identifying and managing conditions that affect the health of the 
patients with DD. Observing DD patients’ behavior, developing the ability in 
differentiating the subtle changes in the patient behavior and paying attention to 
the caregiver reports about patient behavioral changes, even though time 
consuming and demanding openness on part of the healthcare provider, can aid in 
providing medical attention to the DD patients.  
(v) Ability to recognize that a person with developmental disabilities may not be able to be 
served in a typical medical setting: 
 Adults with DD might have difficulty in accessing care in typical health settings 
and settings such as patient homes and board and care facilities might be 
preferred. For instance, special diagnostic equipment suitable for screening or 
examining adults with DD might have to be arranged. Also, convincing the 
patients to undergo physical exams and assisting patients with physical 
positioning while examining them may require careful preplanning and 
investment of extra time and patience on healthcare provider’s behalf. Healthcare 
providers should have the ability to recognize these special needs of the patients 





(vi) Ability to identify, coordinate, and communicate with members of the patient’s 
       interdisciplinary team: 
Healthcare providers’ ability to identify, coordinate and communicate with the 
multi-disciplinary team comprising of caregivers, specialty physicians, case 
coordinators and service providers can ensure that adults with DD receive 
comprehensive care and their treatment plan is assessed by a variety of experts. 
Communicating with community partners and agencies can also prove to be a 
useful resource to direct the patients with DD towards the much-needed services. 
III)Attitudes: 
(i) Cultural insensitivity: 
Another issue that needs attention in the context of patients with DD is cultural 
insensitivity. Though such patients may be affected by the insensitivity on the 
basis of factors like race and gender, which also affect general patient population, 
they may also face problems due to insensitivity to their disabilities and the 
negative social attitudes associated with them (Reichard 2004). Training providers 
and caregivers about culturally appropriate behavior that also takes into account 
the disability culture may help attain cultural sensitivity. Some example of 
culturally sensitive behavior may include respectful language and terminologies 
related to patient’s condition, and providing language assistance when needed to 
communicate with the patient (University of California at San Francisco website).  
Harboring a patient and family centered attitude can foster trust and confidence 
about the healthcare provider among the patients with DD and their families. 




patients and their families part of the healthcare decision making process, use the 
right terminology while addressing the patients, and converse with them directly. 
(ii) Physician Conscientiousness: 
Inability of the patients with DD to communicate their symptoms or have a 
regular follow up with their healthcare providers can make the diagnosis 
challenging and can result in medical decision making with incomplete 
information and failure of the planned therapy. Healthcare providers should be 
flexible, compassionate, possess good listening skills, be understanding towards 
the day to day challenges contributing to therapy non-compliance in DD patients, 
and be sensitive to their needs including their living conditions and the special 
accommodations that they need. In situations where patients with DD might not 
be able to vocalize their health concerns or symptoms, healthcare providers 
should be receptive to the concerns comprehended by the families of the patients 
or formal caregivers or health advocates. 
d) Physician services during visits:  
(I)Specialist services:  
Specialist services are an important part of treatment regimen for adults with DD. 
A study conducted in adults aged 20-50 years with DD living in Sydney, Australia 
found that these adults had a greater need of visiting hospitals, by as much as two 
times more, compared to adults without DD (Beange 1995, Wallace 2008). Adults 
with DD often require many specialist services, which involves their primary 




physiotherapists, occupational and language therapists, and mental healthcare 
providers to assist with motor and communication skills, coordination, speech, 
morale, and better bonding with the society. Disparities in access to specialized 
services occur among adults with DD due to lack of formal training among 
physicians to provide care to patients with DD and help them transition through 
different stages of adult life (Linsey 2002). 
(II)Outpatient services:  
There is a need for establishing local outpatient healthcare facilities that can 
specifically fulfill mental and physical health needs in adults with DD. Adults 
with DD visit the ED department to a far larger extent compared to adults without 
DD; this can be attributed to the lack of sufficient centers providing specialized 
outpatient services to this unique group of patients and lack of continuity of 
primary and specialist care (Lunsky 2012). 
(III)Family training:  
Many adults with DD live with their families and at times it is possible that the 
family members who are also their informal caregivers are unaware about the 
needs for regular physician visits and screenings that have to be conducted from 
time to time. In a survey study administered to adults with DD aged 18 years and 
older and their informal caregivers/family members residing in Victoria, 
Australia, researchers found that compared to adults with DD living with their 




physician about two to five times more and also underwent more health 
screenings for metabolic and cardiovascular disorders.  (Iacono 2006) 
(IV)Cooperation with service providers:  
Lack of physician training is one of the major barriers that impedes them from 
providing the appropriate therapy and reaching out to the patients with DD.  
Collaboration among different healthcare professionals at the local and national 
level is essential to develop standards of care for patients with DD. Dissemination 
of information and better understanding and training to cater to the emotional and 
specialized physical needs of the adults with DD on a continuous basis may also 
help improve the quality of care (Meuwese-Jongejeugd 2005). 
D) Appropriateness:  
 a) Healthcare needs met:  
 Inability to take into consideration the wishes of patients and their caregivers, lack 
of sufficient counseling, communication barriers, lack of structural 
accommodations, and inability to properly screen patients or schedule them for 
visits pose hurdles to access of care among minority patients with DD residing in 
segregated neighborhoods; these factors may also contribute to increase in disease 
severity (Hughes 1996, Bolden 1993, Kopac 1998, Palfrey 1994). 
b) Quality of care:  
Healthcare professionals who are respectful, honest and considerate towards the 




Simons 1987, Wilson 1994). Practices such as providing incorrect treatment, 
withholding information concerning the health of the minority patients with DD, 
delaying the necessary treatment, or having insufficient time to provide care are 
regarded inappropriate by the caregivers of the minority patients with DD (Ebert 
1995, McEwen 1988, Welner, 1998, Brooks 1997, Barnett 1988, Grabois 1999, 
Reichard 2001, Nosek 1995, Ralston 1996). 
2.2.7 Chronic disease management in patients with developmental disabilities 
Patients with DD have a higher risk of developing type 2 diabetes as well as a higher prevalence 
of the same. Sedentary lifestyle, poor nutrition and high rates of obesity can lead to an increased 
risk of type 2 diabetes in patients with DD.  (Yamaki 2005, Rimmer 2006). Also, compared to 
DD patients living in supported housing and residential facilities, the BMI and the risk of 
developing type 2 diabetes are higher in DD patients living with their families or living on their 
own. When DD patients live independently, there is a higher likelihood of leading an unhealthy 
lifestyle with less dietary restrictions (Taggart 2012).  
Patients with type 2 diabetes have the following symptoms: fatigue, increased thirst, headaches, 
blurred vision, increase in frequency of urination, difficulty in concentrating, loss of weight, 
changes in mood, withdrawal, agitation and verbal and physical aggression.  (UKPDS 1998) The 
onset of type 2 diabetes is generally slower and there is a possibility that the disease condition 
remains undiagnosed for a long duration in patients with DD. Symptoms of type 2 diabetes in 
DD patients can be difficult to detect due to challenges faced by this population in 
communication, or the medication that is being prescribed for pre-existing conditions or the 




as ‘diagnostic overshadowing’. Diagnostic overshadowing might make it difficult for the staff to 
provide the patients with the necessary care that they need to delay or prevent type 2 diabetes 
(UKPDS 1998, Taggart 2012). 
In North America, the prevalence of type 2 diabetes in the DD population can vary from 7.1% to 
14% (Havercamp 2004, Shiremen 2010, McDermott 2006, Lunsky 2011). Besides type 2 
diabetes, the prevalence of cardiovascular complications and healthcare utilization is also higher 
in the DD population. A study in Northern Sydney showed that among people with DD, 
prevalence of type 2 diabetes complications, medical consultations, inpatient visits and mortality 
were higher compared to the people without DD. The study population also had many undetected 
conditions. Out of the 5.4 medical conditions that each patient had on an average, half the 
conditions were undetected during previous physician visits (Beange 1995). Another similar 
study conducted by Lennox et al (2007) also showed that the large number of people with DD 
who were diabetic and obese, went undiagnosed or without any management. When patients are 
diagnosed with diabetes, as part of their annual regimen, they are subjected to a screening 
whereby their primary care physician can diagnose other chronic comorbidities associated with 
diabetes. Many type 2 diabetes patients have hypertension and CVD, which can cause mortality 
in type 2 diabetes patients. As a result, proper statin therapy and anti-hypertensive medication 
therapy are needed to control CVD and BP to control disease severity in type 2 diabetes patients 
(UKPDS 1998). However, there is a high likelihood that diabetic patients with DD get screened 
less compared to diabetics without DD due to fewer opportunities to actively engage in 
educational sessions pertaining to disease screening. Also, diabetes management can become 
quite difficult in case of patients with DD who live in shared housing away from their homes, 




their diabetes may be apprehensive and may perceive that they are unable to provide the 
necessary care. In many cases, the turnover of the caregivers is quite high which might interfere 
with the continuity of diabetes care provided to the DD patients (Rey-Conde 2007). This 
indicates that diabetics with DD are at a greater disadvantage, in spite of being at a higher risk to 
developing diabetes related complications due to under diagnosis. This can be avoided if DD 
patients are screened annually given the increased proclivity to a sedentary lifestyle. ADA has 
several guidelines and supporting research studies for preventing or delaying type 2 diabetes in 
pre diabetic patients at a higher risk of developing type 2 diabetes through appropriate lifestyle 
interventions and proper diet intake (ADA 2002). 
2.2.8 Racial health disparities in patients with developmental disabilities  
Adults with DD have high health risk behaviors, inadequate emotional support and poor 
healthcare utilization compared to disabled adults without DD. A study conducted using the 2001 
North Carolina Behavioral Risk Factor Surveillance System and the North Carolina National 
Core Indicators survey showed that compared to disabled adults with DD, adults with DD had a 
significantly higher prevalence of chronic disease conditions such as diabetes, obesity, high 
blood pressure, arthritis, CVD and chronic pain. They were also more likely to be sedentary, 
performed less amount of physical activity, received seven times less emotional support and had 
low breast cancer and cervical cancer screenings (Havercamp 2004, Ouellette-Kuntz 2005). 
Studies conducted in Ontario among adults with DD showed that they had significantly higher 
rates of undiagnosed disease conditions and higher rates of inpatient visits for ambulatory care 
sensitive conditions (Ouellette-Kuntz 2005).  The comorbid conditions associated with DD are 
more prevalent among adults with low income who also face socioeconomic disparities in 




healthcare and therefore have poor health outcomes (Surgeon General Report 2002). In studies 
conducted in US and Australia, mortality rate was higher among African Americans adults with 
Down syndrome compared to Caucasians and among aboriginal adults with DD (Ouellette-Kuntz 
2005). Among racial minority adults with an emotional or physical or mental disability, who 
require special equipment for performing day to day functions, disparity seems to exist while 
reporting health status. The percentage of African Americans, Hispanics, Asians and Native 
Americans with disabilities reporting fair or poor health are 50%, 50%, 38% and 52% compared 
to 11%, 19%, 6% and 9% of African Americans, Hispanics, Asians and Native Americans 
without disabilities (Drum 2011). There seems to be a necessity to design culturally appropriate 
health prevention and health promotion interventions for minorities.   
2.2.9 Quality of care in diabetic adults with developmental disabilities 
It is important to study quality of care in patients with DD since it is an important contributing 
factor to better healthcare service utilization and healthcare outcomes in patients with DD. Racial 
and ethnic disparities in quality of care persist due to a variety of barriers such as socioeconomic 
status, segregation, language barriers, and discrimination (LaVesit 2008, Yu 2009, Rust 2007). 
Comprehensive diabetes management includes monitoring HbA1c and serum lipids and getting 
eye examinations on an annual or semiannual basis to prevent diabetes severity, less utilization 
of health resources and improved quality of life. The quality of diabetes management or in other 
words, the quality of the care provided to the diabetic patients can be determined by the extent to 
which the healthcare providers adhere to the quality indicators and evidence based guidelines 
provided by accreditation organizations such as the National Committee for Quality Assurance 
(NCQA). The Healthcare Effectiveness Data and Information Set (HEDIS) is a quality of care 




non-profit organization that provides accreditation and HEDIS measures to the healthcare plans 
who in turn report those measures, indicating the quality of care provided to their employers. The 
HEDIS also assesses quality of diabetes care for health plan enrollees aged 18-75 years through a 
variety of measures that indicate management of diabetes and its related complications. These 
measures look at the number of people who get tested for HbA1c level, have a poorly controlled 
HbA1c of more than 9%, have a HbA1c level of less than 8% during the first year of diabetes 
diagnosis, are screened for serum cholesterol level (LDL‐C), have LDL‐C level less than 100 
mg/dl, have an eye exam done and have blood pressure of 130/80 mmHg (NCQA 2006). HEDIS 
measures used to compare quality of diabetes care in different patient groups are reliable, 
consistent, defined in a detailed manner and are updated on a regular basis (HEDIS website). 
The 2008 National Committee for Quality Assurance (NCQA) report about the state of 
healthcare quality states that the quality of comprehensive diabetes care is high in patients 
enrolled in both the Medicare and the private health plans. Compared to 77% diabetics enrolled 
in Medicaid who get their annual HbA1c monitored, 88% of the Medicare and private insurance 
enrollees get their annual HbA1c monitored. Similar statistics were reported for LDL-C 
screening and eye examinations. Compared to 71% and 50% Medicaid enrollees undergoing 
LDL-C screening and eye examinations respectively, about 83% and 55% Medicare and private 
insurance enrollees had their LDL-C screening and eye examinations respectively (NCQA 2008). 
These results were similar to a study conducted within the Kansas Medicaid population in 2006-
2007. This study showed that although 93.5% Medicaid enrollees had at least one annual primary 
care visit, only 51.7%, 44.3%, 29.3% and 18.5% Medicaid enrollees got their annual HbA1c 
monitored, cholesterol screened, eye examined and micro albuminaria screened respectively 




compared to the Medicaid enrollees. However, there is a disparity in the delivery of quality 
diabetes care even among the Medicaid enrollees, and managed care Medicaid enrollees tend to 
receive enhanced diabetes care compared to the fee for service Medicaid enrollees (Landon 
2007, Roohan 2006).   
Research about treatment of comorbid conditions using evidence based guidelines in 
hypothetical patients has shown that it yields marginal benefits and is an expensive process 
(Boyd 2005, Tinetti 2004). Evidence based guidelines about a target condition might not 
consider the related complicated comorbid conditions and patient preferences, thus causing 
unintended consequences or harm. Also, at times applying evidence based care for two existing 
conditions might interact negatively or clinicians might perceive that aggressively providing 
evidence based care might bring little change to the diabetes management of the patients due to 
their DD. The neurologic, psychiatric and physical impairment in DD patients might discourage 
the physicians from providing diabetes care similar to that being provided to diabetes patients 
without DD (Nuyen 2005, Doescher 2000, Reschovsky 2008, Betancourt 2004, Reichard 2004). 
Even though previous research indicates that providing evidence based care in patients with 
multiple comorbidities impacts quality of care due to risk of adverse events and, probability of 
overlapping guidelines and clinicians divesting time focusing on several aspects of patient care, 
the research does not focus on patients with DD (Rost 2000, Field 2004, Tinetti 2004). 
Management of diabetes reduces mortality and improves quality of life. There are very few 
evidence based guidelines for patients with comorbid conditions since such patients are not 
included in randomized controlled trials conducted to generate evidence for framing evidence 
based guidelines for disease conditions. Evidence based guidelines for diabetes management 




diabetes care in DD patients requires a team based patient centered approach, and not a disease 
oriented approach since integrating individual patient needs with the disease perspective is a 
characteristic of effective care (Starfield 2003). 
2.3 Theoretical model  
This study examines the predictors of type 2 diabetes medication adherence in DD Medicaid 
enrollees. It also further explores the impact of medication adherence on patients’ healthcare 
utilization and costs. The theoretical framework for this study is based on two health behavior 
models. One model is the modification of health belief model by Becker and Maiman that 
describes the association of sociobehavioral determinants of adherence with health and medical 
recommendations. The other model is the Aday-Andersen’s model for healthcare utilization. 
According to this model, healthcare utilization is a function of three sets of determinants: 
predisposing factors, enabling factors, and need-related factors. The detailed explanation of both 
the models is provided below in the following sections: 
2.3.1 Health Belief model: 
The health belief model (HBM) is a psychological model based on value expectancy theory. 
HBM posits to explain individual behavior under uncertain circumstances. According to the 
model, individuals desire to avoid illness or become healthy by believing in the performance of 
certain actions. HBM, which was initially used to explain screening behaviors by Rosenstock 
was further adapted to explain preventive care, illness behavior and sick-role behavior. HBM 
proposes that the action taken by individuals to prevent illness occurs only under certain 
possibilities are met such as a) in the presence of the risk of developing a condition and provided 




disease condition or b) the feeling that undertaking appropriate actions will have serious 
implications or c) the feeling that the undertaking actions will decrease the susceptibility to 
disease or severity of the disease condition or d) if more benefit is perceived compared to more 
harm given the performance of the intended action.  
The HBM consists of six components:  
(1) Perceived threat: This indicates an individual’s perceived susceptibility to contract a disease 
condition.  
(2) Perceived severity: This indicates the importance that is placed on a disease condition and 
the consequences of non-treatment of the same.  
(3) Perceived benefit: This indicates the patient’s perception about the effectiveness of the 
action to mitigate the perceived severity of the disease. The rationale behind this is that an 
appropriate action will be performed to alleviate the perceived threat, and the action chosen will 
be beneficial to the person taking it.  
(4) Perceived barriers: These are the barriers that prevent an individual from taking the required 
action that prevents illness. Before executing the actual action, the individual tries to contemplate 
if the benefits of the intended action outweigh its risks  
(5) Cues to action: The factors that determine an individual’s readiness to take action, act as 
cues for initiating that particular action. These factors could be internal such as physical 
sensation or external such as stimulus triggered by mass media to encourage beneficial health 
behavior.   
(6) Self efficacy: This indicates the patient’s belief in successfully executing the health behavior 
in order to experience the desired outcomes (Becker 1967, Kogan 1964, Becker 1974, 

















            
Figure 2.2 Original Health Belief Model developed by Rosenstock 
2.3.2 The modified Health Belief Model by Backer and Maiman 
Health Belief Model (HBM) was originally proposed to explain general preventive health 
behavior and since has been modified to explain behavior in a wide range of health behavior 
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contexts. The Becker and Maiman model (1975), derived from the Health Belief Model, was 
specific to adherence and persistence as target behaviors. This modified model by Becker and 
Maiman conceptualizes three dimensions as primary contributors to adherence behavior. These 
are: 
1. Readiness to undertake recommended adherence behavior: The key contributors to this 
dimension are the perceptions of ‘susceptibility’ and ‘severity’; here ‘susceptibility’ refers to the 
perceived likelihood of getting affected by an illness and ‘severity’ refers to the extent of 
perceived consequences of the illness. This component is influenced by a range of factors like 
patients’ motivations (concern about health issues, willingness to seek and implement medical 
advice,), value of illness threat reduction (perceived vulnerability, presence of symptoms etc) 
and patients’ perceptions about the efficaciousness of the recommended behavior. 
2. Modifying and enabling factors: These factors modify the patient readiness towards the 
recommended behavior. They involve the individual’s evaluation of the behavior in terms of its 
feasibility and effectiveness, and potential barriers to performance of the behavior. These may 
include a wide range of factors such as demographic, structural, interaction based, attitudinal, 
and enabling factors. This study included demographic, clinical and medication related variables 
as part of predisposing, modifying and enabling factors to measure medication adherence in the 
study population.  
3. Compliant behavior: This is the likelihood of the patients’ adherence with recommended 
health behavior. The modified model proposed in this study examined patient outcomes such as 
healthcare costs and healthcare utilization as a consequence of medication adherence in type 2 
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2.3.3 Application of Health Belief Model to type 2 diabetes  
(A) Patient beliefs: 
According to Gentili et al (2001), Health Belief Model is an appropriate framework to plan 
diabetes management programs and develop approaches for counseling diabetic patients (Gentili 
2001). The four key predictors of health behavior according to HBM are perceived susceptibility, 
perceived severity, perceived benefit, and perceived barriers. In the context of diabetes, 
variations in perceived susceptibility may alter patients’ estimation of their chance of contracting 
diabetes; patients with higher perceived susceptibility may be more likely to follow the 
recommended health behavior. For example, someone whose parents are diabetic may consider 
oneself more susceptible and therefore is more likely to perform the recommended health 
behavior. Perceived severity refers to the extent/degree of negative consequences associated with 
the illness. Perceived severity in diabetes patients may include evaluation of consequences such 
as inpatient visits and co morbidities, or consequences related to cost and life style changes. The 
perceived benefits associated with diabetes patients’ adherence to recommended behaviors are 
improved glycemic control, reduction in healthcare costs, and overall, a better quality of life. 
Patients may face different barriers like unwanted side‐effects, difficult dosing regimen, and 
medication costs and be unwilling to make lifestyle and dietary modifications.  
(B) Caregiver Beliefs: 
In case of patients who are severely cognitively impaired, symptom management can be largely 
driven by caregiver knowledge and beliefs. In case of patients who are entirely dependent on 




in caregivers. At times, caregivers who also work can have limited time for themselves due to the 
care giving demands. Increase in work responsibility can result in frustration among caregivers 
which can manifest in the form of neglect for the patients. Caregivers may also engage in 
behaviors such as yelling, withholding food and hitting or neglect patient’s nutrition and pain 
management. Caregivers might believe that they are unable to care for the patients due to 
patient’s cognitive impairment, when care giving is criticized or when care givers take wrong 
care decisions (Reinhard 2008). One of the issues that caregivers grapple with is pain 
management in DD patients. Caregivers provide care, medications, social support, comfort, 
measuring blood sugar, interpreting symptoms and making care decisions for the DD patients. 
For performing their duties appropriately, caregivers need training for monitoring and 
differentiating patient symptoms, reporting those symptoms to physicians and procuring services 
from community agencies.  Caregivers also have to gain knowledge about disease management. 
Caregiver beliefs about providing relief to the patients from their pain depend essentially on their 
understanding of the patient symptoms.  Caregivers, who believe that the patient is in pain, might 
make an inaccurate assessment while caring for patients with communication difficulties. 
(Reinhard 2008) In a study conducted by Allen et al (2002), researchers found that the perception 
of pain in caregivers of cognitively impaired patients was the same as caregivers of patients 
without cognitive impairment. The study also found that 3.4% caregivers were unable to 
precieve the patient’s pain when the patient was actually in pain. On the other hand, almost 29% 
of patients were not in pain but their caregivers perceived that they were in pain.  Family 
caregivers tend to rely more on non verbal cues of pain in patients with cognitive impairment.  
Female patients tend to respond more to pain and possess more knowledge about pain 




chronic disease management including pain can help them in better assessment of the patient 
symptoms, improve their attitudes and knowledge, make them more confident and can reduce 
their depression, fatigue and anxiety (Ferell 1995).  
2.3.4 The Aday Andersen model for healthcare utilization 
The Aday Anderson’s model of healthcare utilization has been used extensively to study 
healthcare seeking behaving and predicting healthcare utilization. According to the model 
several factors are responsible for determining healthcare utilization and these factors have been 
clubbed under three main factors: predisposing factors, enabling factors, and need‐related 
factors. The model posits how different factors influence an individual’s propensity, ability and 
need to access the available resources that result in medication usage and healthcare service 
utilization (Aday 1974, Andersen 1995). The model provides an understanding of the 
characteristics of the vulnerable population at risk. The three factors are described as follows: 
Predisposing factors: These factors exist in individuals or group of individuals prior to them 
having the disease condition. These factors indicate the tendency of the individuals towards 
utilization of healthcare services and they include socio-demographic characteristics like patient 
age, gender, race, education level etc. (Aday 1974, Andersen 1995). 
Enabling factors: These factors consist of the means that affect an individual’s predisposition to 
utilize healthcare services i.e. they influence the accessibility to services and insurance status, 
access to care, source of care and income level (Aday 1974, Andersen 1995). 
Need factors: These include self-perception of individuals about their health status and the 
evaluation of the individual’s healthcare provider. They comprise of perceived health status, 
severity of disease, number of physician visits, presence of comorbidities and quality of life 

















Figure 2.4. The Aday-Andersen Model for determinants of healthcare utilization 
2.3.5 Theoretical model proposed for the study 
The proposed model for this study was based on the Health belief model and the Aday 
Andersen’s model of healthcare utilization (Figure 2.3.5) (Aday 1997, Andersen 1973, Andersen 
1995, Becker 1975). The Aday Andersen’s model is based on the premise that healthcare 
outcomes are a result of a) factors that predispose individuals to seek care, b) factors that might 
enhance or pose barriers to access care and c) factors that can aid the healthcare professionals or 
patients to make an assessment about their health status. Together the predisposing, enabling and 
need factors determine the patient’s health behavior and outcomes.  
In the proposed model, the predisposing factors were race, gender, age and patient/caregiver 
health beliefs. The enabling factors that could improve or impede access to care were availability 
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of care, affordability of care, accessibility to healthcare services and appropriateness of 
healthcare services. Factors such as access to physician services and clinical logistics 
(accessibility to healthcare services) or information and referral systems (availability of care) 
were included as part of enabling factors since the study looks at Medicaid enrollees with DD, a 
highly vulnerable population. The need factors in the model that determined the need to seek 
care were level of illness, presence of comorbidities and number of prescription refills. In 
addition to type 2 diabetes, presence of other chronic disease conditions were accounted for, by 
including them in the Charlson comorbidity index.   
The proposed model shows an interaction between race and medication adherence. The 
interaction allows for determining the influence of race and medication adherence on healthcare 
utilization and healthcare costs at many different levels. These levels can be classified as 
Caucasians with high medication adherence, Caucasians with low medication adherence, African 
Americans with high medication adherence and African Americans with low medication 
adherence. The influence of these levels on the health outcomes were measured after controlling 
other covariates (Mobley 2009).  
Health behavior, according to the proposed model, was determined by the predisposing, enabling 
and the need factors. In turn, health behavior influenced health outcomes. The health behavior 
variables in this study were anti diabetic medication adherence and medication persistence that 
influenced healthcare utilization (inpatient visits, outpatient visits and ER visits) and healthcare 
costs (medication costs, inpatient and outpatient costs and overall costs). The model has many 
covariates that are part of enabling factors such as availability of care, accessibility to healthcare 
services and appropriateness of healthcare services. There is evidence that supports that these 




measured. The stronger influence of predisposing factors (race) and enabling factors (health 
insurance, income) on healthcare utilization compared to need factors can indicate disparity in 
access to care whereas the stronger influence of need factors on healthcare utilization compared 
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Chapter 3 Methodology 
The methodology used in the study will be discussed in the sections below. The sections 
discussed will be: data source, study design, study perspective, database elements, descriptive 
variables, statistical analyses, hypothesis and different types of analytical methods to be used in 
the study. 
3.1 Database and Management  
This section describes in details the contents of the dataset to be employed for the study as well 
as the process of derivation of the final sample size.  
3.1.1 Marketscan Multi-State Medicaid Database  
The database used for this study was the MarketScan® Multi-State Medicaid Database. The 
licensure for using this data was obtained from Thomson Reuters®. The database consists of 
enrollee information residing in eight states of the US covered by Medicaid insurance and 
amounts to about 22 million people.  For purposes of privacy, the names of the states are not 
disclosed. However, the eight states are dispersed across each of the six regions of the US.  
The MarketScan® Multi-State Medicaid Database contains a variety of disease conditions that 
patients have. The disease conditions include diabetes, hypertension, hyperlipidemia, breast 




outpatient services, prescription drug claims, as well as information on long‐term care and other 
medical care. Data on eligibility (by month) and service and provider type are also included. In 
addition to standard demographic variables such as age and gender, the database includes 
variables of particular value to researchers investigating Medicaid populations, such as aid 
category (blind/disabled, Medicare eligible) and race. The time period of the MarketScan® 
Multi-State Medicaid Database is from January 1st, 2003 to December 31, 2007.  
To protect the privacy of patient data, the MarketScan™ research databases fully comply with 
the Health Insurance Portability and Accountability Act (HIPAA) of 1996. The MarketScan™ 
data features encrypted member and service provider identification numbers. All patient‐level 
and provider‐level data within the MarketScan™ research databases contains synthetic 
identifiers to protect the privacy of individuals and data contributors. 
3.1.2 Characteristics of the database 
The MarketScan® Multi-State Medicaid Database contains a unique enrollee identifier 
(ENROLID) which is a personal level identifier and is assigned to each enrollee, thereby making 
it easy to longitudinally track patients and families. The ENROLID is created by encoding 
personal information provided by employers.  Thus the ENROLID cannot be linked to recipient 
ID, social security number, or any other external identifier, thereby protecting patient 
confidentiality. ENROLID consists of information such as the employee identification, the 
relationship of the enrollee to the contract holder, the gender of the enrollee, and the enrollee’s 
date of birth. The standardized fields in each of the individual 8 databases are combined and are 
linked across data types and through the different years (Marketscan 2007, Adamson 2008). The 




ways: by diagnosis and by procedure. The diagnosis codes in the dataset are based on the 
International Classification of Disease, 9th Division, Clinical Modifications (ICD-9-CM). These 
codes are 3 to 5 digit long and upto 2 diagnoses (DX1 and DX2) are recorded for inpatient 
services.  In case of hospital claims, inpatient admissions are identified as discharge diagnosis.  
Each inpatient admission record has 14 secondary diagnosis codes taken from inpatient service 
records and are numbered from DX2 to DX15 whereas each outpatient service record has up to 2 
diagnosis codes (DX1 and DX2). Each facility head has nine diagnosis codes numbered from 
DX1 to DX9 (Marketscan 2007, Adamson 2008). 
For diagnosing procedures, Marketscan dataset uses 3 classification systems: the Current 
Procedural Terminology- the 4th Edition (CPT-4) procedure codes, the ICD-9-CM procedure 
codes, and the HCFA Common Procedural Coding System (HCPCS) procedure codes. The CPT-
4 and ICD-9-CM codes are used more frequently in the dataset. The CPT-4 codes are 5 digit 
numbers and are used for identifying physician claims and outpatient facility claims. The ICD-9-
CM codes are 3 to 4 digit numbers and are used primarily for identifying hospital claims. Each 
inpatient service record has one procedure code (PROC1), which represents one inpatient 
admission. Each PROC1 is named as the principal procedure (PPROC). Each inpatient service 
record has upto 14 secondary procedure codes numbered from PROC2 to PROC15 whereas each 
outpatient service record has only 1 procedure code (PROC1). Each facility header has upto 6 
procedure codes. Certain diagnosis and procedure codes provided by payers or administrators are 
edited by Thomson Reuters® to maintain data quality (Marketscan 2007, Adamson 2008). 
3.1.3 Advantages of the database  




Marketscan is one of the largest proprietary databases available in the market since 1996 with a 
good representation of Americans covered under commercial insurance and Medicaid. During 
the recent five years, the MarketScan™ Commercial and Medicare Supplemental dataset has 29 
million patients with at least 12 month continuous enrollment in either a government or private 
insurance plan. The Marketscan data is coded comprehensively with diagnosis codes for 99% 
claims, procedure codes for 85% of physician claims, complete payment information including 
amount paid by the patient, complete outpatient prescription drug claims including copayments, 
mail order pharmacy claims, injectable claims, specialty pharmacy claims, carve out care claims, 
electronically submitted claims, plan/formulary summaries and fully paid and adjudicated 
claims. The Marketscan data contains claims for patient’s inpatient and outpatient visits, mainly 
for different services and drug therapy obtained through physician office visits, hospital stays, 
retail pharmacy, mail order pharmacy, specialty pharmacy and carve out care. Capturing claims 
for both the inpatient and outpatient care procured by patients can help in measuring if the 
patients get continuous care or not. The Marketscan Hospital Drug dataset has hospital discharge 
records with claims for inpatient drug utilization. A proprietary projection method can provide 
insight about drug usage in the hospitals, switching drugs, combination drug therapy and impact 
of drug introduction at an earlier stage on clinical and economic outcomes of the patients. The 
claims for the outpatient drug utilization in the Marketscan database helps researchers to study 
the actual drugs usage patterns unlike other claims databases, by  identifying the type of disease 
that the patient has, the drugs prescribed in combination and the impact of the clinical, 
demographic and provider characteristics on drug prescribing.   
The Marketscan dataset is also useful for designing studies with different methodologies such as 




studies, surgical and pharmaceutical treatment studies, forecasting and modeling studies, studies 
assessing evidence based practices and guidelines and clinical trials. Marketscan dataset follows 
patients over many years, thereby monitoring care received by patients on a continuous basis. 
The duration of tracking patients in the Marketscan database is much longer compared to other 
claims datasets since the data is generally obtained from employers running large firms and these 
employers have the ability to track patients across multiple health plans. The tracking of patients 
across different health plans also helps to capture patients who change health plans when they 
change jobs and thus prevents the loss of information by almost 17% as seen with other claims 
datasets.  (Marketscan 2007, Adamson 2008) 
3.1.4 Limitations of the database 
The Marketscan database has certain disadvantages mainly due to the nature of its sample and 
the claims that it contains. The data in the Marketscan dataset is generally provided by employers 
representating large firms.  Marketscan dataset does not contain claims of people employed by 
small and medium firms. Also the sample of the Marketscan dataset is a large convenience 
sample with many biases and little generalizability to other populations (Marketscan 2007, 
Adamson 2008). 
3.1.5 Construction of the MarketScan® Multi-State Medicaid Database  
The MarketScan® Multi-State Medicaid Database consists of inpatient and outpatient service 
claims and prescription drug claim records which are collected from employers, health plans, and 
state Medicaid agencies. After the data is obtained, Thomson Reuters® performs the case 
construction process that involves assembling the inpatient paid services into a single record per 




information in the form of therapeutic class, therapeutic group, manufacturers’ average, 
wholesale price, and generic product identifier. The financial, clinical, and demographic data are 
also standardized as per the commonly established definitions. The construction of the 
Marketscan dataset involves several quality checks such as checking diagnosis against age, 
diagnosis against gender and checking charge against payment to improve data validity and 
prevent incorrect coding during data construction process. The process of Marketscan dataset 
creation is detailed in figure 3.1.  The complete Marketscan dataset provides one of the largest 
collections of patient data procured from 77 employers, 126 unique carriers and 12 health plans, 
featuring over four billion patient records of 69 million covered lives.  The entire MarketScan™ 
database comprises of a total of 8 claims databases:  Commercial Claims and Encounters, 
Medicare Supplemental and Coordination of benefits (COB), Health and Productivity 
Management (HPM), Benefit Plan Design, Health Plan and Medicaid. The present study makes 























































































































3.2 Study Design  
This study was a retrospective cohort study. The MarketScan® Multi-State Medicaid Database 
was used to identify the study population.  
3.2.1 Study population  
The study population comprised of DD patients aged between 18 to 64 years who were 
diagnosed with type 2 diabetes and were prescribed at least one new oral hypoglycemic drug 
during the index period. The diagnosis of the study population was identified using the 
International Classification for Disease Code 9th revision Clinical Modification (ICD-9) codes: 
250.0x, where x=0 or 2, 343.0-343.4, 343.8,343.9, 299.00,299.01, 758.0, 317, 318.0, 318.1, 
318.2 and 319. The data from January 1st, 2003 to December 31st, 2007 was collected for 
conducting the study.  Approval from the Institutional Review Board (IRB) at the University of 
Michigan was sought prior to the approval of the study.  
3.2.2 Definitions of the terms used  
Monotherapy: an OHA medication with a single drug regimen  
Dual therapy: drug regimen with 2 anti diabetic medications taken separately (2 pills) 
Fixed-dose combination therapy: drug regimen with 2 anti diabetic medications combined 
together in fixed doses (1 pill containing both medications) 
Study period: from January 1, 2003 to December 31, 2007. Entire study period was further 
classified into three specific periods:  
Follow up periods:  
 




Medicaid eligibility of patients for baseline characteristics before starting any therapy, such as 
predisposing, need and enabling variables as specified in the theoretical model. Also, this helped 
to determine patients who did not have any OHA claims in this period and confirm a new start of 
the OHA medications in the index date. 
  
(2) Identification period: the period from January 1, 2004 to December 31, 2006 was used to 
identify patients who newly started the OHA medication/s.  
 
(3) Postindex period: this period began after the patient’s index date and extended until the end 
of the study duration. It was used to ensure that the patients had at least 12 months of follow‐up 
period, such as continuous medication prescription. Health‐related behaviors (e.g., medication 
taking behavior) and outcomes (e.g., costs) were examined in this period.  
Index date: date of first prescription claim in the identification period of patients who remain on 
the same medication therapy throughout the study period 
Index prescription: first anti diabetic prescription for patients remaining on the same 
medication therapy throughout the study duration 
Drug naïve patients: These patients had no anti-diabetic prescriptions in the pre-index period. 
Patients who were already on anti-diabetic medications (established patients) were excluded 
from the study on account of the differences in medication use behavior. Apparently, newly 
treated patients beginning their first course of medication (first-line patients) are likely to have 
significantly different medication use behavior and responses to medications compared to those 
who are on a particular therapy. The study included only newly started cases to understand the 
medication use behavior of patients who were naïve to the anti-diabetic medications therapy.  




a) therapy without a lapse of >120 days between the date of days’ supply expiration of any 
prescription fill and the subsequent claim date (days between end date of first fill and first date of 
next fill) and b) at least 2 prescriptions of the index medication 
3.2.3 Inclusion criteria  
1. Patients with continuous Medicaid eligibility in the pre and postindex periods (12 
months before and after the index date). The continuous enrollment criteria ensured that all 
patients had the same follow‐up period and reduced bias due to failure to follow‐up. We included 
patients who had continuous enrollment in each year for ≥10 months. 
2. Patients with type 2 diabetes and DD diagnosis. Patients were identified using the 
International Classification for Disease Code 9th revision Clinical Modification (ICD‐9‐CM) for 
at least one primary or secondary diagnosis of type 2 diabetes (250.0x, where x=0 or 2) and DD 
(Cerebral palsy: 343.0-343.4, 343.8,343.9, Autism: 299.00,299.01, Down syndrome: 758.0, 
Mental retardation: 317, 318.0, 318.1, 318.2, 319) from outpatient or inpatient claims during 
January 1, 2003 to December 31, 2007.  
3. Patients aged 18 to 64 years old at the index date. The reason for excluding patients aged 65 
years and above was that these patients may be dual beneficiaries (Medicare and Medicaid 
enrollees) and therefore obtaining complete data on these patients may not be possible.  
4. Drug naïve patients in the preindex period. This criteria concerns that newly treated 
patients beginning their first course of medication (first‐line patients) are likely to have 
significantly different medication use behaviors and responses to medication than those who are 
already on a particular therapy. The current study included only newly started cases to 




5. Patients starting OHA medication therapy during the index period window (January 1, 
2004 to December 31, 2006). An index prescription date was assigned to each patient. Evidence 
of OHA use was identified using therapeutic class in the MarketScan® Multi-State Medicaid 
Database. Therapeutic Class refers to a 3-digit code that indicates the therapeutic/pharmacologic 
category of the drug product. For example, the Therapeutic Class value equal to 173 and 174 
refers to patients who had an administrative claim for taking OHA. The Therapeutic Class was 
used to identify patient’s OHA use status. 
3.2.4 Exclusion criteria 
The following criteria were used to filter out the final cohort: 
1. Patients with dual eligibility (Medicaid and Medicare coverage). These patients also get 
reimbursed by Medicare hence it is difficult to get complete healthcare utilization data for them. 
These dual eligible patients mainly include elderly patients aged 65 years and above. Hence, the 
subjects of this research were limited to only Medicaid recipients younger than 65 years. Also, 
patients 18 years and younger were excluded because the present study was intended to focus on 
adults and also those patients are more likely to be type 1 diabetes.  
2. Patients diagnosed with type 1 diabetes (ICD‐9‐CM=250.0x‐250.9x, where x=1 or 3) or 
gestational diabetes (ICD‐9‐CM=648.8x, where x=0‐9). These patients were excluded from the 
study as they mainly use insulin therapy and the primary objective of this study was to measure 
OHA medication adherence.  
3. Patients who were already on OHA medication therapy (established patients) in 




4. Patients were prescribed insulin therapy. The reason for excluding these patients is that 
these are high risk patients whose level of severity is high compared to those on oral therapy. 
Additionally, medication use behavior for patients on insulin therapy is substantially different 
from those taking oral medications due to complexity of dosing regimen.  
5. Patients taking OHA medications other than sulfonylurea, metformin and TZDs. 
Research has shown that there are very few patients on meglitinides and α‐glucosidase inhibitors; 




































MarketScan® Multi-State Medicaid Database 
The study duration: 
January 1st, 2003 to December 31st, 2007 
Initial Study Cohort 
 
1.Patients newly diagnosed with ICD-9-CM codes: 250.0x‐250.9x, 
where x=0 or 2, 343.0-343.4, 343.8,343.9, 299.00,299.01, 758.0, 317, 
318.0, 318.1, 318.2, 319; during the index period: January 1st, 2004 
and December 31st, 2006. An index diagnosis date was assigned for 
each patient.  
 
2. Patients newly prescribed at least OHA during the study period: 
one year follow up after the index diagnosis date  
 
3. Patients with maintained continuous Medicaid eligibility one 
year before and one year after the index diagnosis  date  
 
Final study cohort 
 
1. Patients aged between 18 to 64 years during the study period.  
2. Drug naïve patients.  





Table 3.1 Selected variables in the main dataset 
1)Eligibility/enrollment file: 
  
   Enrollee ID (ENROLID)  
   BOE category (BOE)  
   Date enrollment start (DTSTART)  
   Day enrollment end (DTEND)  
   Patient birth year (DOBYR)  
   Gender of patient (SEX)  
   Race (STDRACE)  
   Medicaid case number (MCASENUM)  
   Medicare eligibility (MEDICARE)  
   Member days (MEMDAYS)  
   Medicaid Capitation flag (CAP)  
 
2. Inpatient admission:  
 
Enrollee ID (ENROLID)  
   Date of admission (ADMDATE)  
   Date of discharge (DISDATE)  
   Diagnosis related group (DRG)  
   Major diagnostic category (MDC)  
   Diagnosis principal (PDX)  
   Diagnosis 1 (DX 1)  
   Diagnosis 2 (DX 2)  
   Discharge status (DSTATUS)  
   Date claim paid (PDDATE)  
   Procedure principal (PPROC)  
   Procedure 1 (PROC 1)  
   Length of stay (DAYS)  
COB and other savings total case (TOTCOB) 
   Coinsurance total case (TOTCOINS)  
   Copayment total case (TOTCOPAYS)  
   Deductible total case (TOTDED)  
   Payments net case (TOTNET)  
   Payments total case (TOTPAY)  
 
3. Inpatient services:  
   Enrolled ID (ENROLID) 
   Case and services link (CASEID)  
   COB and other savings (COB)  
   Coinsurance (COINS)  
   Copayment (COPAY)  
    Diagnosis primary (PDX)  




Revenue code (REVCODE)  
Sequence number (SEQNUM)  
Place of service (STDPLAC)  
Service type (STDSVC)  
Type of provider (STDPROV)  
Date service incurred (SVCDATE)  
Date of service ending (TSVCDAT) 
 
  
4. Outpatient claims:  
 
  Enrollee ID (ENROLID)  
  Date service incurred (SVCDATE)  
  Date of service ending (TSVCDAT)  
  Date year incurred (YEAR)  
  Diagnosis 1 (DX1)  
  Diagnosis 2 (DX2)  
  Procedure 1 (PROC 1)  
  Procedure group (PROCGRP)  
  Procedure code type (PROCTYPE)  
  Place of service (STDPLAC)  
  Provider type (STDPROV)  
  Quantity of services (QTY)  
  Major diagnostic category (MDC)  
  Payment (PAY)  
  Payment net (NETPAY)  
  Date claim paid (PDDATE)  
  COB and other savings (COB)  
  Coinsurance (COINS)  
  Copayment (COPAY)  
  Coverage indicator drug (DRUGCOVG)  
 
5. Prescription drugs:  
 
Enrollee ID (ENROLID)  
Date service incurred (SVCDATE)  
Coverage indicator drug (DRUGCOVG)  
Date claim paid (PDDATE)  
National Drug Code (NDCNUM)  
Day supplied (DAYSUPP)  
Quantity of services (QTY)  
Average wholesale price (AWP)  
Ingredient cost (INGCOST)  
COB and other savings (COB)  
Coinsurance (COINS) 
Copayment (COPAY)  




Generic indicator (GENIND)  
Generic product ID (GENERID)  
Dispensing fee (DISPFEE)  
Metric quantity (METQTY)  
Refill Number (REFILL)  
Therapeutic class (THERCLS)  






























































22,093 DD patients (intellectual disability, cerebral palsy, autism) aged 18 to 64 
years had a diagnosis of type 2 diabetes from January 1st, 2004 to December 
31st, 2006 (the index period) were included. Each patient was assigned to have 
an index diagnosis date. There were 21,617 patients who had medication 
information. Patients with dual Medicare and Medicaid eligibility were 
excluded.  There were 8772 patients meeting these exclusion criteria. 
Step 3: 
 
Patients who were diagnosed with DD and were prescribed with an OHA 
during the index period were included in the study. The Medicaid IDs 
(ENROLID) were used to link the prescription drug claim to the detailed 
enrollment claim. 4,641 patients met these criteria. 
Step 4: 
 
Patients having using any OHA during the pre-index period (12 months before 
the index diagnosis date) were also excluded. There were 2505 patients 
excluded in this step. Patients were required to be continuously enrolled from 
12 months (the pre-index period) before and 12 months (the study period) after 
the index diagnosis date.  There were 1529 patients who met the criteria and 
constituted towards the final sample of this study. 
Step 1: 
 
There were 213,644 DD patients in the MarketScan® Multi-State Medicaid 




3.3 Study Perspective  
A) Patient’s perspective: 
The burden of chronic disease conditions in adults with DD is high. In addition to their disability, 
the intake of numerous medications can increase their risk of side effects and drug interactions 
(Horwitz 2000). High prevalence of chronic disease conditions, deinstitutionalization, lack of 
adequate number of trained PCPs, providers showing reluctance to treat DD patients, availability 
of few education materials for physicians, inadequate preventive care and unavailability of care 
in rural areas are some of the issues that impede DD patients’ access to care (Lewis 2002, 
Messinger-Rapport 1997). Adults with DD are subjected to prejudice and their encounters with 
primary care physicians might be painful and stressful at times.  Some providers tend to exclude 
women with DD from preventive screenings due to their assumption that they are asexual. Lower 
rates of PAP smears and mammograms in women with DD increase their risk of breast cancer 
compared to women without DD (Brown 2002, Havercamp 2004). Also higher rates of dental 
problems in this population can lead to a higher prevalence of chronic diseases such as diabetes, 
respiratory disease, osteoporosis and CVD (Horowitz 2000). Interventions such as a)providing 
health advocacy training for family members and unpaid caregivers, reimbursing them for 
regularly monitoring the health of the DD patients and ensuring that they receive the necessary 
screenings (Moss 2008) b) building patient centered planning teams involving health advocates 
and case managers, c) expanding dental coverage for Medicaid enrollees (U.S. General 
Accounting Office 2000) and d)training PCPs and specialty care providers (Fenton 2003) can 
improve continuity of care in DD patients. Interventions should focus on delivering the needed 
care quickly in DD patients. Depending on the disability, patients might not be able to make 




guardian caregivers can provide valuable insight about the DD patient’s condition. Both the 
physicians and the case managers should chalk out the best treatment options for the DD patients 
based on the patient’s quality of life and the benefits/risks associated with the treatment (Ellison 
2007). 
B) Physician’s perspective: 
There is disproportionate distribution of PCPs that serve the Medicaid population and with the 
increase in number of Medicaid patients from 2014; this need will become more pressing. The 
PCPs that are supposed to get moderate share of the Medicaid patients but end up serving more 
Medicaid population, practice in small groups whereas PCPs that are supposed to get high share 
of Medicaid patients but serve less Medicaid patients practice in hospitals and community 
centers and offer resources that are difficult to procure somewhere else. One of the reasons for 
this discrepancy in delivering care is that high share PCPs practice in high income areas that are 
more accessible to Medicare population rather than the Medicaid population (Sommers 2011).  
Larger hospitals acquiring or collaborating with small private practices can help in expanding 
access to Medicaid services, provided such a change takes place at the national level and not just 
locally. Physicians also tend to deny Medicaid patients due to lower reimbursements but besides 
that, there are several other reasons that impede the access to care in Medicaid patients such as 
lack of infrastructure, longer working hours, paperwork, difficulty in referring to specialists, 
burden of illness and hassle of attending to the non-medical needs of the Medicaid population. 
From physician’s perspective, with the enactment of the Affordable Care Act, the coverage for 
Medicaid has increased and physicians might see more of slightly healthier Medicaid patients 
than their current or past patients, thereby increasing access to services for those patients 




C) Payer’s perspective: 
This study is conducted from payer’s perspective .i.e. from Medicaid program’s perspective. The 
study looks at the combined effect of race and medication adherence on healthcare utilization in 
diabetic adults with DD. These adults and their families who are being provided health assistance 
by Medicaid have a low SES and might have dependent children.  Medicaid programs get their 
funding from the state and the federal government and the present study can help policy makers 
frame coverage policies which can in turn benefit this vulnerable group of individuals.  Medicaid 
reimbursements are made on a retrospective, fee‐for‐service basis and payments made for filling 
prescriptions comprise either the lower end of the usual payment rates or a pre-established rate of 
$1-$4. Some Medicaid programs reimburse for inpatient visits, emergency room visits, and 
physician visits for eligible patients. The payer’s perspective is chosen since better medication 
usage could potentially reduce Medicaid reimbursements alongwith reduced healthcare costs and 
resource utilization. The findings of the current study can pave the way for designing 
interventions for reducing medication non adherence, improving overall healthcare utilization 
and allocating limited healthcare resources among type 2 diabetes patients.   
3.4 Database Elements  
The dataset in this study was retrieved from the MarketScan® Multi-State Medicaid Database. 
Variables were further categorized into five groups: eligibility/enrollment, inpatient admissions, 
inpatient services, outpatient claims, and prescription drugs. Social demographic variables such 
as age, gender and race were also retrieved. Variables associated with health service utilization 






3.5 Study Variables and Measurement  
The operational definitions of the study variables and their measurements are described in this 
section. The dependent variables in this study included medication adherence, medication 
persistence, inpatient visits, outpatient visits, emergency room (ER) visits and healthcare costs. 
The key tested hypothesized independent variables were race, comorbidity, and the interaction 
effect of race and comorbidity. Other independent variables (covariates) included age, gender, 
access to healthcare, and the disease severity. A detailed operational definition of each variable is 
described in the following sections.  
3.5.1 Dependent variables  
(A)Medication Adherence:  
Medication adherence was the first dependent variable in this study.  Medication adherence 
indicates medication usage by patients.  It is act of conforming to physician’s recommendations 
with regards to the timing, dosage, and frequency of medication intake.The International Society 
of Pharmacoeconomics and Outcomes research defines medication adherence as the compliance 
of the patients with the recommended medication dosage (Hess 2006). MPR is an indirect 
measurement of patients’ medication adherence, especially when using administrative claim data. 
MPR is defined as administered doses per defined period of time, reported as a proportion (%) of 
prescribed doses (D) taken at the prescribed time interval (T) as measured by the period of time. 
In order to take the last days supply into consideration, MPR was further modified (MPRm), by 
dividing the total days‟ supply of medications by the period between the last claim date and the 





MPRm = [Number of days supply obtained/(Date of the last claim―Date of the first 
claim┼Days’ supply of the last claim)] * 100 
Medication adherence can be measured in an inexpensive and efficient way using the 
administrative claims data.  There are many ways of measuring medication adherence. It can be 
measured either directly through biological markers, blood and urine assays or indirectly through 
patient interviews, pill counts, prescription refills, and electronic monitoring (Claxton 2001, Hess 
2006). 
Knowledge of medication adherence can provide information about the frequency and timeliness 
of refills of prescribed medication and the patients are unaware if they have been measured 
which eliminates the Hawthorne effect. Karve et al (2008) reviewed eight different 
measurements of medication adherence using administrative claims data and found that MPR 
had the highest predictive validity for measuring medication adherence. Pharmacy records have 
good predictive validity for measuring medication gaps and fills (Steiner 1998).  
Recording MPRs can be challenging in presence of unusual refill patterns, multiple conflicting 
drugs and in case of patients visiting multiple pharmacies. Also, since this study will assume that 
a prescription filled is a prescription taken, it will not be possible to measure actual medication 
consumption (Balkrishnan 2005, Hess 2006). In this study, medication adherence was coded as a 
dichotomous variable. The cut off for MPR was set to 0.8 based on the evidence presented by 
Karve et al (2008). This cut off could accurately predict inpatient visits caused by medication 
non adherence especially in type 2 diabetes patients.  
Working Definition of Medication adherence:  




OHAs. Since the current study uses a claims dataset, claims for prescription refills were used to 
measure medication adherence. In the current study, the observation period begins with the first 
date of dispensing within each year and ends with the last dispensing date of the last prescription.  
Information about filled prescriptions was extracted from the Medicaid claims. Each prescription 
record had the following information: dosage, quantity dispensed, date of the drug supplied, and 
number of days supplied. Specific formulae for computing the MPR was as follows: 
For monotherapy or fixed dose regimen: MPR= Total days’ supply obtained/ (Date of 
the last claim―Date of the first claim ┼ Days’ supply of the last claim) 
 
For dual therapy or fixed dose regimen: MPR= (Total days’ supply obtained/2)/(Date 
of the last claim―Date of the first claim ┼ Days’ supply of the last claim) 
The Marketscan Medicaid database has claims for a 30 days supply of OHAs. The days supply 
was calculated by dividing the total amount of dispensed OHAs by the maximum amount of 
OHAs used in aday. The observation period for the current study included the post-index period 
or at least a 12 month follow up period. The number of hospital days were subtracted from the 
denominator since any OHA intake during this period was supplied by the hospital and could be 
captured in pharmacy records (Cramer 2008, Vanderpoel 2004, Karve 2009, Karve 2008, Hess 
2006, Farmer 1999, Balkrishnan 2005). 
 (B)Medication persistence: Medication persistence measures the duration from the initiation to 
the discontinuation of a medication. It measures the accordance of the patient with the drug 
therapy for the intended duration. It was possible to measure medication persistence in the 




this study, medication persistence was be defined as the duration of an OHA intake i.e. the 
number of days during which an OHA is started and discontinued. Studying gap between 
medication refills can help understand medication persistence. Delay in medication refill can be 
an indicator of poor medication adherence but not necessarily an indicator of poor medication 
persistence. Delay in medication refill can be attributed to reasons such as improvement in 
clinical outcomes or occurrence of adverse events. Hence, studying medication persistence to 
OHAs is important.  Patients were defined as non-persistent if they had a refill gap greater than 
120 days in the current study (Cramer 2008, Linden 2000, Mullins 2005, Mullins 2006, Farmer 
1999). 
 
(C) Outpatient visits: The number of outpatient visits was a count variable identified from the 
MarketScan® Multi-State Medicaid Database. Outpatient visits were also coded dichotomously. 
In the data, each procedure was assigned to have a procedure code. Patients who had the 
procedure code equal to 101 (office visits for new patients) or 104 (office visit for existing 
patients) were determined as having an outpatient visit during the study period.  
(D)Inpatient visits: Inpatient visit was a dichotomous and a count dependent variable in this 
study. Patients were identified as having an inpatient visit if they had an event of any inpatient 
visit in the claims. Variables such as date of admission and date of discharge in the MarketScan® 
Multi-State Medicaid Database were used to identify patients’ inpatient visits.  
(E)Emergency Room (ER) visit: Patients were identified as having an ER visit if they had any 
of the following events reported in the MarketScan® Multi-State Medicaid Database. Based on 
the procedure codes, the MarketScan® Multi-State Medicaid Database provided an indicator 
variable for the type of related outpatient procedures. Patients who had the procedure group 




room visits) were determined as having an ER visit during the study period. The ER visit 
variable was coded as a dichotomous (yes/no) variable and as a count variable.  
Type 2 diabetes has the ICD-9-CM code of 250.0x, where x=0 or 2. Any patient utilization 
related to the above ICD-9-CM code was defined as type 2 diabetes related healthcare utilization. 
For example, a type 2 diabetes-related office visit, coded as dichotomous (yes/no), was 
determined by whether patients had an office visit related to type 2 diabetes during the study 
period.  
(F)Healthcare costs: Patients healthcare costs were directly identified from the MarketScan® 
Multi-State Medicaid Database. The overall healthcare costs included patient’s inpatient, 
outpatient, and prescription expenditures during the study period. Type 2 diabetes healthcare 
costs were the expenditures that were relevant to the DDs identified using the ICD-9-CM codes.  
3.5.2 Independent variables  
(A)Race: Race was self-reported information obtained from patients when they were first 
enrolled in the Medicaid program. The variable was directly derived from the MarketScan® 
Multi-State Medicaid Database. It was categorized as Caucasians, African Americans and other 
races.  
(B) Medication Adherence: Medication adherence during the 12 month study period was 
calculated using MPRm. Medication adherence with a MPRm>0.8 was classified as high 
medication adherence and MPRm<0.8 was classified as low medication adherence.  DD patients 
with a diagnosis of type 2 diabetes were classified as having low or high medication adherence 
for anti-diabetic medications. MPRm was coded as dichotomous (>0.8/<0.8) variable. 




interaction term between race and medication adherence.   
3.5.3 Other independent variables (covariates)  
The selection of covariates was based on the proposed theoretical framework in Figure 2.5. 
Variables were categorized into three groups: predisposing factors, enabling factors, and need 
factors. Predisposing factors included sociodemographic variables, such as age and gender. 
Enabling factors included variables related to access to healthcare and economic variables. Need 
factors were variables related to the severity of the disease.  
Each group of covariates is described in the following sections.  
(A)Predisposing factors:  
Sociodemographic variables: Sociodemographic variables in this study included patients age 
and gender. Patient’s age was calculated as the year of index date minus the year of birth. All 
sociodemographic variables were identified from the MarketScan® Multi-State Medicaid 
Database.  
(B)Enabling factors:  
Economic variables: The economic variables in the current study were determined by the type 
of health plan (FFS vs. capitation vs dual). The type of health plan was directly identified from 
the MarketScan® Multi-State Medicaid Database.  
(C)Need factors:  
Need factors: Need factors in the Andersen model were referred as the severity of the disease. 
Need factors in this study included number of prescription refills, variables of the pre-index 




(D)Variables of the pre-index period resource utilization:  
Several variables in the pre-index period considered to have an influence on medication-related 
outcomes in the index period were included and adjusted when performing data analyses. 
Patients having high health resource utilization in the pre-index period could also have high 
health resource utilization in the index period. Therefore, variables in the pre-index period 
related to health resource utilization were controlled. Variables related to health resource 
utilization in the pre-index period included the outpatient visits in the pre-index period (yes/no), 
inpatient visits in the pre-index period (yes/no) and Charlson comorbidity index in the pre-study 
period (yes/no).  A comorbidity index was used to adjust the influence of comorbid conditions 
other than DD on health outcomes. The Charlsonr index used to adjust the comorbid conditions 
in this study, will be discussed in the following sections.  
(E)The Charlson comorbidity index: Comorbidity indices identify the comorbid conditions in 
patients and apply weights to those conditions depending on the disease severity. The weight that 
is assigned to a comorbid condition depends on its impact on the main disease condition.  In 
1987, Charlson developed a comorbidity index based on 17 comorbidities (Charlson 1987).  The 
comorbid conditions included in the Charlson’s index are myocardial infarction, congestive heart 
failure, peripheral vascular disease, cerebrovascular disease, dementia, rheumatologic disease, 
ulcer, mild liver disease, hemiplegia, moderate or severe renal  disease, any tumor, leukemia, 
lymphoma, moderate or severe liver disease, metastatic solid tumor, and AIDS. ICD-9-CM codes 
used to identify these conditions are given in table 3.2.  The Charlson index assigns weights of 1, 
2, 3 or 6 to the 17 comorbid conditions based on their severity. The diseases that have a higher 
impact on mortality such as cancer or AIDS have a weight of 6 as opposed to conditions such as 




for all the 19 comorbidities are totaled for each patient to calculate the index severity score. The 
index has been used to measure in hospital mortality (Poses 1996, Sundararajan 2007) and post 
discharge mortality (Charlson 1994).  To assess the risk of mortality, occurrence of disease in 
patients can be accessed through medical charts, medical examinations, interviews and 
recollection of events. The Charlson index, though mainly developed for measuring mortality as 
an outcome, is now being used to measure outcomes such as healthcare utilization and healthcare 
costs (Charlson 2008). The Charlson index has been adapted for its use in administrative claims 
databases (Deyo 1992, D’Hoore 1993, Romano 1993). This study uses the Deyo’s modification 
of the Charlson index. The Deyo version can be used to measure the risk of mortality associated 














Table 3.2 ICD-9-CM codes of conditions included in Charlson Index 
        Comorbidity                      ICD-9-CM Codes 
1. Myocardial infarction     410.x, 412.x 
2. Congestive heart failure    428.x 
3. Peripheral vascular 
    disease  
  443.9, 441.x, 785.4, V43.4 
   Procedure 38.48 
4. Cerebrovascular disease   430.x–438.x 
5. Dementia  290.x 
6. Chronic pulmonary 
Disease 
 490.x–505.x, 506.4 
7. Rheumatic disease  710.0, 710.1, 710.4, 714.0–714.2, 714.81, 725.x 
8. Peptic ulcer disease  531.x–534.x 
9. Mild liver disease  571.2, 571.4–571.6 
10. Diabetes without chronic 
Complication 
250.0–250.3, 250.7 
11. Diabetes with chronic 
Complication 
250.4–250.6 
12. Hemiplegia or paraplegia  344.1, 342.x 
13. Renal disease  582.x, 583–583.7, 585.x, 586.x, 588.x 
14. Any malignancy, 
including lymphoma 
and leukemia, except 
malignant neoplasm of 
skin  
15. Moderate or severe liver 
disease 













3.6 Statistical Analyses and Hypothesis Testing  
The objective of the current study was to examine the association of race and medication-related 
outcomes (medication utilization, medication persistence, medication adherence, and medication 
expenditures) in Medicaid-enrolled DD patients with type 2 diabetes. The required statistical 
analyses employed in examining the study objectives and hypothesis testing are described in the 





3.6.1 Study objectives  
Objective 1: To describe select patient characteristics (sociodemographic factors and 
medication-related factors) of Medicaid-enrolled DD patients with a diagnosis of type 2 diabetes 
and examine the predictors of medication adherence in Medicaid-enrolled DD patients with a 
diagnosis of type 2 diabetes, after adjusting for select confounders.  
Descriptive statistics were used to describe patient characteristics, which included 
sociodemographic factors and medication-related factors such as healthcare costs, prescription 
utilization, and health service utilization of DD patients with diagnosis of type 2 diabetes. The 
average value (mean) was used to describe the continuous variables and a proportion (%) was 
used to describe the categorical variables. The Student‟s t-test was used to differentiate the mean 
difference of the continuous variables between DD patients with a diagnosis of type 2 diabetes. 
Chi-square tests were used to assess the difference of the categorical variables between DD 
patients with a diagnosis of type 2 diabetes.  
Medication adherence was assessed by MPRm, which was the dependent variable in the 
regression model. An Ordinary Least Squares (OLS) regression model was used to assess the 
association between MPRm and key tested variables as well as other covariates. When the 
dependent variable is skewed and heteroskedastic, a log-transformation for the dependent 
variable is needed. Shapiro-Wilk test and White test were used to test the normality and 
heteroskedasticity (D'Agostino 1971). A log-transformed MPRm is not necessary if the 
distribution of MPRm values is normal.  The OLS regression model was used to examine the 
association between medication adherence and race. The key tested variable was race. The 
selection of covariates was based on the proposed theoretical framework shown in Figure 2.5. 




included age and gender. Enabling factors in this study were determined by the type of health 
plan (FFS vs. Capitation). Need factors in the study referred to the number of prescription refills 
and severity of the disease. The factors determined were if patients had inpatient visits in the pre-
study period (yes/no), if patients had outpatient visits in the pre-study period (yes/no), if patients 
had ER visits in the pre-study period (yes/no), the Charlson comorbidity index during the study 
period and the Charlson comorbidity index during the pre-study period. The following equations 
show the OLS regression model that includes key tested variables, predisposing factors, enabling 
factors, and needed factors as well as their relationship with MPRm. 
Y:MPRm = β0 + β1 (race) + β2 (predisposing factors) + β3 (enabling factors) + β4 (need factors) 
+ error 
 
The interpretation of the association between MPRm and covariates is that for every unit 
increase in a particular covariate, the value of MPRm will be assumed to change with a 
parameter unit of the particular covariate, holding all other variables in the model constant. In 
addition to evaluating medication adherence as a continuous variable, medication adherence was 
further categorized into a dichotomous variable. A value of MPRm smaller than 80% (MPRm< 
80%) was defined as lower adherence (Karve 2009). Logistic regression was used to examine the 
association between the likelihood of being adherent to the medications and race, after adjusting 
for other covariates. The following logistic regression model describes the association. 
Y:Medication adherence (yes/no) = β0 + β1 (race) + β2 (predisposing factors) + β3 (enabling 
factors) + β4 (need factors) + error 
 




patients with a diagnosis of type 2 diabetes, after adjusting for select confounders.  
Medication persistence in this study was operationally defined as the duration for which 
prescriptions were taken. It was the number of days determined by the initiation of taking the 
medicine to the end of taking the medicine. Medication persistence is a time-dependent variable. 
The censored time was referred as the time of persistently taking anti-diabetics during the study 
period. Unadjusted Kaplan-Meier survival curves were used to compare the differences of 
censored time between Caucasian and African American DD patients with a diagnosis of type 2 
diabetes. A Cox proportional hazard model was used to estimate the different hazard ratios in 
patients from different races who were the first to stop taking OHAs, after adjusting for other 
covariates. The following equation describes the Cox proportional hazard model. 
Y:Medication persistence (time) = β0 + β1 (race) + β3 (predisposing factors) + β4 (enabling 
factors) + β5 (need factors) + error 
 
Objective 3: To examine the effect of race, medication adherence, and the combined effects of 
race and medication adherence on type 2 diabetes related health resource utilization (outpatient 
visits, inpatient visits and emergency room (ER) visits) in Medicaid enrolled DD patients with a 
diagnosis of type 2 diabetes, after adjusting for select confounders.  
Type 2 diabetes related health resource utilization in DD patients such as outpatient visits, 
inpatient visits, and ER visits were considered as count dependent variables in this study. OLS 
regression was not appropriate to obtain a robust estimate for assessing the association between 
healthcare utilization and race. Due to the differences between the variance and the mean, the 
negative-binominal distribution was more appropriate for assessing the association. Since the 




regression model was used to model the association of type 2 diabetes related health resource 
utilization with race, medication adherence, and combined effects, adjusting for other covariates. 
Multivariate logistic regression analyses constituted the first part of the two-part model. Logistic 
regression analyses were used to estimate the probability of occurrence of any event of health 
resource utilization. Then, the second part was the multivariate negative binominal regression 
analyses. It was used to estimate the level change of health resource utilization among patients 
having at least one event of health resource utilization.  
 
Logistic regression analyses:  
Y: type 2 diabetes related office visits (yes/no) = β0 + β1 (race) + β2 (medication adherence ) + 
β3 (combined effect) + β4 (predisposing factors) + β5 (enabling factors) + β6 (need factors) + 
error 
 
Y: type 2 diabetes related inpatient visits (yes/no) = β0 + β1 (race) + β2 (medication adherence ) 
+ β3 (combined effect) + β4 (predisposing factors) + β5 (enabling factors) + β6 (need factors) + 
error 
 
Y: type 2 diabetes related ER visits (yes/no) = β0 + β1 (race) + β2 (medication adherence ) + β3 
(combined effect) + β4 (predisposing factors) + β5 (enabling factors) + β6 (need factors) + error 
 
Negative binominal distribution regression analyses 
Y: type 2 diabetes related office visits (a count variable, the number of office vists) = β0 + β1 





 (enabling factors) + β6 (need factors) + error 
 
Y: type 2 diabetes related inpatient visits (a count variable, the number of inpatient visits) = β0 + 
β1 (race) + β2 (medication adherence) + β3 (combined effect) + β4 (predisposing factors) + β5 
(enabling factors) + β6 (need factors) + error 
 
Y: type 2 diabetes related ER visits (a count variable, the number of ER vists) = β0 + β1 (race) + 
β2 (medication adherence) + β3 (combined effect) + β4 (predisposing factors) + β5 (enabling 
factors) + β6 (need factors) + error 
 
Objective 4: To examine the effect of race, medication adherence , and the combined effects of 
race and medication adherence on type 2 diabetes related costs including medications, medical 
and overall costs in Medicaid enrolled DD patients with diagnosis of type 2 diabetes after 
adjusting for select confounders.  
An OLS regression model with log transformation was used to assess the association between 
type 2 diabetes related healthcare costs and key tested variables as well as covariates in the 
regression model. Since the healthcare costs were highly skewed, log transformation was needed 
to obtain normality. The log-transformed OLS model was an exponential model, with non-linear 
estimated regression coefficients. In order to obtain the incremental effect of a one-unit change 
of the estimated regression coefficients, retransformation was necessary. A “smearing” term was 
incorporated in the retransformation process (Manning 1998, Duan 1983). The assumption of the 




homoscedasticity exists among the errors. A Breusch-Pagan test was used to test the 
heteroskedasticity in this study (Breusch 1979). 
Y:Ln (type 2 diabetes related medication costs) = β0 + β1 (race) + β2 (medication adherence) + 
β3 (combined effect) + β4 (predisposing factors) + β5 (enabling factors) + β6 (need factors) + 
error 
 
Y:Ln (type 2 diabetes related medical costs) = β0 + β1 (race) + β2 (medication adherence) + β3 
(combined effect) + β4 (predisposing factors) + β5 (enabling factors) + β6 (need factors) + error 
 
Y:Ln (type 2 diabetes related overall costs) = β0 + β1 (race) + β2 (medication adherence) + β3 
(combined effect) + β4 (predisposing factors) + β5 (enabling factors) + β6 (need factors) + error 
 
3.7 Regression Diagnostics  
An OLS regression model has certain assumptions such as existence, linearity, independence, 
homoscedasticity and normality that need to be met so that robust estimates can be obtained. The 
assumption of existence means that the dependent variable Y with a finite mean and variance 
depends on value of the independent variable X. Linearity assumption means that the mean value 
of dependent variable Y is a straight-line function of independent variable X. In this study, MPR 
is a linear function of the independent variables and other covariates. Thus, the current study 
meets both the assumptions of existence and linearity. The current study also meets the other 
statistical assumptions such as independence, homoscedasticity and normality by using a variety 
of regression diagnosis described in the sections below. Overall, the OLS model to be 





3.7.1 Autocorrelation  
Cross sectional studies generally meet the OLS assumption that each dependent variable is 
independent of the other dependent variables i.e. each Y is not correlated with others Ys in the 
study.  When this assumption is violated, autocorrelation, a time series problem occurs and errors 
from one period are correlated with errors from another period. Autocorrelation is generally seen 
in studies involving medication adherence to chronic disease conditions and therefore OLS 
regression model should always be checked for autocorrelation. Due to autocorrelation, the 
estimators become inefficient and biased. Autocorrelation can be detected using the Durbin-
Watson test. The null hypothesis of this test states that autocorrelation gets removed over time. 
The Durbin-Watson test statistic value is between 0 and 4 and a value of 2 indicates no 
autocorrelation over time. In terms of interpretation, a positive autocorrelation can be detected if 
the Durbin-Watson test statistic value is close to 0.143 and a negative autocorrelation can be 
detected if the Durbin-Watson test statistic value is close to 4. The positive and negative nature 
of autocorrelation can be determined by plotting the graph of residuals against time. 
Autocorrelation can be removed from the model by using lagged variables in the model or GLS 
regression (Kleinbaum 1998, Gujarati 2003). 
3.7.2 Heteroskedasticity  
One of the assumptions of the OLS model employed in this study is that the variance of error 
term is constant for any value of independent variable. This assumption is called 
homoskedasticity. If the variance of the error term is correlated with any of the independent 
variables, the error variance will also be different for each observation. Heteroscedasticity is an 
OLS violation. Heteroscedasticity occurs in an OLS model in error learning models, upon use of 




outliers and when the distribution is skewed.  Heteroskedasticity leads to biased standard errors 
of parameter estimates even though the parameter estimates are not biased, less significant F and 
t test due to large standard errors, narrow confidence intervals and very large OLS variance 
estimators. The Busch -Pagan-Godfrey test can detect heteroskedasticity in an OLS model. In the 
Busch-Pagan-Godfrey test, OLS is estimated followed by obtaining residuals and error variance. 
The squared residuals are divided by error variance to construct a variable p which is regressed 
on Z’s; some or all of independent variables can serve as Z.  The explained sum of squares (ESS) 
is obtained, θ is defined as ESS/2 and the null θ hypothesis of homoscedasticity states that θ 
follow the chi-square distribution with (m -1) degrees of freedom, where m is number of Z’s. 
Thus the Breusch-Pagan-Godfrey test looks at the dependence of the estimated variance of the 
residuals obtained by running an OLS model on the values of the independent variables.  
If the null hypothesis is rejected, heteroskedasticity exists. Unlike the Breusch-Pagan-Godfrey 
test, the Goldfeld-Quandt test works accurately  provided a certain number of central 
observations are omitted the independent variable related to variance is identified. Breusch-
Pagan-Godfrey test is a desirable test for identifying heteroskedasticity (Kleinbaum 1998, Gujarati 
2003). 
3.7.3 Normality  
The accuracy and reliability of an OLS regression model depends on the fulfillment of its 
normality assumptions. Robustness of the point estimates and confidence intervals in an OLS 
regression model can be obtained by making the distribution of the fixed values of X and Y 
normal. Normality can be confirmed employing the Shiparo-Wilk test and a plot histogram of 
residuals. If the distribution is normal, the dependent variable Y can be log transformed. 




transforming the log of Y, it is necessary to confirm that non violation of the assumptions of 
homoscedasticity (Kleinbaum 1998, Gujarati 2003). 
3.7.4 Multicollinearity  
When an OLS regression model is to be applied, the model should satisfy the basic assumptions. 
With the basic assumptions satisfied, the model should be checked for multicollinearity. 
Multicollinearity occurs when one or more independent variables are linearly related with other 
independent variables. If multicollinearity persists, the beta coefficients of the mutlicollinear 
variables cannot be measured correctly since there is not enough variation between them which 
makes estimating their separate effects challenging.  Multicollinearity can be attributed to many 
causes such as true linearity between the independent variables, inadequate data collection, over 
determined model and addition of too many polynomial variables. Multicollinearity is less than 
perfect and it can lead to instability of the point estimate and the standard error. The OLS 
estimate changes are correlated with small changes in data. In case of imperfect 
multicollinearity, the beta coefficients can still be estimated using OLS which provides the best 
linear unbiased estimates but also large standard errors, statistically insignificant t and large 
confidence intervals for parameter estimates. Multicollinearity can be detected using the 
Variance Inflation Factor (VIF), an index that determines the change in the magnitude of the 
variance of an estimated coefficient that correlates with multicollinearity. The VIF value is 
directly proportional to the degree of multicollinearity in the model and a VIF value of 10 
indicates severe multicollinearity.  Other ways of detecting multicollinearity are observing the 
correlations between independent variables, checking for high R-squared and presence of several 
insignificant t tests, wrong signs for coefficients and big changes in estimated coefficients upon 




model, running auxiliary regressions (obtained by regressing one independent variable over 
others) and gathering more sample data or expressing variables in deviation terms (Kleinbaum 
1998, Pagano 2000). 
3.7.5 Model Specification 
When one or more applicable variables are not included in the model or when one or more 
unrelated variables are included in the model, a specification error occurs. If the applicable 
variables are absent in the model, the common variance may be erroneously shared by the 
applicable variables and this may lead to inflation of the error terms in the model. On the other 
hand, if the unrelated variables are present in the model, the common variance may be 
erroneously shared by the applicable variables and this may lead to deflation of the error terms in 
the model. The regression coefficients can be affected considerably due to presence of 
specification errors in the regression model (Vittinghoff 2004). 
3.7.6 Model diagnostics 
Specification errors can be detected in the linear regression models using the specification error 
link test. The goodness of fit for the logistic regression models can be determined by using the 
Hosmer Lemeshow chi square test. The discrimination power of the model can be measured 
using the Receiver Operating Characteristics (ROC) curve. For the multivariate negative 
binomial regression models, the likelihood ratio (LR) test and the Vuong test can be performed 
respectively. Both the LR and the Vuong test are considered significant if their p value is less 
than 0.05 (Vittinghoff 2004). 
3.7 Data Management and Analyses  
The data extraction, management and analysis of the Marketscan ® Multi-State Medicaid 




(StataCorp 2013, SAS Institute 2011). Estimates of means, proportions, and standard errors with 
95% confidence intervals (CI) were derived from the statistical estimation. Two-tailed tests and a 
0.05 level of significance were used to determine statistical significance. The study protocol was 



























Chapter 4 Manuscript One  
 
Title: Predictors of medication adherence and persistence in Medicaid Enrollees with 
Developmental Disabilities and type 2 diabetes  
 
Abstract 
Objectives: The prevalence of diabetes mellitus is high among patients with developmental 
disabilities (Cerebral Palsy, Autism, Down’s syndrome and cognitive disabilities). 
Developmentally disabled individuals experience delays in detection of chronic comorbidities, 
poor disease management and low quality of care.  This research examines the racial health 
disparities in medication adherence and medication persistence in developmentally disabled 
adults with type 2 diabetes enrolled in Medicaid.  
Methods: This was a retrospective cohort study based on the Health belief model and Aday 
Anderson’s model of healthcare utilization. The dataset used for this research was the 
MarketScan® Multi-State Medicaid Database.  Adults aged 18-64 years with a prior diagnosis of 
a developmental disability (cerebral palsy/autism/down’s/cognitive disabilities) and a new 
diagnosis of type 2 diabetes enrolled in Medicaid from January 1, 2004 and December 31, 2006, 
were included. Adults were included if they had a continuous enrollment for at least 12 months 
and were excluded if they were dual eligible. Anti-diabetic medication adherence and diabetic 
medication persistence were measured using multivariate logistic regression and the Cox-





Results: The study population comprised of 1529 patients. After controlling for covariates, 
African Americans had significantly lower odds (25%) of adhering to anti-diabetic medications 
compared to Caucasians (OR = 0.75, 95% CI = 0.58-0.97, p<0.05).  Also, after controlling for 
other covariates, the hazard was higher in African Americans compared to Caucasians (Hazard 
Ratio = 1.03, 95% CI = 0.91-1.18, p<0.629).  
Conclusion: The needs of the developmentally disabled individuals are somewhat different than 
the needs of individuals without disabilities. Policy recommendations should focus on increasing 
the number of outpatient centers as well as primary caregivers who can understand the disease 
management needs of the patient and accordingly collaborate with other specialized healthcare 















Developmental disabilities (DD) are a group of conditions that begin during the developmental 
period, and may result in physical, learning, language, or behavioral impairments. These 
conditions, affecting around one in six children in U.S., may impact everyday functioning, and 
usually last through a person’s lifetime (Boyle 2011).  According to recent estimates, about 15%, 
of children aged 3 through 17 years have one or more DD. These disabilities include ADHD, 
autism, cerebral palsy, downs syndrome, hearing loss, intellectual disability, learning disability, 
vision impairment and other developmental delays (Boyle 2011). Research shows that adults 
with developmental disabilities (DD) tend to have a more sedentary lifestyle, do not exercise 
often and tend to consume high calorie diet (McGuire 2007, Temple 2003, Ewing 2004). These 
practices can lead to obesity which is a risk factor for type 2 diabetes. Type 2 diabetes is a 
leading cause of morbidity, mortality, functional disability, reduced quality of life and several 
micro and macrovascular complications such as cardiovascular illnesses and blindness (Norris 
2011, Gregg 2002).  
According to the 2011 Centers for Disease Control and Prevention estimates, 25.8 million 
children and adults out of 311 million have diabetes and out of these 25.8 million, there are about 
7 million people who have undiagnosed diabetes. In 2009, the number of diabetic people was 
23.6 million so in just 2 years, this number has increased by 2.2 million (CDC 2011, U.S. Census 
Bureau). Adults older than 65 years have a seven times higher risk of developing type 2 diabetes 
compared to adults aged 20-44 years old (Diabetes Report Card 2012). In 2007-2009, the age 
estimated numbers stated that adults aged 20 years or more who were diagnosed with diabetes 
constituted 16.1% American Indians and Alaskan Natives, 12.6% non Hispanic African 




respectively (CDC 2011). Medicaid enrollees have twice the prevalence of diabetes compared to 
the general US population (Cohen 2007, Smith 2006). Debilitating comorbidities in diabetic 
patients can make the process of medication adherence challenging since more the number of 
conditions the patient has, more are the medications and more complex is managing several 
conditions at the same time. About 40% patients with diabetes have as many as three 
comorbidities (Maddigan 2005). Medication therapy in type 2 diabetes helps in achieving 
optimum glycemic control (Rozenfeld 2008, Ho 2006, Krapek 2004, Lawrence 2006, Schectman 
2002, Pladevell 2004), controlling the related micro and macro vascular complications (UKPDS 
33 1998, Stratton 2000) and reducing mortality (Ho 2006). The National Diabetes Statistics 
estimated by the 2007-2009 National Health Interview Survey show that among US based adults 
with either type 1 or type 2 diabetes, 58% consume only oral medications, 14% take both insulin 
and oral medications, 12% take only insulin and the remaining 16% do not take either of the two 
respectively (National Diabetes Statistics 2011). In a study by Krepek (2004), higher adherence 
levels were associated with a 10% reduction in HbA1c (Krapek 2004). 
According to Adams et al (2005), African –Americans were more likely to display increased 
HbA1c in a HMO setting after adjusting for baseline Hba1c, Body Mass Index (BMI), age, 
annual measures of type of diabetes medications, diabetes-related hospitalization, number of 
HbA1c tests, physician visits, and non-diabetes medications. Minority patients with DD face 
cultural and language barriers in accessing healthcare and therefore have poor health outcomes.  
(Surgeon General Report 2002) In studies conducted in US and Australia, mortality rate was 
higher among African Americans with Down syndrome compared to Caucasians and among 
aboriginal adults with DD respectively (Ouellette-Kuntz 2005). 




Medical Expenditures Panel Survey (MEPS) showed that the prevalence of diabetes was higher 
in adults with cognitive disabilities (19.4%) compared to adults without cognitive disabilities 
(3.8%) (Reichard 2011).  Adults with DD experience disparity in receipt of healthcare due to 
their physical and mental chronic comorbidities (Havercamp 2004, Fisher 2004, Parish 2006, 
Phillips 2002). Limited information exists about the prevalence and management of type 2 
diabetes in adults with DD. The management of diagnosed chronic disease conditions in DD 
patients is poor (Beange 1995). Adults with cognitive disabilities are more likely to have four or 
more chronic disease conditions (Reichard 2011). 
One study conducted in the Kansas Medicaid population showed that DD patients with diabetes 
had lower quality of care compared to the national standards (Shiremen 2010). Another study 
conducted in the same state showed that the screening rates of patients were better than the 
national standards, provided the diabetic patients had only physical disabilities (Reichard 2012). 
There is not a single study to date that has looked at the medication usage outcomes in adults 
with DD and type 2 diabetes. The life expectancy of the adults with DD has increased in recent 
decades but the additional years brought along by the increase in life expectancy have also 
brought along the burden of morbidity. There is a national concern about the health of adults 
with DD. They possess a higher risk for developing type 2 diabetes, need special 
accommodations for getting the appropriate care and face a number of challenges in accessing 
healthcare. Hence, this research looks at the fulfillment of type 2 diabetes needs in adults with 
DD enrolled in Medicaid, with regards to medication adherence and medication persistence. 
Methods  
Data source: 




data representing eight states in the United States. The Marketscan database also has information 
about the enrollment history, diseases that patients have, inpatient and outpatient claims, clinical 
variables, demographics and prescription claims. Patients’ chronic disease conditions were 
diagnosed by using ICD-9-CM codes. Each patient also has a unique enrollee identifier which 
remains same during the entire period of enrollment in the database (Thomson Reuters 2007).
 
 
Sample selection:  
The study is a retrospective cohort study with the study population enrolled from January 1st, 
2003 to December 31st, 2007.  The inclusion criteria comprised of participants aged 18-64 years 
with a developmental disability (DD) and a new diagnosis of type 2 diabetes. The index period 
was from January 1st, 2004 and December 31st, 2006. The study measured claims for oral 
hypoglycemic drugs newly started during the index period. Each subject was assigned an index 
diagnosis date when they first got a prescription filled for diabetes. The study population had a 
continuous enrollment of 12 months after the index diagnosis date. Patients with Medicaid and 
Medicare coverage (dual eligibles) were excluded.  Only subjects who did not have claims for 
oral hypoglycemic medications in the 12 months before the index diagnosis date were included. 
After employing all the inclusion and exclusion criteria, the final study sample had 1,529 
patients. Figure 4.1 presents a flowchart outlining the process of sample selection. ICD-9 codes 







Study variables:  
Dependent variables:  
Adherence:  
The first dependent variable in this study was medication adherence.  Medication adherence was 
measured by using the Medication Possession Ratio (MPR). MPR is a widely accepted measure 
used in administrative claims dataset for determining medication adherence. MPR is defined as 
the number of days’ supply during the study duration divided by the total number of days in the 
study duration (Karve 2008). The modified MPR (MPRm) takes into consideration the last day’s 
supply. MPRm is defined as the total days supply of medications divided by the difference 
between the days supply of medications on the first and the last claim date added to the days 
supply of medications on the last date (Hess 2006, Vanderpoel 2004). In this study, MPRm was 
treated as a continuous variable and categorized as a dichotomous variable with a value of 
greater than or equal to 0.8 (high adherence) and less than 0.8 (low adherence) (Karve 2008). 
Persistence: 
The second dependent variable of the study was medication persistence. Medication persistence 
is defined as “the duration of time from initiation to discontinuation of therapy” (Cramer 2004). 
For the purpose of the study, medication persistence was defined as the period from the start of 
the anti-diabetic medication therapy to its discontinuation. Patients with refill gaps were also 
included in the study since a late refill might indicate lower medication adherence but not 
necessarily non-persistence. A gap of more than 120 days was considered as discontinued anti-
diabetic therapy. In other words, patients with more than 120 days between two medication 




Key tested independent variables:  
In this study, race was the main independent variable. Race was categorized as Caucasians, 
African Americans and other races. The information about race was obtained from patients upon 
initial enrollment in the Medicaid program.  
Covariates:  
The covariates were selected based on the Andersen’s model of healthcare utilization (Andersen 
2008, Andersen 2007). According to the model, healthcare utilization can be predicted by 
predisposing, enabling and need based factors (Andersen 2008, Andersen 1973, Andersen 1995, 
Andersen 2007). The predisposing covariates that were chosen for this study consisted of age 
(grouped as 18-30, 31-40, 41-50, 51-60, and 61-64 years) and gender.  The enabling factor that 
could enable patients to access healthcare was the type of health plan (fee-for-service, capitation, 
and dual). Severity of the disease is a need factor and it was measured in the study by 
determining the number of prescription refills (2-5, 5-10 and >10), the number of outpatient 
visits during the pre-index period (yes/no), the number of inpatient visits during the pre-index 
period (yes/no) and the Charlson comorbidity index during the pre-index period (0 and ≥1). The 
Charlson comorbidity index was used to control the overall severity of the illness in the study 
population. The index comprises of 19 different disease conditions and can predict mortality due 
to the severity of the comorbid disease conditions (Charlson 1987). 
Statistical analyses  
Patient demographic characteristics were studied using descriptive statistics.  A student’s t test 
and chi square test were used to compare MPRm in type 2 diabetic patients with DD by race 




syndrome and Cognitive disability), respectively.  A multivariate linear regression and a logistic 
regression (MPRm ≥ 0.8) were employed to assess the racial disparities in type 2 diabetic 
medication adherence in DD patients respectively, after controlling for other covariates. 
Medication persistence was measured by conducting survival analysis and a Cox proportional 
hazards model. The censored time was defined as the time during which patients persistently 
took anti-diabetic medications during the enrollment period. Racial and condition based 
differences in the censored time of the DD patients were studied using the unadjusted Kaplan-
Meier survival curves. A Cox proportional hazard regression model was used to evaluate the 
racial differences in the hazards of time associated with discontinuing type 2 diabetic 
medications, after adjusting for other covariates.  Data for the study was analysed using STATA 
13 (StataCorp 2013). Statistical significance was attributed to variables with a p value of less 
than 0.05. The study proposal was approved by the Institutional Review Board (IRB) at the 
University of Michigan.  
Results  
The demographic characteristics of the study population are presented in table 4.2. There were a 
total of 1529 Medicaid enrollees with DD and type 2 diabetes in the study, meeting the inclusion 
and exclusion criteria.  There were 57.49% females, 42.12% African Americans and 75.21% 
enrolled in the fee for service (FFS) Medicaid plan. During the pre-study period, 97.65% people 
had an outpatient visit and 26.10% people had an inpatient visit (Figure 4.2).   
Table 4.3 describes the racial distribution of type 2 diabetes patients with different types of DD. 




Downs syndrome patients (61.18%) and Dognitive disability patients (50.63%) whereas African 
Americans had the highest number of Autism patients respectively (50%).  
Adherence:  
Table 4.4 compares the MPRm between Caucasians and African Americans with DD and type 2 
diabetes. The MPRm variable is treated as continuous and as dichotomous for this comparison 
(<0.8 versus ≥0.8). Based on student’s t test analysis, African Americans had significantly lower 
MPRm than Caucasian patients (0.91 vs. 0.88, p<0.01). Also, based on the chi square test, 
African Americans had significantly lower MPRm than Caucasian patients (0.80 vs. 0.74, p< 
0.01). 
The multivariate regression model (table 4.5) presents the predictors of medication adherence.  
MPRm was first analyzed as a continuous variable. Results showed that holding all the other 
covariates constant,  among DD patients with type 2 diabetes, African Americans were 
negatively associated with the MPRm variable (β = -0.03, SE = 0.01, p<0.05). Also, holding for 
all the other variables constant, females with DD and type 2 diabetes were negatively associated 
with the MPRm variable (β = -0.03, SE = 0.01, p<0.05). Then, the MPRm variable was 
dichotomized as high adherence (MPRm<0.8) and low adherence (MPRm≥0.8). Controlling for 
all other covariates, compared to DD Caucasian patients with type 2 diabetes, the expected odds 
for anti-diabetic medication adherence were 29% lower in DD African-American patients with 
type 2 diabetes (OR=0.71, 95% CI = 0.55-0.93, p<0.05). Also, the adjusted odds of adhering to 
anti-diabetic medications in DD patients with type 2 diabetes was 25% lower in females 






Figure 4.2 presents the Kaplan-Meier survival curves showing anti-diabetic medication 
persistence in different races (Caucasians, African Americans and other races). The results of the 
Log Rank test were not significant even though the Kaplan-Meier survival curves showed that 
medication persistence in African American DD patients was less that of the Caucasian DD 
patients. Table 4.6 demonstrates the racial differences in anti-diabetic medication persistence. 
Compared to African American DD patients, slightly higher number of Caucasian DD patients 
persistently used anti-diabetics during the study period (30.3% vs. 29.3%). The median duration 
during which the Caucasian DD patients consumed anti-diabetics was higher than the duration 
for African American DD patients (189 days vs. 159 days).  
Figure 4.3 presents the Kaplan-Meier survival curves showing anti-diabetic medication 
persistence in different types of DD patients (Cerebral palsy, Autism, Downs syndrome and 
Cognitive disability). The results of the Log Rank test were not significant even though the 
Kaplan-Meier survival curves showed that medication persistence in Autistic DD patients was 
the lowest among the different DD patients. Table 4.7 demonstrates the differences in the 
medication persistence across different types of DD patients. Patients with Cognitive disability 
(30.0%) persistently took anti-diabetics more than patients with Cerebral palsy (20.9%), 
followed by patients with Downs’s syndrome (10.5%) and Autism (10.2%) respectively.  The 
median duration during which the Cognitive disability patients (181 days) consumed anti-
diabetics was more compared to the Autism patients (157 days), followed by the Downs 
syndrome patients (124 days) and the Cerebral palsy patients (94 days) respectively. 




adjusting for all the other covariates, the hazard was higher in African American DD patients 
compared to Caucasian DD patients (Hazard Ratio = 1.03, 95% CI = 0.91-1.18). The hazard was 
however, non-significant.  
Sensitivity analysis:  
Table 4.10 shows medication adherence at different MPRm cut-off points. The cut-off points 
range from 0.4 to 0.9. The medication adherence decreased as the cut-off range was increased. 
The adherence drop was the highest (23.9%) when the cut-off point increased from 0.7 to 0.8. In 
the sensitivity analysis, the drop of 23.9% was the highest compared to any other drop when the 
MPRm cut-off was increased by 0.1 point.   
Discussion 
This research showed that African American Medicaid enrollees with DD and type 2 diabetes 
were less likely to adhere to anti-diabetic medications as well as persistently adhere to anti-
diabetic medications compared to Caucasian Medicaid enrollees with DD and type 2 diabetes. 
The bivariate and multivariate statistics showed that racial disparities in type 2 diabetes 
medication adherence were significant. However, even though the survival statistics showed that 
African Americans showed lower persistence in adhering to anti-diabetic medications as well as 
the Cox-proportional hazards regression analyses suggested that African Americans experienced 
higher hazards of not persistently taking anti-diabetic medications compared to Caucasian 
patients respectively, the results for either were not statistically significant.  
                    The results of this research indicating poor medication adherence among racial 
minorities were similar to a previous study conducted among the North Carolina Medicaid 




metabolic control and worse healthcare outcomes (Schectman 2002). Poorer glycemic control is 
observed among non-Hispanic blacks and Mexicans compared to non- Hispanic whites. In 
addition to higher burden of diabetes, treatment affordability, insufficient knowledge, complex 
medication dosing and desire for quicker relief might be some of the reasons that affect 
medication adherence in racial minorities (Shenolikar 2006, Dailey 2001, Paes 1997). In African 
Americans, poor glucose control is also associated with poor diet quality (Betancourt 2013) and 
social and internal diet temptations (Betancourt 2013). Both African American and Hispanics are 
significantly more likely to have borderline or poorly controlled hypertension, diabetes 
associated neuropathy, retinopathy, and diabetes-related amputations than non-Hispanic whites 
(Bonds 2003, Ness 1999, Harris 1998).  In case of DD patients with chronic disease conditions, 
some of the reasons for medication non adherence are difficulty in communicating symptoms 
due to reduced cognitive functioning, polypharmacy, vision and hearing impairment, refusal or 
misuse of medications due to unpleasant side effects, incorrect medication consumption, 
incorrect medication consumption times, failure to understand the goals of treatment, non-
supportive caregivers, insufficient resources, non adherence promoting contingencies (attention 
seeking behavior or escape tendency) and fragmented care (Juntunen 2012, Wallace 2006). 
Lower type 2 diabetes medication persistence in DD African Americans compared to DD 
Caucasians, though not significant, may have important implications in the form of 
microvascular and macrovascular complications that may have higher likelihood of occurring in 
racial minorities due to reduced medication persistence (Cramer 2008, Yeaw 2009). The reasons 
for higher hazards in racial minorities might be not getting their prescriptions refilled within 90 
days, the  complex medication regimens consisting of multiple medications, consuming free 




agents in one pill) and higher medication copayments. The higher hazards found in our study 
were similar to previous studies conducted in patients with major depressive disorder with 
comorbid anxiety disorder (Wu 2012) and patients with hypertension (Ferdinand 2013) 
respectively. The sensitivity analysis indicates that when the cutoff point of MPRm was 
increased from 0.8 to 0.9, the drop in medication adherence was quite sharp. Generally, in 
administrative claims database, the conventional cut-off point for medication adherence is 
considered to be 0.8 (Karve 2008). Higher medication adherence in DD patients with type 2 
diabetes aged more than 50 years may indicate better community support and coordinated care 
for ageing population.  (Vasek 2013) 
                    The data for this study represents the Medicaid population from eight states enrolled 
from 2003 to 2007, contibuting to the generalizability of the study.  Based on the generalizability 
of the study, policy makers can frame health policies to reduce racial disparities in healthcare 
outcomes experienced by the DD population.    
The study is not without its limitations. Due to the observational nature of the study, there is no 
causal effect. The dataset did not capture variables such beliefs, attitudes or intentions associated 
with medication intake. These variables might vary by race and could help researchers better 
understand access to care among different races.  Also, the data does not represent patients who 
have Medicare only, are uninsured, or are dual eligibles. The dual eligible population might have 
a higher severity of type 2 diabetes and related comorbidities, resulting in different medication 
intake and healthcare utilization patterns. Patients taking insulin were excluded from the study 
population since they represent the more severe cases. The assumption that a prescription filled 
was a prescription taken was made for calculating medication adherence of the study population. 




such as Morisky scale, asking the patients about their medication intake can be a viable tool for 
actual medication adherence assessment.  Information about the educational background of the 
patients in not captured in the claims dataset. Due to lack of education, it is possible that patients 
might face challenges in understanding and following complex medication regimens, leading to 
lower medication adherence.   
Conclusion  
In this study, we found that there were racial disparities in anti-diabetic medication adherence 
among Medicaid enrollees with DD.  The studies conducted in the future should look at the 
predictors that impact access to care, availability of primary and specialized care, social support 
as well as beliefs of the patients seeking care.   
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22,093 DD patients (intellectual disability, cerebral palsy, autism) aged 18 to 64 
years had a diagnosis of type 2 diabetes from January 1st, 2004 to December 
31st, 2006 (the index period) were included. Each patient was assigned to have 
an index diagnosis date. There were 21,617 patients who had medication 
information. Patients with dual Medicare and Medicaid eligibility were 
excluded.  There were 8772 patients meeting these exclusion criteria. 
Step 3: 
 
Patients who were diagnosed with DD and were prescribed with an OHA 
during the index period were included in the study. The Medicaid IDs 
(ENROLID) were used to link the prescription drug claim to the detailed 
enrollment claim. 4,641 patients met these criteria. 
Step 4: 
 
Patients having using any OHA during the pre-index period (12 months before 
the index diagnosis date) were also excluded. There were 2505 patients 
excluded in this step. Patients were required to be continuously enrolled from 
12 months (the pre-index period) before and 12 months (the study period) after 
the index diagnosis date.  There were 1529 patients who met the criteria and 
constituted towards the final sample of this study. 
Step 1: 
 
There were 213,644 DD patients in the MarketScan® Multi-State Medicaid 




Figure 4.2 The Kaplan-Meier Survival Curves of Antidiabetic Persistence between 
Caucasian and African-American Patients
§ 
 
§: Log-Rank Test, p<0.5642 
 
Figure 4.3 The Kaplan-Meier Survival Curves of Antidiabetic Persistence in Patients with 




§: Log-Rank Test, p<0.3271 
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Table 4.1 ICD-9-CM codes* 
Disease Diagnosis Codes± 
Cerebral Palsy                           Infantile cerebral palsy 
Congenital Diplegia                                                  
Congenital Hemiplegia 
Congenital Quadriplegia 
Congenital Monoplegia  
Infantile Hemiplegia  
Other specified infantile cerebral palsy 









Autism Infantile autism                                                                
Autistic Discord-Current                                                    




Downs syndrome                         Downs syndrome                                                              758.0
Mental retardation Mild mental retardation 
Moderate mental retardation                                         
Severe mental retardation                                              
Profound mental retardation                                         
























Table 4.2 Descriptive Characteristics of the Study Population (N= 1529)                                                                              
                                                          Frequency               %                                                        
______________________________________________________________________          
 Race 
   Caucasians                                          788                     51.54 
   African Americans                             644                      42.12 
   Other races                                          97                        6.34 
 Age (years) 
   18-30                                                   443                     28.97 
   31-40                                                   362                     23.68 
   41-50                                                   394                     25.77 
   51-60                                                   275                     17.99 
   61-64                                                   55                        3.60 
Gender 
  Male                                                     650                     42.51                                            
  Female                                                  879                     57.49 
FFS vs. Capitation 
  FFS                                                       1150                   75.21                                            
  Capitation                                             312                     20.41 
  Dual                                                      67                       4.38 
Comorbidity  
(Charlson Index)  
  0                                                           917                     59.97                                         
  ≥1                                                         612                     40.03 
Comorbidity pre- 
index period  
(Charlson Index)    
  0                                                           1036                   67.76 
  ≥1                                                         493                     32.24 
Inpatient visit 
pre-index period    
  0                                                           1130                   73.90                                             
  1                                                           399                     26.10 
Outpatient visit 
pre-index period    
  0                                                           36                       2.35                                             
  1                                                           1493                   97.65 
Number of 
Medication refills 
 2-5                                                        1187                   77.63 
 6-10                                                       211                    13.80 
 >10    
   
          
                              







Table 4.3. Distribution of diabetic population with different types of DD by race (N=1529) 








Race Frequency (%) Frequency (%) Frequency (%) Frequency (%) 
Caucasians 
(n=788) 
116 (57.71) 30 (44.12) 52 (61.18) 684 (50.63) 
African 
Americans(n=644) 
71 (35.32) 34 (50) 29 (34.12) 578 (42.78) 
Other races (n=97) 14 (6.96) 4 (5.88) 4 (4.70) 89 (6.59) 
 
Table 4.4 Comparison of Medication Possession Ratio (MPRm) by race (N=1529)
§
 
 A: MPRm as a continuous variable:  
________________________________________ 
   MPRm
Ω
                 Obs    Mean
#
     SD  
________________________________________   
Caucasians                788      .91        .18     
African Americans   644      .88
**
      .19  
________________________________________     
Ω: Medication Possession Ratio modified  
§: MPRm of the study population is  0.90 
#: Student's T -test of MPRm between Caucasians and African Americans 
Note: * p < 0.05, ** p < 0.01, *** p < 0.001 
 
B: MPRm as a dichotomous variable:  
________________________________________ 
   MPRm
Ω
                   Obs    Mean
#
     SD  
________________________________________   
Caucasians                 788      .80        .40     
African Americans     644      .74
**
     .44  
________________________________________     
Ω: Medication Possession Ratio modified  
§: MPRm of the study population is  0.90 
#: Student's T -test of MPRm between Caucasians and African Americans 














Table 4.5 Predictors of Antidiabetic Adherence in Medicaid Enrollees with Developmental 
Disabilities: Multivariate Linear Regression Model and Multivariate Logistic Regression 
Model (N=1529) 
______________________________________________________________________________ 
                                                                                                            Odds ratio for medication  
                                                                                                           adherence (80% of MPRm)
±
 
                                                             MPRm
#
 
                                                   Coef.                    SE                       Odds ratio             95% CI 
______________________________________________________________________________           
Race 
   Caucasians                            Reference            Reference                Reference             Reference 
   African Americans                  -0.03
**
                   0.01                         0.71
* 
               (0.55-0.93) 
   Other races                              -0.00                      0.02                         1.42                 (0.79-2.56) 
Age (years) 
   18-30                                   Reference             Reference                Reference             Reference 
   31-40                                      -0.01                       0.01                         0.90                 (0.64-1.27) 
   41-50                                       0.00                       0.01                         1.02                 (0.73-1.43) 
   51-60                                       0.02
*
                      0.01                        1.43
 
                 (0.96-2.14) 
   61-64                                       0.02                       0.03                         2.26
 
                (0.96-5.35) 
Gender 
  Male                                     Reference             Reference                Reference             Reference 
  Female                                    -0.03
**
                     0.01                         0.75
* 
               (0.57-0.97) 
FFS vs. Capitation 
  FFS                                       Reference            Reference                 Reference             Reference 
  Capitation                               -0.02                       0.01                          0.79
  
               (0.58-1.07) 
  Dual                                        -0.05
*
                     0.02                           0.65                (0.39-1.08) 
Comorbidity  
(Charlson Index)  
  0                                           Reference            Reference                 Reference              Reference 
  ≥1                                             0.00                      0.00                           0.95                (0.85-1.08) 
Comorbidity pre- 
index period  
(Charlson Index)    
  0                                           Reference            Reference                  Reference             Reference 
  ≥1                                            -0.01                     0.01                           0.99                 (0.84-1.15) 
Inpatient visit 
pre-index period    
  0                                           Reference            Reference                  Reference             Reference 
  1                                               0.00                     0.00                           1.02                 (0.93-1.12) 
Outpatient visit 
pre-index period    
  0                                          Reference            Reference                  Reference               Reference 
  1                                               0.00
***
                 0.00                          1.00
**









                                                                                                            Odds ratio for medication  
                                                                                                           adherence (80% of MPRm)
±
 
                                                             MPRm
#
 
                                                   Coef.                    SE                       Odds ratio             95% CI 
______________________________________________________________________________          
Number of 
Medication refills 
 2-5                                        Reference               Reference                Reference             Reference 
 6-10                                           0.03
 
                     0.02                          1.13
 
                (0.75-1.69)                   
 >10    
   
          
                              
        0.09
*** 
                 0.02                          3.07
***
             (2.20-4.30)                 
 Constant                                    0.86
***
                  0.02                          1.89
**
               (1.25-2.87) 
Adjusted R
2    
                             0.07                                                       0.07 
_____________________________________________________________________________________________  
Note: * p < 0.05, ** p < 0.01, *** p < 0.001  
#: Multivariate linear regression analysis  
±: Multivariate logistic regression analysis 
 
 
Table 4.6 Comparisons of medication persistence between Caucasian and African-




   Races                                     Censored(cases,%)
#¤




Caucasians (n=788)                      239(30.33%)                        189(154-221) 
African Americans (n=644)         189(29.34%)                         159(121-196) 
Other races (n=97)                        36(36.11%)                           123(66-189) 
________________________________________________________________________     
#: No. of patients who persistently used antidepressants until the end of the follow-up period  
 ¤: The follow-up period is one year (365 days)  
 §: Estimated median time that patients persistently used antidepressants  
Ω: Log -Rank test, p<0.0946 
 
 
Table 4.7 Comparisons of medication persistence between MDD Patients with and without 




   Races                              Censored(cases,%)
#¤




CP(n=201)                                42(20.90%)                         94(62-150) 
Autism(n=68)                           7(10.29%)                           157(68-247) 
Downs syndrome(n=85)           9(10.59%)                           124(49-306) 
Cognitive(n=1351)                   406(30.06%)                        181(155-207) 
______________________________________________________________________________  
#: No. of patients who persistently used antidepressants until the end of the follow-up period  
 ¤: The follow-up period is one year (365 days)  
 §: Estimated median time that patients persistently used antidepressants  







Table 4.8 Factors Associated with Antidiabetic Persistence in Medicaid Enrollees with  
Developmental Disabilities: Cox-proportional Hazard Regression Analysis (N=1529) 
_____________________________________________________________________ 
                                                      Cox Proportional Hazard Analysis                                                                                 
                                                            Hazard 
                                                              Ratio                95% CI                                                     
______________________________________________________________________          
 Race 
   Caucasians                                     Reference             Reference 
   African Americans                             1.03
  
               (0.91-1.18) 
   Other races                                         1.10                 (0.81-1.49) 
   Age (years) 
   18-30                                              Reference            Reference 
   31-40                                                  0.87                 (0.72-1.05) 
   41-50                                                  0.86                 (0.72-1.04) 
   51-60                                                  0.80
* 
               (0.66-0.97) 
   61-64                                                  0.73
 
                (0.53-1.00) 
Gender 
  Male                                                 Reference           Reference                                                 
  Female                                                 0.95
 
               (0.84-1.09) 
FFS vs. Capitation 
  FFS                                                  Reference            Reference                                                 
  Capitation                                            0.99                (0.84-1.17) 
  Dual                                                     0.81
 
               (0.64-1.03) 
Comorbidity  
(Charlson Index)  
  0                                                      Reference             Reference                                                 
  ≥1                                                         0.92
*
               (0.86-0.99) 
Comorbidity pre- 
index period  
(Charlson Index)    
  0                                                      Reference             Reference                                                 
  ≥1                                                        1.06                 (0.98-1.14) 
Inpatient visit 
pre-index period    
  0                                                      Reference            Reference                                                  
  1                                                          1.02                 (0.97-1.07) 
Outpatient visit 
pre-index period    
  0                                                      Reference            Reference                                                  
  1                                                          1.00
*  
               (1.00-1.00) 
Number of 
Medication refills 
 2-5                                                  Reference               Reference            
 6-10                                                0.88
 
                  (0.53-1.46)                 
 >10    
   
          
                              
             0.50
*** 





Note: * p < 0.05, ** p < 0.01, *** p < 0.001  
 






































Chapter 5 Manuscript Two 
 
 
Title: Association of Race and Medication Adherence with Healthcare Utilization and 




Adults with developmental disabilities have higher prevalence of chronic disease conditions such 
as diabetes, obesity, high blood pressure, arthritis, CVD and chronic pain. They also have poor 
healthcare utilization and screened less for chronic disease conditions. Very few studies have 
looked at the diabetes related health outcomes in developmentally disabled adults.  The objective 
of this study was to examine the association of race, and medication adherence, and their 
interaction with healthcare utilization and healthcare costs in Medicaid enrollees with 
developmental disabilities (DD) and type 2 diabetes.  
Methods:  
This was a retrospective cohort study that identified the DD adults with type 2 diabetes from the  
MarketScan® Multi-State Medicaid Database. Enrollees aged 18-64 years who received new 
anti-diabetic medications from January 1, 2004 and December 31, 2006 were included. An index 
diagnosis date was assigned to each patient and adults with a continuous enrollment for at least 




and emergency department visits) in DD adults were computed using multivariate logistic 
regression models. Multivariate negative binomial regression was used to measure the rate of 
change in type 2 diabetes related healthcare utilization in DD patients. Multivariate linear 
regression with log-transformation was used to determine type 2 diabetes related healthcare costs 
in DD Medicaid enrollees.  
Results:  
The study population comprised of 1529 patients. After controlling for all the covariates, 
compared to DD Caucasians, DD African Americans were more likely to have type diabetes 
related inpatient (OR=1.71; 95% CI, 1.02-2.85) and emergency department visits (OR, 1.67; 
95% CI, 1.02-2.73). African Americans with DD and type 2 diabetes had significantly higher 
healthcare costs compared to Caucasians with DD and type 2 diabetes.  
Conclusion:  
Racial disparities exist in healthcare utilization in DD Medicaid patients with type 2 diabetes.  
Access to culturally competent healthcare providers, providers who accept Medicaid patients and 
continuous care can reduce inpatient visits and emergency room visits in racial minorities.  
More attention should be given to designing culturally appropriate health prevention and health 










Diabetes Mellitus, a serious metabolic disorder is the seventh leading cause of death in the 
United States (US) (CDC 2011, Wild 2004, U.S. Census Bureau, Huang 2009, Deshpande 2008, 
Narayan 2006). The cost of diabetes related healthcare places a huge burden on the US economy 
with treatment costs and loss of productivity accounting for $174 billion in 2007. These costs are 
estimated to rise to $336 billion in 2034 (CDC 2011, Deshpande 2008, Huang 2009, Narayan 
2006, Wild 2004, Huang 2009). About 15% of children in the agegroup of 3-17 years have 
disabilities like ADHD, cerebral palsy, (CP) hearing loss, intellectual disability, Downs 
syndrome, learning disability, vision impairment, autism spectrum disorders (ASDs) and other 
developmental delays (Boyle 2011). According to CDC, the lifetime cost to care for an 
individual with CP is nearly $1 million (2003) dollars (CDC 2004). According to CDC estimates, 
in U.S., around 6000 babies are born each year with Downs syndrome (Parker 2010). People 
with ASD have higher medical expenditure than those without ASDs. The mean expenditure for 
people with ASDs is 4.1-6.2 times ($4,110-$6,200/year) greater than those without ASDs 
(Shimabukuro 2008). Sedentary lifestyle, poor nutrition and high rates of obesity lead to 
increased risk of type 2 diabetes in patients with DD (Yamaki 2005, Rimmer 2006). When DD 
patients live independently, there is a higher likelihood of an unhealthy lifestyle with less dietary 
restrictions (Taggart 2012). Patients with developmental disabilities (DD) have a higher risk of 
developing type 2 diabetes.  In 2006, the prevalence of diabetes in adults with cognitive 
disabilities was 19.4% compared to 3.8% in patients without cognitive disabilities respectively 
(Reichard 2011). 
                 A study conducted using the 2001 North Carolina Behavioral Risk Factor Surveillance 




disabled adults with DD, adults without DD performed less amount of physical activity, received 
seven times less emotional support, had high health risk behaviors and had low breast cancer and 
cervical cancer screenings (Havercamp 2004, Ouellette-Kuntz 2005). The comorbid conditions 
associated with DD are more likely to be found among adults with low income, who also face 
socioeconomic disparities in access to healthcare (Surgeon General Report 2002). In North 
America, the prevalence of type 2 diabetes in the DD population can vary from 7.1% to 14%.  
(Havercamp 2004, Shiremen 2010, McDermott 2006, Lunsky 2011) A study in Northern Sydney 
showed that among people with DD, prevalence of type 2 diabetes complications, medical 
consultations, hospitalizations and mortality were higher compared to the people without DD. 
The study population also had many undetected conditions. Out of the 5.4 medical conditions 
that each patient had on an average, half the conditions remained undetected during previous 
physician visits (Beange 1995). 
A study exploring relationships between access to diabetes care and health outcomes 
demonstrated that patients with restricted access to healthcare had higher Hba1c levels than those 
using acute care facilities. Also, patients without a usual source of care reported significantly 
higher Hba1c levels than patients receiving care at doctor’s clinics (Rhee 2005). Medication 
adherence has been associated with fewer hospitalizations (Lau 2005) and lower health‐care 
costs (Sokol 2005, Hepke 2004). Some of the common causes of non-adherence among adults 
with DD are fragmentation of care, comorbidity, polypharmacy, and consideration of medication 
side effects (Ince 2009). Paying for healthcare and prescriptions may compete with other basic 
needs and priorities and may create strong bottlenecks for access and adherence. Exploring the 




twice as likely to cut down on necessities and incur debt in order to cope with medication costs 
compared to the white respondents (Heisler, 2005).      
Medicaid covers uninsured and unemployed individuals, mainly comprising of pregnant women,                                     
children, adults with physical and developmental disabilities, and elderly and frail individuals.  
Individuals with disabilities make up just 14% of all the Medicaid enrollees and yet are 
accountable for 42% of the total Medicaid expenses.  Research has shown that people with 
disabilities have higher rates of diabetes, depending on the type of disability (McDermott 2007, 
McDermott 2006). Among people with disabilities, rates of diabetes in patients with sensory or 
psychiatric disabilities are 31.6% and 24.7% respectively compared to 15.8% in patients without 
disabilities. Compared to patients with sensory or psychiatric disabilities, diabetes is seen in only 
10.4% patients with DD. The rates of obesity are seen in 67% patients with DD, sensory and 
psychiatric disabilities. Chronic disease conditions including diabetes, are not managed properly 
in patients with DD (Beange 1995).  Adults with DD have a higher risk of having multiple 
chronic disease conditions, generally four or higher (Reichard 2011). Two studies assessing 
health outcomes in Medicaid patients DD with diabetes have been conducted in Kansas. Results 
from one study state that the quality of care received by DD patients with diabetes was lower 
than the national recommended standards (Shiremen 2010). The other study showed that adults 
with physical disabilities and diabetes had better screening rates for chronic disease conditions 
compared to the national recommended rates (Reichard 2012). With increase in life expectancy 
of the patients with DD, their burden of morbidity and challenges in accessing care have also 
increased. The literature looking at healthcare utilization and costs in DD patients with type 2 
diabetes is scarce. This study determines the racial disparities in healthcare utilization, primarily 




diabetes enrolled in Medicaid. It also looks at the association of interaction of race and 
medication adherence with healthcare utilization and costs in the diabetic DD population 
enrolled in Medicaid.  
Methods  
Data sources:  
The Marketscan Multi-State Medicaid database was used for conducting this study. It is a pooled 
Medicaid dataset that consists of claims from eight states in the United States and has variables 
that provide information about disease conditions, clinical outcomes and demography of the 
enrolled subjects. The dataset also has information about the enrollment periods of the enrollees, 
claims for inpatient visits, outpatient visits and prescriptions. The diagnoses in the dataset were 
identified using the ICD-9-CM codes. Each patient is assigned a confidential enrollee identifier 
and this identifier can be used to track patients longitudinally. The identifier is also same across 
different sets of claims (Thomson Reuters 2007).
 
  
Sample selection:  
This retrospective cohort study was conducted with data from January 1
st
, 2003 to December 
31
st
, 2007.  Patients aged 18-64 years with diagnosis of developmental disabilities (DD) and a 
new prescription of oral hypoglycemic medications during January 1
st
, 2004 and December 31
st
, 
2006 were included in the study. Each patient was assigned an index diagnosis date. Only drug 
naïve patients, i.e. patients who did not have any drug claims during the 12 months before the 
index diagnosis date, were included in the study.  If patients were drug naïve, it was an indication 
that the patients were new users. Patients with continuous Medicaid enrollment for 12 months 




insulin and patients who were dual eligibles were excluded. After applying inclusion and 




The main dependent variables were type 2 diabetes related healthcare utilization and type 2 
diabetes healthcare costs. Type 2 diabetes related healthcare utilization variables included 
inpatient visits, outpatient visits and ER visits respectively.  Type 2 diabetes related healthcare 
costs included medication costs, medical costs (inpatient costs + outpatient costs) and overall 
costs (medication costs + medical costs) respectively. The term “type 2 diabetes related DD 
patients” comprised of patients with a primary diagnosis of DD (autism, cerebral palsy, downs 
syndrome, cognitive disability) and a secondary diagnosis of type 2 diabetes. The ICD-9-CM 
codes for DD were 299.0x (autism, where x=0-2), 317, 318.x and 319 (intellectual disabilities, 
where x=0-2), 343.x (cerebral palsy, where x=0-9) and 758 (Downs syndrome) and for type 2 
diabetes were 250.x (where x=0,2).  All the patient healthcare utilization with the above ICD-9-
CM codes were defined as type 2 diabetes related healthcare utilization in patients with 
DD.  Each healthcare utilization variable was coded dichotomously (yes/no).  For example, type 
2 diabetes related outpatient visits were coded ‘yes’ for patients having at least one outpatient 
visit (yes) and ‘no’ for patients having no outpatient visits during the study period. The 
healthcare costs variable was defined as the healthcare costs incurred by the patients during the 






Key independent variables: 
Race, medication adherence and the interaction of race and medication adherence were the three 
main independent variables in the study. The variable race was obtained from the participants 
upon enrollment into Medicaid. Race was categorized as Caucasians, African Americans, and 
other races. Claims for type 2 diabetes medications were identified in DD patients during the 
enrollment period after their index diagnosis date. DD patients with type 2 diabetes diagnosis 
were identified as having comorbid type 2 diabetes. The interaction term was the interaction 
between race and medication adherence. Since race might not completely account for the 
differences in healthcare outcomes and medication adherence is low in racial minorities, the 
interaction term was one of the main independent variables.  
Covariates:  
The covariates in this study were based on Andersen’s model of healthcare utilization (Andersen 
2008, Andersen 2007). According to this model, predisposing factors, enabling factors and need 
factors can predict healthcare utilization (Andersen 2008, Andersen 1973, Andersen 1995, 
Andersen 2007). For the purposes of this study, predisposing factors included age (grouped as 
18-30, 31-40, 41-50, 51-60, and 61-64 years) and gender.  The enabling factors determine access 
to healthcare. In this study, the enabling factor was the type of health plan (fee-for-service, 
capitation, and dual). The need factors in the study were number of prescription refills (2-5, 5-10 
and >10) and severity of the disease, which was measured by the number of outpatient visits 
during the pre-index period (yes/no), the number of inpatient visits during the pre-index period 




Charlson comorbidity index during the study duration (Andersen 1973, Andersen 1995). This 
study used the Charlson comorbidity index, an index consisting of 17 different disease conditions 
used to predict mortality associated with the severity of comorbid conditions. This index was 
used as a measure to assess the overall severity of the illness in the study population (Charlson 
1987). The modified MPR (MPRm) that includes the patient’s last day of anti diabetic 
medication supply was also one of the covariates in the study. MPRm was categorized as high 
adherence if the value was greater than 0.8 and low adherence if the value was less than or equal 
to 0.8 (Hess 2006, Karve 2009). 
Statistical analyses 
Descriptive statistics were computed to study the patient characteristics. Healthcare utilization 
(outpatient visits, inpatient visits and ER visits) was compared using student’s t-test. Comparison 
between Caucasians and African Americans on healthcare costs (medication costs, medical costs 
and overall costs) was also conducted using student’s t-test. Multivariate regression analysis was 
performed to determine the association between type 2 diabetes related healthcare utilization 
(number of outpatient visits, number of inpatient visits, and number of ER visits), and race, 
medication adherence and their interaction.  First, multivariate logistic regression analyses were 
done to estimate the probability of occurrence of any of the healthcare utilization independent 
variables (outpatient visits, inpatient visits and ER visits). Then, multivariate negative binominal 
regression analyses were performed to determine the change in outpatient visits given the 
patients had at least one outpatient visit. Similarly, multivariate zero negative binominal 
regression analyses were conducted to determine the change in inpatient and ER visits, given the 
patients had at least one inpatient and ER visit respectively. Multivariate linear regression 




adherence, their interaction, and other covariates. In the study, data management was performed 
using SAS v.9.3 (SAS Institute 2011). All the data analysis was completed using STATA 13 
(StataCorp 2013) Statistical significance was determined by obtaining a 0.05 level of 
significance in two tailed tests and other analyses. This study was approved by the Institutional 
Review Board (IRB) at the University of Michigan. 
Results  
Table 5.2 describes the demographic characteristics of the study population. Among 1529 
Medicaid enrollees with DD and type 2 diabetes, 28.97% people were aged 18-30 years, 57.49% 
were females, 42.12% were African Americans, 97.65% had an outpatient visit during the pre-
index period and 26.10% had an inpatient visit during the pre-index period.  
Table 5.3 illustrates the mean differences in healthcare utilization (number of outpatient visits, 
number of inpatient visits and number of ER visits) among different races with DD and type 2 
diabetes. Compared to Caucasians with DD and type 2 diabetes, African Americans with DD and 
type 2 diabetes had significantly less number of outpatient visits (125.67 versus 10.7.93, p<0,05). 
Also, among DD patients with type 2 diabetes, compared to Caucasians, African Americans had 
higher number of inpatient visits (0.77 versus 1.02) and ER visits (2.66 versus 3.17) respectively, 
even though these differences were not statistically significant.   
Table 5.4 presents the mean differences in healthcare costs (medication costs, medical costs and 
overall costs) among different races with DD and type 2 diabetes. Compared to Caucasians with 
DD and type 2 diabetes, African Americans with DD and type 2 diabetes had significantly higher 
medication costs ($1284.69 versus $1114.85, p<0,05). Similarly, among DD patients with type 2 




versus $43423.2) and overall costs ($40363.22 versus $44707.89) respectively, even though 
these differences were not statistically significant.   
Table 5.5 shows the association between race, medication adherence and their interaction with 
type 2 diabetes related healthcare utilization in DD patients enrolled in Medicaid using 
multivariate logistic regression models. Controlling for all the other covariates, the adjusted odds 
of having type 2 diabetes related inpatient visits in African Americans with DD were 1.70 times 
greater than the adjusted odds of having type 2 diabetes related inpatient visits in Caucasians 
with DD (OR =1.71, 95% CI = 0.53-1.16, p<0.05).  Controlling for all the other covariates, the 
adjusted odds of having type 2 diabetes related outpatient visits in African Americans with DD 
were 19% lower than the adjusted odds of having type 2 diabetes related inpatient visits in 
Caucasians with DD (OR =0.81, 95% CI=0.38-1.76). Controlling for all the other covariates, the 
adjusted odds of having type 2 diabetes related ER visits in African Americans with DD were 
1.67 times greater than the adjusted odds of having type 2 diabetes related inpatient visits in 
Caucasians with DD (OR =1.62, 95% CI=1.03-2.73, p<0.05). The interaction between race and 
medication adherence was significant. After controlling for all the other covariates, DD African 
American with lower medication adherence had higher probability of having type 2 diabetes 
related ER visits compared to DD African Americans with higher medication adherence, 
Caucasians with higher medication adherence, and Caucasians with lower medication adherence 
(OR = 2.05, 95% CI =1.19-3.55, p<0.05).  
Tables 5.6 shows the association between race, medication adherence and their interaction with 
type 2 diabetes related healthcare utilization in DD patients enrolled in Medicaid. These 
associations were computed using multivariate negative binomial regression models. The 




72% (RR =1.77, 95% CI = 1.12-2.63, p<0.05) greater compared to the expected number of type 
2 diabetes related inpatient visits in Caucasians, after controlling for other covariates. The 
expected number of type 2 diabetes related outpatient visits in African Americans with DD was 
5% (RR =0.95, 95% CI = 0.76-1.19) lower compared to the expected number of type 2 diabetes 
related inpatient visits in Caucasians, after controlling for other covariates. The expected number 
of type 2 diabetes related ER visits in African Americans with DD were significantly higher than 
the expected number of type 2 diabetes related inpatient visits in Caucasians, after controlling for 
other covariates (RR =1.76, 95% CI = 1.18-2.61, p<0.01). After controlling for all the other 
covariates, compared to DD African Americans with higher medication adherence, Caucasians 
with higher medication adherence and Caucasians with lower medication adherence, DD African 
Americans with lower medication adherence had higher probability of having type 2 diabetes 
related ER visits (RR =1.88, 95% CI = 1.22-2.91, p<0.01).  
Table 5.7 presents the associations between race, medication adherence, and the interaction 
between race and medication adherence with log-transformed healthcare costs (medication costs, 
medical costs and overall costs). Among DD patients with type 2 diabetes, after holding all the 
other covariates constant, higher medication adherence (≥80%) was negatively associated with 
medication costs (β = -0.32, p<0.01), medical costs (β = -0.48, p<0.001) and overall healthcare 
costs  (β = -0.52, p<0.001).  After holding all the other covariates constant, among DD patients 
with type 2 diabetes, compared to Caucasians, African American patients had 23% higher 
medication costs, 26% higher medical costs and 21% higher overall costs respectively. The 
interaction between medication adherence and race was not statistically significant for any of the 






This study found that African Americans with DD and type 2 diabetes had higher healthcare 
expenditures, ER visits and inpatient visits compared to Caucasians with DD and type 2 diabetes. 
There is a need for establishing local outpatient healthcare facilities that can specifically fulfill 
mental and physical health needs in adults with DD. Patients with DD going for a physical 
examination can require three times more time as compared to patients without cognitive 
disabilities due to barriers such as difficulty in communicating symptoms, inability to tolerate 
longer waiting times, displaying aggressive behavior or reluctance to get a physical, fear of 
needles, fear of examination of private areas, fear of new physicians and need for physical 
assistance for many procedures (Doostan 1999). Adults with DD visit the ED department to a far 
larger extent than adults without DD; this can be attributed to the lack of sufficient centers 
providing specialized outpatient services to this unique group of patients and lack of continuity 
of primary and specialist care (Lunsky 2012). Previous research on healthcare access in 
minorities shows that minorities tend to drop out more from community programs, receive less 
comprehensive services, lack access to trained culturally competent or bilingual healthcare 
providers, and are more underserved (National Council on Disability website).  The risk of 
higher healthcare utilization can be reduced by increasing the number of primary and specialty 
providers who accept Medicaid patients, improving access to culturally sensitive and competent 
minority healthcare providers with cultural backgrounds similar to minority patients’, physicians 
using respectful language and terminologies during patient encounters, providing language 
assistance to patients, and increasing rates of out of home placement for minority DD patients 
with chronic diseases.  (National Center for Cultural Competence website, Smedley 2002, Hsu 




In this study, 26% patients had an inpatient visit and 32% patients had comorbidities during the 
pre-study period. This shows that the DD Medicaid enrollees in this study were vulnerable and 
had poor health status. Medicaid population is generally less educated and has lower SES. 
Compared to Caucasians, lower medication adherence in African Americans might be associated 
with a higher prevalence of diabetes, limited access to multi drug regimen and higher HbA1c 
levels (Schectman 2002). Some of the reasons for low medication adherence in DD patients are 
incorrect medication intake, wrong medication intake times, failure or refusal to consume 
medications, failure to understand the goals of treatment, insufficient resources and failure to 
comply with medication therapy (Wallace 2006). It can be quite challenging for minority DD 
patients with chronic disease conditions to access and utilize healthcare services. Hence the 
interaction term (being African American and having low medication adherence) shows a 
reduced effect on healthcare utilization.  
This study found that DD patients enrolled in capitated Medicaid plans had lower anti diabetic 
medication adherence, higher inpatient visits, lower outpatient visits and higher ER visits 
compared to DD patients enrolled in FFS Medicaid plans. These findings were similar to a 
previous study conducted in Medicaid patients with type 2 diabetes, who were enrolled in 
capitated and FFS plans. Medicaid enrollees have very low copayments and out of pocket 
expenditures ($1-$3) for most of the services.  Patients in capitated plans have limited 
prescription drug benefits due to presence of a cap on medication related spending. Out of pocket 
expenditures increase once the cap is reached and this may lead to reduced medication adherence 
or discontinuation of therapy.  In capitated plans, reduced adherence, inadequately provided 
health services, shorter treatment periods, limited patient follow up, and poor treatment can 




This study provides important implications for health research and policy. The study has high 
generalizability since the Medicaid population chosen as the study population represents eight 
states enrolled from 2003 to 2007.  The study findings provide important information about the 
association of race, medication adherence, and their interaction with healthcare outcomes in 
Medicaid enrollees with DD and type 2 diabetes. One of the advantages of conducting this study 
was that the study variables were based on the Aday Andersen’s model of healthcare utilization 
which made it feasible to determine the predictors of medication usage and related healthcare 
utilization (Andersen 2007). The usage of the model helped in controlling predisposing, 
enabling, and need factors so that the association between race, medication adherence and its 
interaction with healthcare utilization could be determined. 
The study has a few limitations. Causation cannot be attributed due to the observational nature of 
the study. Variables such as beliefs, attitudes or intentions that are associated with healthcare 
utilization were not captured in this study. The study does not represent the people enrolled in 
Medicare, commercial insurers or dual eligibles. Claims data also does not have clinical 
measures such as HbA1c levels which are a measure of diabetes severity level.   Hence, the 
healthcare utilization in the pre-study period was used as a proxy to determine the severity of 
type 2 diabetes. It is not possible to capture patient satisfaction using claims data. While 
information about primary and specialized care can be obtained from the claims dataset, 
collaboration between different types of providers for a particular patient cannot be measured. In 
case of developmentally disabled individuals, coordination of care can reduce hospitalization 
(Criscione 1995, Pincus 1987, Walsh 1997). Activities that are not reimbursed such as care 
coordination by social workers or the extent of caregiving provided by family members cannot 





Racial disparities were existent in healthcare utilization and healthcare costs in type 2 diabetes 
patients with DD enrolled in Medicaid. African Americans were more likely to have inpatient 
and ER visits respectively. Also, African Americans were more likely to have higher type 2 
related healthcare costs compared to Caucasians.  Future studies should focus on determining the 
effect of interventions involving access to culturally competent providers, continuity of care and 
coordinated care on healthcare utilization in racial minorities. Studies should also assess the 
healthcare utilization and healthcare costs in DD patients with other chronic disease conditions 
such as CVD, hypertension, chronic kidney disease, asthma, etc.   
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Table 5.1 ICD-9-CM codes* 
Disease Diagnosis Codes± 
Cerebral Palsy                           Infantile cerebral palsy 
Congenital Diplegia                                                  
Congenital Hemiplegia 
Congenital Quadriplegia 
Congenital Monoplegia  
Infantile Hemiplegia  
Other specified infantile cerebral palsy 









Autism Infantile autism                                                                
Autistic Discord-Current                                                    




Downs syndrome                         Downs syndrome                                                              758.0
Mental retardation Mild mental retardation 
Moderate mental retardation                                         
Severe mental retardation                                              
Profound mental retardation                                         
























Table 5.2 Descriptive Characteristics of the Study Population (N= 1529)                                                                              
                                                          Frequency               %                                                        
______________________________________________________________________          
 Race 
   Caucasians                                          788                     51.54 
   African Americans                             644                      42.12 
   Other races                                          97                        6.44 
 Age (years) 
   18-30                                                   443                     28.97 
   31-40                                                   362                     23.68 
   41-50                                                   394                     25.77 
   51-60                                                   275                     17.99 
   61-64                                                   55                        3.60 
Gender 
  Male                                                     650                     42.51                                            
  Female                                                  879                     57.49 
FFS vs. Capitation 
  FFS                                                       1150                   75.21                                            
  Capitation                                             312                     20.41 
  Dual                                                      67                       4.38 
Comorbidity  
(Charlson Index)  
  0                                                           917                     59.97                                         
  ≥1                                                         612                     40.03 
Comorbidity pre- 
index period  
(Charlson Index)    
  0                                                           1036                   67.76 
  ≥1                                                         493                     32.24 
Inpatient visit 
pre-index period    
  0                                                           1130                   73.90                                             
  1                                                           399                     26.10 
Outpatient visit 
pre-index period    
  0                                                           36                       2.35                                             
  1                                                           1493                   97.65 
 Number of 
Medication refills 
 2-5                                                         1187                  77.63 
 6-10                                                        211                    13.80 
 >10    
   
          
                              







Table 5.3 Racial differences in healthcare utilization in type 2 diabetes patients with  DD 
(N= 1529) 
 
   Healthcare                               Caucasians                 African Americans 
   Utilization                            Mean
 
         SD                 Mean
 
         SD 
                                                      (N=788)                           (N=644) 
___________________________________________________________   
No. of outpatient visits            125.67     195.39             107.93
*
     178.30 
No. of inpatient visits              0.77         1.83                 1.02
 
          2.96 
No. of ER visits                       2.66         4.98                 3.17           7.66                  
___________________________________________________________  
Note: * p < 0.05, ** p < 0.01, *** p < 0.001   
Student's T -test of healthcare utilization between Caucasians and African Americans   
 
 Table 5.4 Racial differences in healthcare costs in type 2 diabetes patients with  DD (N= 
1529) 
 
   Healthcare                               Caucasians                 African Americans 
   Costs                                    Mean
 
         SD                 Mean
 
         SD 
                                                      (N=788)                           (N=644) 
___________________________________________________________   
Cost of medications               1114.85     1687.92          1284.69
*
    1822.73 
Medical costs                         39248.37    2520.66          43423.2     2586.64 
Overall costs                          40363.22    2530.09          44707.89    2601.27 
___________________________________________________________  
Note: * p < 0.05, ** p < 0.01, *** p < 0.001 
Medical costs = Inpatient costs + Outpatient costs 
Overall costs = Cost of medications + Medical costs 























Table 5.5 Predictors of healthcare utilization in type 2 diabetes patients with DD: 
Multivariate logistic regression models (N=1529) 
______________________________________________________________________________ 
                                                 Inpatient visits                        Outpatient visits                          ER visits 
  
                                          Odds Ratio     95% CI               Odds Ratio     95% CI          Odds Ratio     95% CI              
_____________________________________________________________________________________________            
Adherence                           
   MPRm<80%                   Reference       Reference           Reference       Reference          Reference        Reference 
   MPRm≥80%                  0.78           (0.53-1.16)               1.05           (0.57-1.94)             0.59**           (0.40-0.87) 
Race 
   Caucasians                       Reference      Reference           Reference      Reference            Reference        Reference 
   African Americans              1.71
* 
          (1.02-2.85)               0.82          (0.38-1.76)              1.67
* 
           (1.02-2.73)       
   Other races                           1.64
 
         (0.82-3.31)                1.12
 
         (0.40-3.16)               1.66
 
            (0.88-3.11)       
Interaction between race      
and MPRm 
0                                           Reference       Reference           Reference     Reference            Reference       Reference 
1                                               1.35
 
          (0.75-2.42)               0.60
 
         (0.25-1.46)               2.05
* 
          (1.18-3.55) 
Age (years) 
   18-30                                Reference       Reference            Reference      Reference            Reference      Reference 
   31-40                                      0.99
 
          (0.69-1.42)              0.77
 
          (0.45-1.35)               0.99
 
          (0.74-1.35)     
   41-50                                      1.46
* 
         (1.06-2.02)              0.69
 
          (0.40-1.19)               1.06
 
          (0.79-1.44)     
   51-60                                      1.37
   
         (0.95-1.97)              0.38
** 
        (0.21-0.68)               0.86
 
          (0.61-1.21)      
   61-64                                      2.76
*** 
       (1.57-4.85)              1.19
 
          (0.32-4.42)               1.47
 
          (0.80-2.71) 
Gender 
  Male                                     Reference       Reference          Reference     Reference            Reference      Reference 
  Female                                     0.96
 
           (0.75-1.23)             1.32
* 
        (0.89-1.95)               1.42
** 
       (1.14-1.78) 
FFS vs. Capitation 
  FFS                                       Reference       Reference           Reference     Reference            Reference     Reference 
  Capitation                                 1.15
 
          (0.83-1.58)              1.01
 
         (0.64-1.58)               1.47
** 
       (1.11-1.96) 
  Dual                                          1.49
 
          (0.87-2.54)              1.00           (omitted)                 1.73
   
        (0.99-3.03) 
Comorbidity  
(Charlson Index)  
  0                                           Reference       Reference           Reference     Reference            Reference      Reference 
  ≥1                                             1.61
*** 
       (1.38-1.86)                1.66
** 
     (1.16-2.36)              1.62
*** 
    (1.34-1.96) 
Comorbidity pre- 
index period  
(Charlson Index)    
  0                                           Reference       Reference           Reference     Reference            Reference      Reference 
  ≥1                                            1.00
 
           (0.83-1.21)                0.85
 
         (0.57-1.26)               1.06
 
       (0.85-1.32) 
Inpatient visit 
pre-index period    
  0                                           Reference       Reference           Reference     Reference            Reference      Reference 
  1                                               1.85
*** 
       (1.57-2.18)                0.98
 
         (0.81-1.18)               2.06
*** 
    (1.67-2.54) 
Outpatient visit 
pre-index period    
  0                                          Reference       Reference           Reference     Reference             Reference      Reference 
  1                                               1.00
**
        (1.00-1.00)                1.06
*** 
      (1.05-1.08)               1.00
** 
     (1.00-1.00) 
Number of 
Medication refills 
 2-5                                       Reference       Reference           Reference         Reference           Reference     Reference 
 6-10                                          1.28
 
          (0.78-2.08)                2.36
** 
       (1.38-4.05)                1.15
    
     (0.76-1.75) 
 >10    
   
          
                              
    1.63
* 
         (1.10-2.40)                12.38
*** 
     (7.32-20.92)             1.53
*  
     (1.10-2.14) 
Constant                                     0.09
*** 
      (0.05-0.16)                0.55
   
        (0.25-1.19)                0.43
*** 
   (0.21-0.54) 
Adjusted R
2    





Note: * p < 0.05, ** p < 0.01, *** p < 0.001 
 
Table 5.6 Predictors of healthcare utilization in type 2 diabetes patients with DD: 
Multivariate negative binomial regression models (N=1529) 
______________________________________________________________________________ 
                                                 Inpatient visits                          Outpatient visits                          ER visits 
                                           Relative
Ω
          95% CI             Relative
Ω 
     95% CI             Relative
Ω
        95% CI 
                                              Risk                                               Risk                                        Risk             
_____________________________________________________________________________________________            
Adherence                           
   MPRm<80%                    Reference       Reference           Reference      Reference           Reference       Reference 
   MPRm≥80%                        0.80
 
          (0.60-1.07)               1.13
       
      (0.93-1.35)              0.50
***  
      (0.38-0.67) 
Race 
   Caucasians                       Reference      Reference           Reference        Reference            Reference       Reference 
   African Americans             1.72
* 
          (1.12-2.63)               0.95           (0.76-1.19)               1.76
**
         (1.18-2.61)       
   Other races                          1.27 
 
         (0.73-2.22)               0.78
 
          (0.59-1.03)                1.39
 
           (0.85-2.28)       
Interaction between  
race and MPRm 
0                                          Reference       Reference           Reference     Reference            Reference       Reference 
1                                               1.47
 
          (0.90-2.39)               0.96
 
         (0.75-1.24)               1.88
** 
        (1.22-2.91) 
Age (years) 
   18-30                               Reference       Reference            Reference      Reference            Reference       Reference 
   31-40                                     1.08
 
          (0.78-1.48)              1.17
* 
         (1.00-1.36)              0.92
 
            (0.72-1.17)     
   41-50                                     1.18
  
         (0.89-1.57)              1.12
   
         (0.96-1.30)              0.90
 
            (0.71-1.14)     
   51-60                                     1.14
  
         (0.82-1.57)              0.99
 
          (0.85-1.15)               0.73
* 
          (0.56-0.95)      
   61-64                                     1.57
*     
       (1.03-2.45)              1.07
 
          (0.79-1.47)              0.85
 
           (0.52-1.38) 
Gender 
  Male                                 Reference       Reference           Reference        Reference            Reference      Reference 
  Female                                   0.96
 
           (0.78-1.19)            1.17
**  
        (1.04-1.30)
 
                1.20
* 
         (1.00-1.43) 
FFS vs. Capitation 
  FFS                                   Reference       Reference           Reference     Reference             Reference       Reference 
  Capitation                              1.08
 
          (0.83-1.40)              0.79
*** 
      (0.69-0.90)                1.57
*** 
       (1.26-1.95) 
  Dual                                       1.30
 
          (0.88-1.93)              1.38
*
          (1.08-1.77)                1.78
**  
       (1.22-2.60) 
Comorbidity  
(Charlson Index)  
  0                                       Reference       Reference           Reference       Reference             Reference       Reference 
  ≥1                                         1.51
***      
    (1.37-1.67)                1.15
***   
    (1.09-1.21)               1.40
***       
  (1.28-1.53) 
Comorbidity pre- 
index period  
(Charlson Index)    
  0                                       Reference       Reference           Reference     Reference             Reference       Reference 
  ≥1                                         0.97
* 
           (0.87-1.07)                0.92
**  
     (0.86-0.98)               1.01
 
         (0.91-1.11) 
Inpatient visit 
pre-index period    
  0                                       Reference       Reference           Reference      Reference              Reference     Reference 
  1                                           1.47
***      
     (1.37-1.58)                1.03
 
         (0.99-1.07)               1.33
***      
  (1.24-1.42) 
Outpatient visit 
pre-index period    
  0                                       Reference       Reference           Reference       Reference             Reference       Reference 
  1                                         1.00
**
          (1.00-1.00)                1.01
***     
     (1.01-1.01)               1.00
***  









                                                 Inpatient visits                          Outpatient visits                          ER visits 
                                           Relative
Ω
          95% CI             Relative
Ω 
     95% CI             Relative
Ω
        95% CI 
                                              Risk                                             Risk                                        Risk             
_____________________________________________________________________________________________            
Number of 
Medication refills 
 2-5                                    Reference       Reference            Reference         Reference            Reference      Reference 
 6-10                                     1.09
       
      (0.74-1.60)                  1.20
 
          (1.00-1.45)               0.98
          
     (0.70-1.38) 
  >10    
   
          
                           
1.92
***
         (1.38-2.66)                 3.21
***
       (2.75-3.75)               1.74
***    
      (1.31-2.31) 
Constant                              0.15
***       
    (0.09-0.25)                15.16
***
     (12.13-18.96)             0.83
         
     (0.55-1.25) 
Alpha                                     1.83           (1.52-2.22)               0.67             (0.62-0.73)               1.77          (1.57-1.99) 
 
Likelihood-ratio (LR)           Chibar
2
(01) = 860.88                Chibar
2
(01) = 3.15e+05             Chibar
2
(01) = 4492.06 
Test of alpha=0                     Prob>=Chibar
2
 = 0.000             Prob>=Chibar
2
 = 0.000             Prob>=Chibar
2
 = 0.000 
Vuong test                             Z = 5.53; Prob>z=0.054          Z = -14.2; Prob>z =0.054          Z = 4.70; Prob>z=0.052 
Log likelihood                       -1677.45                                   -8044.52                                    -3027.41 
_____________________________________________________________________________________________ 
Note: * p < 0.05, ** p < 0.01, *** p < 0.001 
Ω 
































Table 5.7 Predictors of healthcare costs in type 2 diabetes patients with DD: Multivariate 
linear regression models (N=1529) 
______________________________________________________________________________ 
                                                     Medication                                    Medical                                  Overall 
                                                          costs                                            costs                                       costs     
                                                    β                                                 β                                               β 
                                               coefficient           SE                coefficient          SE                 coefficient          SE              
_____________________________________________________________________________________________            
Adherence                           
   MPRm<80%                     Reference       Reference           Reference       Reference          Reference       Reference 
   MPRm≥80%                  -0.32**              0.11                    -0.48***             0.12                  -0.52***             0.11 
Race 
   Caucasians                          Reference       Reference           Reference        Reference         Reference     Reference 
   African Americans                  0.23
**
             0.08                    0.26
**
               0.09                   0.21
*
              0.09     
   Other races                              0.08               0.13                    0.19                  0.17                   0.14               0.16  
Interaction between race      
and MPRm 
0                                             Reference       Reference           Reference     Reference            Reference      Reference 
1                                                  -0.27               0.16                    -0.11               0.18                   -0.09                0.17 
Age (years) 
   18-30                                  Reference        Reference           Reference       Reference           Reference      Reference 
   31-40                                        0.01                 0.09                    -0.04                0.11                   -0.01
 
             0.10 
   41-50                                        0.10
 
                0.09                    -0.04
 
               0.11                     0.04
 
             0.10 
   51-60                                        0.08
 
                0.10                    -0.16                0.13                   -0.07
 
             0.11 
   61-64                                        0.22
 
                0.16                     0.25
 
               0.19                     0.24
 
             0.18 
Gender 
  Male                                       Reference       Reference           Reference     Reference          Reference       Reference 
  Female                                       -0.01                 0.07                    0.02               0.08                  -0.03               0.07 
FFS vs. Capitation 
  FFS                                        Reference       Reference           Reference      Reference          Reference      Reference 
  Capitation                                   0.07
      
             0.08                  -0.70
***
          0.10                 -0.69
***
             0.09 
  Dual                                            0.24
 
                0.14                   0.29
 
             0.05                  0.24
 
                0.16 
Comorbidity  
(Charlson Index)  
  0                                            Reference       Reference           Reference       Reference          Reference      Reference 
  ≥1                                               0.12
***
             0.03                   0.29
***
           0.04                    0.25
***
            0.04 
Comorbidity pre- 
index period  
(Charlson Index)    
  0                                            Reference       Reference           Reference       Reference          Reference      Reference 
  ≥1                                              -0.10
*    
           0.04                    -0.08
 
              0.05                   -0.08
 
              0.05 
Inpatient visit 
pre-index period    
  0                                            Reference       Reference           Reference     Reference            Reference      Reference 
  1                                                  0.02
   
             0.02                     0.13
*** 
         0.03                    0.12
***
            0.03 
Outpatient visit 
pre-index period    
  0                                            Reference       Reference           Reference     Reference            Reference      Reference 
  1                                                 -0.00
** 
           0.00                     0.01
***
            0.00                    0.01
***
           0.00 
Number of 
Medication refills 
 2-5                                          Reference       Reference           Reference     Reference            Reference      Reference 
 6-10                                              1.21
***
           0.11                     0.94
***
            0.13                    1.04
***
           0.12          
 
 >10    
   
          
                                               
2.77
***
           0.08                      2.25
***
            0.10                    2.47
***
           0.09 
Constant                                        3.96
***
           0.13                     7.17
***
            0.15                    7.26
***





2    
                                0.44                                           0.37                                           0.43 
_____________________________________________________________________________________________  





Chapter 6 Overall Conclusions 
6.1 Study Conclusion 
The prevalence of chronic disease conditions in DD patients is high. Racial disparities are 
existent in developmentally disabled individuals with type 2 diabetes. Since the study population 
has Medicaid insurance, their socioeconomic status is lower and disease severity is more as 
compared to individuals with private insurance coverage or Medicare. The care process of DD 
patients is complex and factors such as medication intake can help researchers to better 
understand this process. The aim of this study was to understand the role of race and other 
predictors that determine medication adherence and medication persistence in type 2 diabetic DD 
patients with Medicaid coverage. In the Medicaid population, compared to Caucasians, the type 
2 diabetes medication adherence was lower in African Americans. Also, African Americans had 
lower anti diabeticmedication persistence and a higher hazard of not persistently taking type 2 
diabetes medications, though the results were not statistically significant.  
The study also looked at the predictors of the type 2 diabetes related healthcare utilization and 
healthcare costs in the DD population respectively. Race was interacted with medication 
adherence of the DD population to study its effect on type 2 diabetes related healthcare 
utilization outcomes such as inpatient visits, outpatient visits and ER visits as well as type 2 




respectively. Type 2 diabetic African American adults with DD enrolled in Medicaid were more 
likely to have higher inpatient visits and ER visits and lower outpatient visits (non-significant) 
compared to type 2 diabetic Caucasian adults with DD enrolled in Medicaid. Also, among adults 
enrolled in Medicaid, the likelihood of higher medication, medical and overall expenditure were 
more in African American adults with DD and type 2 diabetes compared to their Caucasian 
counterparts.  
6.2 Overall Implications 
           This study provides important implications for health research and policy. The study has 
high generalizability since the Medicaid population chosen as the study population represents 
eight states enrolled from 2003 to 2007.  One of the strengths of the study was that the study 
variables were based on the Andersen’s model of healthcare utilization. This model provided a 
theoretical background for the study. It allowed the researchers to control the predisposing, 
enabling, and need factors that helped in explaining the racial disparities in medication use 
outcomes and healthcare utilization in Medicaid enrollees with DD and type 2 diabetes. This 
study has important implications for the association of race, medication adherence, and their 
interaction with healthcare outcomes in Medicaid enrollees with DD and type 2 diabetes.  
6.2.1 Access to care  
                     Families of minority patients with DD face many difficulties in their search for 
primary care and specialty physicians that they can trust (Caudle 1993, Cornelius 1993, 
Friedman 1994, Kindig 1993). Since many physicians are unaware about providing the 
appropriate treatment for DD patients, accessing care is an issue in this population, especially for 
non-English speaking patients with cultural values differing from the physicians’ (Scott 1993, 




face physical barriers when they go for their examination. These barriers comprise of lack of 
wheel chair friendly examination rooms, enlarged door frames, ramps or additional bathroom 
equipment. Lack of the right equipment at home prevents these patients from performing day to 
day activities (Reichard 2004). Lack of transportation in rural areas, longer travelling distances, 
longer waiting times, limited access to specialized services and family members missing work 
for taking patients for physician visits can lead to social exclusion in patients by limiting their 
access to healthcare services, physical activity, recreation and attending health appointments 
(Rask 1994, Smith 1996, Crain 1998, Harbaugh 1998).  
                      Patients with DD going for a physical examination can require three times more 
time as compared to patients without DD due to barriers such as difficulty in communicating 
symptoms, inability to tolerate longer waiting times, displaying aggressive behavior and 
reluctance to get a physical, fear of needles, fear of examination of private areas, fear of new 
physicians and need for physical assistance for many procedures.  Patients with physical 
impairment, when they go for an examination might be mistaken for cognitively impaired 
patients due to their disheveled appearance, communication difficulties, need physical assistance 
for an examination and equipment that can elevate them from the ground (Doostan 1999). This 
study found that African Americans with DD and type 2 diabetes had higher ER visits and 
inpatient visits compared to Caucasians with DD and type 2 diabetes. This risk of higher 
healthcare utilization can be reduced by increasing the number of primary and specialty 
providers who accept Medicaid patients, improving access to culturally competent minority 
healthcare providers with cultural backgrounds similar to minority patients’ and increasing rates 
of out of home placement for minority DD patients with chronic diseases (National Center for 




                       In some cases, DD patients are unable to communicate their symptoms clearly to 
their healthcare practitioner which restricts their relationship with their practitioner. Many 
healthcare practitioners might assume that it is the patient’s responsibility to discuss their health 
issues (Boyer & Lutfey,2010). As a result, the symptoms of the DD patients might worsen. 
Attempts to initiate effective communication with DD patients by physicians can help the 
physicians better understand the problems faced by these patients on a daily basis and they might 
allow some extra time for consultaion for them during future visits. Patients with DD have more 
complex health problems than the general population and are in need of more access to medical 
resources indicated by higher number of healthcare visits as found in this study. Medicaid 
coverage for the general population and the DD population is the same. Compared to the general 
population enrolled in Medicaid, Medicaid enrollees with DD require more resources due to the 
different types of issues occurring at different rates in this population. There is a need for 
developing policies which are based on a deeper understanding of the health issues and the 
health status of the DD population and which can provide the necessary resources to the DD 
population (Boyer & Lutfey,2010). 
 
Care provided to ethnic minorities- Role of cultural sensitivity                        
                     Healthcare providers should keep in mind about the social norms followed by 
people coming from different racial/ethnic backgrounds.  African Americans and Latinos tend to 
utilize services that provide less social support since they depend on their family members for 
love and support. Latinos who are migrants tend to face linguistic barriers in seeking care 
(Cabellero 2007, Gavin 2007). Native American people are unable to access care from state or 




Indian Affairs. Many of these minorities distrust the government programs and healthcare 
professionals (Glassheim 2009). As opposed to the Western perception of attaining autonomy 
and self-reliance for children with DD, Japanese people tend to value interdependence, 
belongingness and reciprocity during the course of provision of care for their DD children (Hsu 
2007(a)). Seeking assistance for social or emotional issues, even though visualized as 
constructive among Caucasians, it may seem shameful in Chinese or Indian culture (Hsu 2007). 
Generally, in these cultures, there is reluctance in discussing about disability due to the stigma 
associated with it and help is sought only when the problems are assumed to be of somatic nature 
(Glassheim 2009). This study showed that medication adherence and healthcare utilization was 
less in African Americans compared to Caucasians. These findings are supported by previous 
research on healthcare access in minorities which states that minorities tend to drop out more 
often from community programs, receive less comprehensive services, lack access to trained 
culturally competent or bilingual healthcare providers and are more underserved (National 
Council on Disability website).   
                        Minority DD patients face cultural insensitivity just like minority patients without 
DD. However, in addition to cultural insensitivity, DD patients also have to face prejudice and 
tolerate negative social attitudes associated with their disability (Reichard 2004). Cultural 
sensitivity can be taught to providers and caregivers by training them to display culturally 
appropriate behavior that takes into account the disability culture, use of respectful language and 
terminologies related to patient’s condition, and providing language assistance when 
communicating with the patient (University of California at San Francisco website). Practices 
followed by physicians such as delaying treatment, providing wrong treatment, spending 




families can be considered inappropriate by caregivers of DD patients (Ebert 1995, McEwen 
1988, Welner, 1998, Brooks 1997, Barnett 1988, Grabois 1999, Reichard 2001, Nosek 1995, 
Ralston 1996). Showing respect for the needs of the DD patient, including patients and their 
families in the decision making process and harboring a patient and family centered attitude can 
foster trust and confidence about the healthcare provider.  
6.2.2 Fragmented care 
                      One of the unique challenges that the DD population faces is fragmented care. This 
is further compounded by additional challenges such as co-occurring chronic conditions, limited 
coverage of care and restricted funding. There is inadequate identification of comorbid 
conditions in DD patients. 20-30% individuals with cognitive disabilities also have comorbid 
psychiatric disorders. However, these disorders upon surfacing tend to get shadowed due to 
communication limitations faced by the DD patients. Diagnostic shadowing is often seen in DD 
patients. It is a phenomenon whereby comorbid conditions in DD patients are overlooked and 
DD patients, due to their inability to communicate their emotional or physical distress tend to 
manifest it through non specific actions such as head banging (Reiss 1982). Families of the DD 
patients, if provided with the appropriate training and information, can help healthcare 
professionals in identifying a baseline behavior in DD children which can, in turn help in 
diagnosing comorbid disorders (Jacobstein 2004).  
The challenges in DD patients are not limited to detection of chronic conditions alone. Even 
after, the comorbid conditions get detected in DD patients, procuring care is a tedious process for 
both the patient and the family.  There is lack of collaboration between healthcare providers such 




professionals and the DD patients and their families can aid in proper disease diagnosis and the 
right referrals to improve continuity of care. Physicians can find catering to the complex health 
care needs of the DD population an arduous task, partly due to lack of training and partly due to 
the communication barriers faced by the patients. Hence, a curriculum focused on cross systems 
training for healthcare professionals can bring to light the barriers and facilitators encountered by 
the medical professionals at different stages of the care process of the DD patients (Jacobstein 
2004).  
In case of children with DD, procuring services is age specific and eligibility criteria might be 
different for different age brackets. Healthcare services for DD patients vary from state to state 
based on the funding availability. The severity of chronic conditions is especially higher for DD 
patients in foster care. There is lack of synchronization in the working of the local welfare 
agencies and the governmental agencies (American Academy of Pediatrics 2002). Due to 
fragmented care, DD patients tend to have limited healthcare services, respite care, home support 
and rehabilitation facilities. There are limited transition services and intensive behavioral 
treatment centers for DD individuals who drop out from schools before the age of 21. Care 
provided in welfare programs for DD patients is often not sufficient for managing physical and 
mental chronic conditions. Training provided to DD children in special education classes in 
schools might focus on just one of all the co-occurring conditions.  All the above reasons 
indicate that adults who receive fragmented care since childhood might have a greater severity of 
chronic disease conditions (Jacobstein 2004). Adults who are not supported by their families face 
additional challenges in procuring services through government programs. Public insurance 
programs do not provide comprehensive care like private insurance programs. Eligibility for 




which drives access to continuous care. These challenges alongwith disparities characteristic to 
the minority populations of all ages makes access to care really challenging (U.S. Department of 
Health & Human Services 2002).  
6.2.3 Coordination of care 
                     According to the National Committee for quality assurance, employing HEDIS 
quality measures by health plans for diabetes management can result in improved screening of 
HbA1c, better glycemic control, lower healthcare costs and less healthcare utilization (inpatient 
visits and ER visits) (National Committee for quality assurance 2005). Even though national 
guidelines exist for treating type 2 diabetes, caring for patients with DD and type 2 diabetes gets 
more complex. Evidence based guidelines for treating DD patients are often established by local 
institutions and due to lack of standardization; it might not be possible to judge the 
appropriateness of primary and specialist care that the patient receives (Epilepsy Action 
Australia website, Glassheim 2009). Lack of evidence based guidelines for chronic disease 
conditions calls attention to the need for funding to conduct research and develop interventions 
that can improve patient outcomes for chronic disease conditions such as diabetes, CVD, 
hypertension, asthma, etc. (Kronick 2007).   
                      The ability of the primary care provider to communicate and collaborate with DD 
patient’s caregivers, specialty providers and case coordinators can improve the patient’s access 
to comprehensive care (Meuwese-Jongejeugd 2005). In absence of case managers, families 
struggle with finding the appropriate care for the DD minority patients and tend to rely on friends 
and acquaintances to direct them towards community based organizations funded by Medicaid, 




minority DD patients and can be associated with the following factors: presence of trust between 
the patient and the provider, affordable care, referrals for specialist care, absence of the need to 
explain patient history repeatedly by family members, specialty providers avoiding moving the 
health records of the DD patient every time they change a primary healthcare provider, improved 
patient health and bedside mannerisms. Collaboration among all the care providers can ensure 
that they are well informed, have the DD patient’s treatment plan, and are better prepared to 
constantly cater to the emotional and physical needs of the patient (Meuwese-Jongejeugd 2005). 
                      Physicians should observe DD patients’ behavior, have the ability to notice the 
slight changes in the patient’s behavior and communicate with the caregiver to procure more 
information about the patient. Providing medical attention to the patients with DD can be time 
consuming and demanding but openness on part of the physician can go a long way in 
establishing trust with the patient. The acute conditions that the DD patients experience from 
time to time might not be detected by a new primary care provider since the symptoms of acute 
conditions often get blanketed by the chronic diseases that DD patients have and the new 
provider might not have updated information about the patient (Lubin 2012). Recognizing 
special needs of the patients with DD such as patients wanting to undergo physical in their 
homes, arranging special diagnostic equipment suitable for screening or examining and 
convincing and assisting patients to undergo examinations can require preplanning and 
investment of extra time on healthcare provider’s behalf. Improving access to medical homes and 
incentivizing case management by providing reimbursement can add to Medicaid costs but in 
turn be cost-effective in the long run by reducing health related disparities, improving continuity 






Pharmacist as a liaison between the DD patients and other healthcare providers, caregivers 
and family members 
                       We found in this study that there were racial disparities in medication adherence in 
DD patients with type 2 diabetes. Some of the reasons for low medication adherence in DD 
patients are incorrect medication consumption, incorrect medication consumption times, failure 
or refusal to consume medications, failure to understand the goals of treatment, non-supportive 
caregivers, insufficient resources, non adherence promoting contingencies (attention seeking 
behavior or escape tendency), failure to comply with medication therapy and resisting routine 
examinations (Wallace 2006). Pharmacists can provide their cognitive services and expertise to 
create a difference in the disease management of patients with DD and chronic conditions. 
Pharmacists can serve as liaisons between the patients and their care givers and other healthcare 
providers. Rather than meeting the DD patient’s caregiver, family member or case manager who 
are responsible for providing medications to the DD patients, communicating directly with the 
DD patients can provide an insight into the complex care that these patients need on a continuous 
basis and the role of each care provider in their lives (Raleigh 2003). In spite of pharmacists 
encountering communication barriers with DD patients, these patients have varying range of 
intelligence and might not be deaf. Hence, asking open ended questions and providing advice to 
the patients can be an effective way of understanding their health issues and conveying useful 
information that can aid the patient/the caregivers in their disease management. Pharmacists can 
assist caregivers aiming to provide high quality of life to their clients by teaching them to detect 
any medication related adverse events early on, by answering medication queries for chronic 




training caregivers to improve medication adherence. Caregivers aim to understand and work 
towards the overall well being of the DD patients and collaborating with them can provide 
pharmacists with valuable information about the success of the medication therapy and 
medication intake patterns of the patients (Raleigh 2003). 
                        Intervention strategies used with elderly patients or patients with linguistic 
barriers might be beneficial in case of patients with DD as well. In particular, techniques that can 
be employed to enhance medication adherence among DD patients with chronic disease 
conditions are, a) antecedent control manipulations, b) reinforcement procedures, and c) 
extinction.  Antecedent control manipulations comprise of interventions such as i) providing 
additional prompts to attain or improve adherence (color coding medication containers and 
putting pictorial labels on medication bottles of “spoon and dish” for intake during meals or of 
“moon and stars” for intake at bedtime), ii) creating conditions that motivate adherence 
(providing DD patients’ access to a activity they crave), iii) reducing the response effort related 
to adherence (keeping health foods handy at home) and iv) eliminating the motivation for 
nonadherence using behavioral momentum (making the DD patients feel special prior to 
engaging in an activity that they resist). Reinforcement procedures comprise of interventions 
such as i) using reinforcers contingent upon the fulfilment of the intended action (making DD 
patients behave favorably using tokens) and ii) using  reinforcers contingent upon elimination or 
reduction of non-adherence (using verbal praise and providing foods or engaging in activites that 
DD patients desire). Extinction consists of eliminating reinforcers contingent upon the 
maintainence of adherent behavior (terminating activities that the DD patients prefer or 
improving their tolerance for aversive side effects of medications and avoiding scolding or 




considerations while interacting with DD patients from racial minorities. It is very important to 
maintain eye contact when listening to or communicating with African Americans. It might be 
difficult to establish trust with the African American patients due to their general distrust in the 
healthcare system, embarrassment arising from less awareness about disease conditions, fear of 
receiving distressing news about their own health, discriminatory treatment experienced by their 
family or friends and lack of sufficient funds. African Americans are very religious and might be 
of the belief that their spiritual faith has more healing power than consuming medications. They 
might believe that praying with the spiritual leader in the church and not acknowledging diabetes 
can rid the body of diabetes, thereby healing the body (Gavin 2007).  
                         Latinos perceive people with plump or overweight bodies as healthy individuals 
who are very well cared for as opposed to people with thin bodies who they perceive might be 
neglected or undernourished. In the Latino culture, as a gesture of endearment, “healthy” 
individuals are often called “gorda” i.e. fat one or “gordito” i.e. little fat one. Similar to the Asian 
culture, for Latinos, their traditional meals connect them to their homelands. Asking Latinos to 
substitute their diet for a healthier diet might be perceived by them that the healthcare 
professionals are asking them to make a major sacrifice. Instead, culturally acceptable dietary 
interventions such as not using the excess grease after cooking meats with high fat content, using 
healthier oils instead of lard and using corn flour instead of refined white flour can be applied 
with more probability of success. It is important to keep in mind that Latinos uses herbal 
supplements with their medications and might be scared of being scolded which prevents them 
from disclosing about it in front of healthcare professionals. Latinos also might be of the belief 
that diabetes can be caused by susceptibility to susto i.e. anger, fright and emotional nature.  




(susto) can make the body more susceptible to developing diabetes. Latinos also have an attitude 
of “fatalism” and many of them assume that since their family members have diabetes, they are 
bound to get it as well and cannot prevent or delay it (Cabellero 2007)  
                       Among Asians, more importance is placed on maintaining harmony i.e. yin and 
yang while cooking meals. Importance is placed on the texture, color and quality of meals rather 
than counting the calories in the meals prepared. Seating down for meals is often seen as a 
custom that brings the family together and cooking food is symbolic of expressing care for an 
individual. When Asians fall sick, rather than giving medications, the caregiver in the family 
provides teas or soups that can restore vitality. Asians believe that  imbalances in the body make 
a person ill and the right diet, instead of strong medications can help the ill person regain his/her 
strength back (Hsu 2007(a)).   
                     DD patients visit several physicians for their multiple health issues and generally 
spend 15 minutes or less with their physicians which might not be sufficient to tend to all their 
problems. Also, in case of DD patients seeing a new physician or multiple physicians, the 
physician/s might not be aware of all the medications that the patient receives from the older or 
other physicians.  However, a pharmacy might hold all the records of medications that the DD 
patients receive from different physicians, if they go to the same pharmacy. In such instances, 
pharmacists can provide their expertise with linking multiple diagnoses, detecting drug 
interactions and answering any health concerns that might have been overlooked unintentionally 
or due to lack of time during the physician visit (Raleigh 2003). Education based interventions 
that focus on improving awareness about disease management such as continuing education 




materials provided to the DD patients or caregivers can  lead to improved health outcomes 
among the DD patients (Martínez-Moreno 2013, Aman 2007). 
6.2.4 Prevention and early intervention 
                      This study found that DD patients enrolled in capitated Medicaid plans had lower 
outpatient visits and higher ER visits compared to DD patients enrolled in FFS Medicaid plans. 
These findings were similar to a previous study conducted in Medicaid adults with type 2 
diabetes enrolled in capitated and FFS plans. Medicaid enrollees have very low copayments and 
out of pocket expenditures ($1-$3) for most of the services. Patients in capitated plans have 
limited prescription drug benefits due to presence of a cap on medication related spending. Out 
of pocket expenditures increase once the cap is reached and this may lead to less medication 
adherence or discontinuation of therapy. Children and young adults staying with parents might 
be able to support themselves and get the necessary healthcare but there is a possibility that older 
adults living by themselves might stop taking medication or utilizing healthcare services  if they 
cannot afford copayments due to lack of employment. Reduced adherence, inadequately 
provided health services, shorter treatment periods, limited patient followup and poor treatment 
can contribute to higher healthcare utilization (Pawaskar 2010). The impact of capitated 
Medicaid plans on outpatient visits is inconclusive. Studies have shown both to improve (Deck 
2000) and reduce outpatient visits in patients enrolled in capitated plans (Balkrishnan 2002).  
                       Interventions such as educating women during pregnancy about getting 
immunization for rubella or measles, abstaining from alcohol to prevent fetal defects and taking 
folic acid supplements to avoid neural tube defects can contribute to preventing developmental 




healthcare providers, can play an important role in their early diagnosis. Parents can proactively 
inquire about DD during well child and sick child visits with pediatricians as well as with 
healthcare professionals other than physicians such as social workers, speech therapists, 
pathologists, nurses, daycare providers, early intervention specialists, occupational therapists, 
school personnel and pharmacists, many of whom come in contact with their children on a 
regular basis and who have the ability to diagnose DD. Early diagnosis of DD in children can 
mean early access to educational and behavioral interventions. As a result, positive outcomes 
such as reduced severity of DD, lesser learning delays, reduced dependence, less social isolation, 
and better self-esteem and productivity can be achieved as these children grow into adults.  
Interventions provided at an early age can be cost-effective, children can require less long term 
services, and the family members can better interact with their children and understand their  
disability (Glassheim 2009).  
                       There are many organizations that focus on educational and behavioral 
interventions in children and youth with DD. Programs such as LEAP (Learning Experiences: 
An Alternative Program for Preschoolers and Parents) and UCLA YAP (Young Autism Project) 
assist children and youth with autism. LEAP is 2-3 year program that focuses on improving 
functional, behavioral and social skills, increasing independence and preventing or reducing 
linguistic impediment in children aged 3-5 years and their families. Autisitc children enrolled in 
LEAP experience better health outcomes and display complex developmental skills (Research 
Autism website (b)).  The UCLA YAP is similar to LEAP and consists of a 3 year program that 
focuses on discrete trail training for pre-school children and detailed monitoring of the child’s 
developmental progress by parents and therapists. The YAP participants have shown an increase 




Screening, Diagnosis, and Treatment (EPSDT) is a federally mandated Medicaid program in 
Michigan for enrollees under 21 years that provides screening to children who are at a risk of 
developing DD or who already have development delays. Parents can take benefit of this 
program during well child visits to healthcare providers (Health Resources and Services 
Administration website).  CEDEN (Center for Development, Education and Nutrition) is part of 
the Substance Abuse and Mental Health Services Administration (SAMHSA) and assists 
children from families with low SES. CEDEN is for children less than 5 years old and includes 
interventions that focus on improving birth outcomes for mothers, delivering home and 
community services based on the need of the family, providing educational materials to enhance 
child development and reducing social isolation of mothers. CEDEN has been known to improve 
immunization rates in children and enhance parent’s satisfaction from learning to care for their 
children and understanding them (U.S. Department of Justice website).  
6.3 Testing the theoretical model 
The theoretical model was based on the Health belief model and Aday-Andersen’s model for 
healthcare utilization (Andersen 2007, Andersen 2008, Andersen 1973). According to the model, 
the predisposing, modifying and the enabling factors impact medication adherence which in turn 
affect the healthcare utilization and healthcare costs.  Patients display willingness to adhere to 
their medications on the basis of their perceptions about disease severity, susceptibility to 
adverse health conditions due to the disease condition, benefits derived from adhering to 
medications and barriers faced in adhering to medications.  The researchers faced some 
limitations using the Marketscan Medicaid dataset since the above variables were not available 
in the dataset and so their influence on medication outcomes could not be determined.  In this 




the patient’s race and gender were associated with medication adherence and healthcare 
utilization. Also, enabling factor such as the type of plan was associated with the likelihood of 
ER visits and need factor such as the number of comorbidities was associated with healthcare 
utilization such as emergency room visits, outpatient visits and inpatient visits and healthcare 
costs.  Patients with certain characteristics had a higher probability of higher ER visits or 
inpatient visits. As proposed by the model, this study showed that higher medication adherence 
was associated with lower risk of ER visits and higher risk of inpatient visits. Higher medication 
adherence was also related to lower medication costs, lower medical (inpatient and outpatient) 
costs and lower overall (medical and medication) costs. Both the Health belief model and Aday 
Andersen’s model of healthcare utilization seem appropriate for explaining the predictors of the 
main outcomes of this study. However, there is need to explore more measurement tools to study 
the impact of the variables that could not be captured using the Marketscan Medicaid dataset.  
6.4 Testing the analytical model   
The Shapiro Wilk test was significant (p<0.000) which indicated that the data was not normal. 
Also, a probability of <0.000 obtained in the Breusch-Pagan-Godfrey test indicated presence of 
heteroscedasticity. Hence MPRm was log transformed for stabilizing the variance. White-Huber 
robust standard errors were computed while running the negative binomial regression models.  A 
VIF value of less than 1.44 for each independent variable showed absence of multicollinearity 
among the study variables. In this study, the Durbin Watson statistic of 1.98 showed the absence 
of autocorrelation among the variables. The Hosmer-lemeshow chi square test was non-
significant for the multiple logistic regression models which indicated that the models were well-
fitted. Also, the squared prediction in the model specification link test was not significant, 




Likelihood ratio test of alpha was significant for negative binomial regression models but the 
Vuong test was not significant. Due to the retrospective nature of the study, it has selection bias. 
In the future studies, this bias can be controlled by using propensity scores to compare the 
diabetic DD population with the non diabetic DD population.  
6.5 Limitations  
The study is not without its limitations. Due to the observational nature of the study, there is no 
causal effect. The dataset did not capture variables such beliefs, attitudes or intentions associated 
with medication intake. These variables might vary by race and could help the researchers to 
better understand access to care among different races. The data does not represent patients who 
have Medicare only, are uninsured or are dual eligibles. The dual eligible population might have 
a higher severity of type 2 diabetes and related comorbidities, resulting in patterns differing in 
medication intake and healthcare utilization.  
Patients taking insulin were excluded from the study population since they represent the more 
severe cases. The assumption that a prescription filled was a prescription taken was made for 
calculating medication adherence of the study population. However, there is no measure in the 
dataset to verify the actual intake of the medications. A questionnaire such as Morisky scale, 
asking the patients about their medication intake can be a viable tool for actual medication 
adherence assessment.  Information about the educational background of the patients was not 
captured in the claims dataset. Due to lack of education, it is possible that patients might face 
challenges in understanding and following complex medication regimens, leading to lower 




Claims data also does not have clinical measures such as HbA1c levels which are a measure of 
diabetes severity level.   Hence, the healthcare utilization in the pre-study period was used as a 
proxy to determine the severity of type 2 diabetes. It was not possible to capture patient 
satisfaction using claims data. While information about primary and specialized care can be 
obtained from the claims dataset, collaboration between the different types of providers for a 
particular patient cannot be measured. In case of DD individuals, coordination of care can reduce 
hospitalization (Criscione 1995, Pincus 1987, Walsh 1997). Activities that are not reimbursed 
such as care coordination by social workers or the extent of caregiving provided by family 
members cannot be captured by claims dataset.   
6.6 Future directions  
This study provides the first comprehensive account about healthcare outcomes in diabetic adults 
with DD and opens up new areas of potential research. Medicaid programs differ from state to 
state in terms of service eligibility and reimbursement systems. Studies’ comparing the Medicaid 
claims data across individual states can provide information about geographic disparities in 
delivery of care.  Future studies could be conducted in DD adults with diabetes with Medicare 
coverage or dual eligibility or commercial insurance or with no insurance. Studies can also be 
replicated in DD adults with chronic disease conditions such as congestive heart failure, obesity, 
hypertension, hyperlipidemia and chronic kidney disease. Understanding the predictors of 
healthcare outcomes associated with different chronic disease conditions can help in the 
comprehensive management of the adults with DD. Alongwith analyzing claims data, data 
should also be collected via survey instruments or focus groups to understand the medication 
intake beliefs, attitudes, intentions and other psychological predictors among different racial 




independence exhibited by the patients and adherence to prescribing practices recommended by 
evidence based guidelines can provide an insight about access to quality care in the DD 
population. Studies can also look at hospital length of stay and hospital readmissions to 
understand the severity and treatment efficacy of the DD population.  Environmental variables 
such as the zip code of the patients and physicians can help researchers understand geographic 
disparities in access to care, availability of specialized and primary care physicians, variations in 
treatment in rural versus urban areas and the nature of accommodation of the patient (shared 
medical home or living with family members).  The literature determining quality of care in DD 
patients with type 2 diabetes is scarce (Shiremen 2010). There is need for more studies assessing 
whether the quality of care provided to the DD patients with type 2 diabetes confirms to the 




















NDC Codes used for the identifying OHAs used as part of analysis of the study: 
 
NDC Codes    Medication 
NDC Codes 
   
















































































Sulfonylureas 00009007002      00009010011    00009014101   00009017105 
00009034101      00009035201    00009344901   00009344903 
00039005110      00039005210    00039005250   00039005270 
00039005305      00039022110    00039022210   00039022310 
00047046324      00047046330    00049155066   00049155073 
00049156066      00049156073    00049162030   00049411066 
00049411073      00049412066    00093936401   00049412073 
00093936405      00069393066    00093936410   00069394066 
00093943301      00078035205    00093943305   00087606313 
00093947753      00087607211    00169008181   00087607311 
00169008281      00087607411    00169008481   00093104801 
00172224560      00093104901    00172297860   00093803501 
00172297960      00093803505    00172298060   00093803601 




00172365060      00093834310    00172365070   00093834401 
00093834405      00093834410    00172433060   00781505201 
00781145601      52544046010    59762372603   00781505201 
00172433160      00781145701    52544046101   59762372704 
00172443260      00781145705    52544046105   59762372706 
00182199501      00781145710    52544046110   59762372707 
00182264701      00781505001    52544055901   59762378201 
00185021301     00781505101     52544055905   59762378203 
00185021501     00781505201     52544056001   97623783010 
00185022101     00904507780     53489046701   59762378302 
00228271811     00904792580     53700506070   60951071170 
00247144330     38245036410     55370050608   60951071185 
00378021001      00185022105     00228265711  3824506420     
0904792440        55953003540     62037067401  59930159201  
59930162201      59930163901     59930163903   62037067501  
62037067601      62269029129   62269029224   62269029229  
62939323100       00378110505   49884073601   59762372501  
00378112501       00536346501   00536466805   3489046901  
5370014607         5370014707     5370014708     5953003570  
5953003640          5953034240     5953034340     5953034370  
5953034440          5953034470     0378111001     0111037201  
0781145310          1285059902     2544046001     0904792460  
0904792480          0904792540     8245036450     8245038110  
8245038120          8245038150     8245043310     8245043350  
8245047749          5953034480     0378111005     0111037301  
0378114201          0536346510     00228265750  00228271511  
00378021010        00378021501    00378023401   00378024001  
00378024401        00378055101    00378110501   49884045201  
57664039788        00378111301    50111037303    51285059904 
52544046005         005364739        00591245501   00536564201 
00591245505        00536564301      00591271301  00536569701 
00591271305         00603283628     0536569801     0536570205 
0591277501           00603375621     0536570201     536570301 
00603376321         00536575101     00536575201   00603612121 
00555038502         00662411066     00555038602    00662411073 
00555038702        00662412066     00591046001    00663394066 
00591046005        00677154501     00591046010    00781145201 
00591046101        00781145210     00591046110    00781145301 
Thiazolidinedione  64764015104    64764030100     64764015105    64764045125 
64764045100    64764015106    11532001100     64764030115  
64764030114    11532001216    11532001300     64764030116  
51129177709    64764045124    51129178206     54868434301  
64764045126    66332001125    64764015118     66332001201  
66332001309    000293158 61   00029315918     00029316001  
05112916220    05974231592    05974231609     05112916218  
05974231581    00007315113    00007315213     00173315200  
00173315213    00173315265    00173315313     00173315365  
00173315113    00173315165    00007315213     00007315265  
00007315266    00007314913    00007314965     00007314966  
00007314813    00007314865    00007314866     00173314813  




49990935030    00029315825    00029315838     00029315813  
00029315818    00029315820    00029315822     00029315866  
00029315938    00029315913    00029315918     00029315920  
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